ticker,title,subject,link,published_est,daily_alpha_pct
"BMRA","REPEAT - Biomerica Reports First Quarter 2024 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/10/13/2760118/0/en/REPEAT-Biomerica-Reports-First-Quarter-2024-Financial-Results.html","2023-10-13 13:10:00",3.630235101463486
"KRON","Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/10/13/2760080/0/en/Kronos-Bio-Presents-Positive-Preliminary-Data-from-Phase-1-Dose-Escalation-Portion-of-Phase-1-2-KB-0742-Study-at-AACR-NCI-EORTC.html","2023-10-13 12:30:00",-14.275744418040404
"CDTX","Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/13/2760048/0/en/Cidara-Therapeutics-and-Mundipharma-receive-positive-CHMP-opinion-for-rezafungin-for-the-treatment-of-Invasive-Candidiasis-in-adults-1.html","2023-10-13 10:34:00",4.689936376690039
"NTLA","Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema","Clinical Study","https://www.globenewswire.com/news-release/2023/10/13/2759953/0/en/Intellia-Therapeutics-Receives-Priority-Medicines-PRIME-Designation-From-the-European-Medicines-Agency-for-NTLA-2002-an-Investigational-In-Vivo-CRISPR-Genome-Editing-Treatment-for-.html","2023-10-13 08:38:00",-0.011517654309204988
"ARQT","Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress","Clinical Study","https://www.globenewswire.com/news-release/2023/10/13/2759915/0/en/Arcutis-Presents-Positive-Patient-Reported-Outcome-Data-from-the-Pivotal-ARRECTOR-Phase-3-Trial-in-Scalp-and-Body-Psoriasis-at-European-Academy-of-Dermatology-and-Venereology-EADV-.html","2023-10-13 08:00:00",-9.378042025458377
"TLSA","Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)","Clinical Study","https://www.globenewswire.com/news-release/2023/10/13/2759869/0/en/Tiziana-Announces-Positive-Qualitative-Six-Month-PET-Scan-Results-With-Intranasal-Foralumab-Treating-Multiple-Sclerosis-Patients-Diagnosed-With-Non-Active-Secondary-Progressive-MS-.html","2023-10-13 07:00:00",6.399338232679355
"OPGN","OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds","Stock Market News","https://www.globenewswire.com/news-release/2023/10/12/2759527/35690/en/OpGen-Enters-Into-Warrant-Inducement-Transaction-for-up-to-11-2-Million-in-Gross-Proceeds.html","2023-10-12 12:32:00",-43.48947392933633
"TGTX","TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/10/12/2759456/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-at-the-2023-European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Meeting.html","2023-10-12 11:00:00",-2.4548620567257062
"KA","Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/10/12/2759423/0/en/Kineta-Announces-KVA12123-and-Anti-CD27-Agonist-Antibody-Abstracts-Accepted-for-Poster-Presentations-at-Society-for-Immunotherapy-of-Cancer-SITC-2023.html","2023-10-12 10:19:00",0.47972471919813864
"VBLT","VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/10/12/2759289/0/en/VBL-Therapeutics-Announces-Results-of-Annual-and-Special-Shareholder-Meeting.html","2023-10-12 09:00:00",6.522267280739394
"TTOO","T2 Biosystems Announces Reverse Stock Split Effective Today","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/10/12/2759299/32489/en/T2-Biosystems-Announces-Reverse-Stock-Split-Effective-Today.html","2023-10-12 09:00:00",-40.46697120077117
"ANVS","Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study","Clinical Study","https://www.globenewswire.com/news-release/2023/10/12/2759203/0/en/Annovis-Bio-Announces-Positive-Interim-Independent-Analysis-for-Statistical-Power-in-Its-Alzheimer-s-Study.html","2023-10-12 08:02:00",3.7517159140796883
"ADAG","Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/12/2759194/0/en/Adagene-Announces-Poster-Presentation-on-Optimal-Dose-Selection-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-Upcoming-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html","2023-10-12 08:00:00",3.2113109206491517
"ADAG","天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/12/2759195/0/zh-hans/%E5%A4%A9%E6%BC%94%E8%8D%AF%E4%B8%9A%E5%B0%86%E5%9C%A8%E7%AC%AC38%E5%B1%8ASITC%E5%B9%B4%E4%BC%9A%E4%B8%8A%E4%BB%A5%E6%B5%B7%E6%8A%A5%E5%BD%A2%E5%BC%8F%E5%85%AC%E5%B8%83%E5%85%B6%E7%B2%BE%E5%87%86%E6%8E%A9%E8%94%BD%E5%9E%8B%E6%8A%97CTLA-4%E5%AE%89%E5%85%A8%E6%8A%97%E4%BD%93SAFEbody-ADG126%E5%89%82%E9%87%8F%E4%BC%98%E5%8C%96%E8%AF%95%E9%AA%8C%E7%BB%93%E6%9E%9C.html","2023-10-12 08:00:00",3.2113109206491517
"INAB","IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma","Clinical Study","https://www.globenewswire.com/news-release/2023/10/12/2759188/0/en/IN8bio-Completes-Dose-Escalation-in-Phase-1-Trial-of-INB-100-a-Potential-First-in-Class-Gamma-Delta-T-Cell-Therapy-for-the-Treatment-of-Leukemias-and-Initiates-Enrollment-for-the-P.html","2023-10-12 08:00:00",0.8556084907158056
"PCRX","American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.","Other News","https://www.globenewswire.com/news-release/2023/10/12/2759161/0/en/American-Society-of-Anesthesiologists-Announces-New-Industry-Supporter-Pacira-BioSciences-Inc.html","2023-10-12 08:00:00",-0.11121129521058783
"LGVN","Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","Warrants and Certificates","https://www.globenewswire.com/news-release/2023/10/12/2759182/0/en/Longeveron-Announces-4-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","2023-10-12 08:00:00",-16.448741973186472
"WINT","Windtree to Present at the ThinkEquity Conference on October 19th in New York City","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/12/2759127/0/en/Windtree-to-Present-at-the-ThinkEquity-Conference-on-October-19th-in-New-York-City.html","2023-10-12 07:30:00",4.241580685880644
"BCAB","BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award","Contests/Awards","https://www.globenewswire.com/news-release/2023/10/12/2759131/0/en/BioAtla-s-Jay-M-Short-Ph-D-Selected-for-The-Explorers-Club-Lowell-Thomas-Award.html","2023-10-12 07:30:00",0.4020569978735639
"KBLB","Kraig Biocraft Laboratories Creates Synergy by Onboarding Key Elements and Scientists from the University of Notre Dame Spider Silk Research Operations","Management Changes","https://www.globenewswire.com/news-release/2023/10/12/2759111/0/en/Kraig-Biocraft-Laboratories-Creates-Synergy-by-Onboarding-Key-Elements-and-Scientists-from-the-University-of-Notre-Dame-Spider-Silk-Research-Operations.html","2023-10-12 07:05:00",-0.14439055560987804
"NSPR","InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/12/2759105/0/en/InspireMD-Supports-CMS-Final-National-Coverage-Determination-NCD-Expanding-Coverage-of-Carotid-Stenting-CAS-to-Include-Both-Asymptomatic-and-Standard-Risk-Patients.html","2023-10-12 07:00:00",5.624842564889017
"PEPG","PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/12/2759094/0/en/PepGen-Inc-Announces-FDA-has-Lifted-the-Clinical-Hold-on-its-Investigational-New-Drug-Application-for-FREEDOM-DM1-Phase-1-Study-of-PGN-EDODM1-for-Myotonic-Dystrophy-Type-1-DM1.html","2023-10-12 07:00:00",-0.714736724867118
"ALERS.PA","EUROBIO SCIENTIFIC : RESULTATS DU 1ER SEMESTRE 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/11/2758684/0/fr/EUROBIO-SCIENTIFIC-RESULTATS-DU-1ER-SEMESTRE-2023.html","2023-10-11 12:52:00",-0.1560904997053601
"ALERS.PA","Eurobio Scientific : Results for the First Half of 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/11/2758684/0/en/Eurobio-Scientific-Results-for-the-First-Half-of-2023.html","2023-10-11 12:52:00",-0.1560904997053601
"VALN","Valneva to Present on Chikungunya at Several Leading Scientific Conferences","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/11/2758633/0/en/Valneva-to-Present-on-Chikungunya-at-Several-Leading-Scientific-Conferences.html","2023-10-11 11:45:00",3.014431206722797
"VALN","Valneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier plan","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/11/2758633/0/fr/Valneva-effectuera-des-pr%C3%A9sentations-sur-le-chikungunya-lors-de-diff%C3%A9rentes-conf%C3%A9rences-scientifiques-de-premier-plan.html","2023-10-11 11:45:00",3.014431206722797
"TGTX","TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/11/2758546/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-at-the-2023-European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Meeting.html","2023-10-11 10:30:00",-4.612186797061757
"MLTX","MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress","Press releases","https://www.globenewswire.com/news-release/2023/10/11/2758532/0/en/MoonLake-Immunotherapeutics-presents-positive-12-week-data-from-the-Phase-2-MIRA-trial-with-Nanobody-Sonelokimab-for-Hidradenitis-Suppurativa-at-the-European-Academy-of-Dermatology.html","2023-10-11 10:15:00",-8.704661399393567
"ANAB","Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress","Clinical Study","https://www.globenewswire.com/news-release/2023/10/11/2758455/0/en/Anaptys-to-Present-Phase-1-Data-on-ANB032-its-BTLA-Agonist-Antibody-at-the-32nd-EADV-Congress.html","2023-10-11 09:15:00",-0.4062855131371331
"RVVTF","Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/11/2758381/0/en/Revive-Therapeutics-Provides-Update-of-Novel-Bucillamine-Formulation-Development.html","2023-10-11 08:50:00",-0.25314265243355805
"YTEN","Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/11/2758365/34378/en/Yield10-Bioscience-Provides-Update-on-Recent-Advancements-in-the-Development-of-Elite-Herbicide-Tolerant-Camelina.html","2023-10-11 08:31:00",2.777157367533997
"CDTX","Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023","Health","https://www.globenewswire.com/news-release/2023/10/11/2758360/0/en/Cidara-Therapeutics-Presents-New-Preclinical-and-Clinical-Data-on-Novel-Drug-Fc-Conjugate-CD388-at-IDWeek-2023.html","2023-10-11 08:30:00",2.337534699091731
"MYNZ","Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark","Clinical Study","https://www.globenewswire.com/news-release/2023/10/11/2758320/0/en/Mainz-Biomed-to-Showcase-ColoAlert-at-UEG-Week-2023-in-Copenhagen-Denmark.html","2023-10-11 08:01:00",0.16352360031198077
"NKGN","NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/11/2758282/0/en/NKGen-Announces-Poster-Presentation-at-the-XXVI-World-Congress-of-Neurology-WCN-Annual-Meeting-2023.html","2023-10-11 08:00:00",1.3291342766235623
"ELTX","Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/10/11/2758314/0/en/Elicio-Therapeutics-Announces-Upcoming-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-2023-Annual-Meeting.html","2023-10-11 08:00:00",-0.25314265243355805
"ECOR","electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/11/2758277/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html","2023-10-11 08:00:00",-0.6241998216715625
"VIR","Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/11/2758321/0/en/Vir-Biotechnology-Announces-Multiple-Abstracts-Highlighting-New-Chronic-Hepatitis-B-and-Hepatitis-Delta-Data-Accepted-for-Presentation-at-AASLD-s-The-Liver-Meeting-2023.html","2023-10-11 08:00:00",-1.1540426825580672
"RZLT","Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism","Clinical Study","https://www.globenewswire.com/news-release/2023/10/11/2758304/0/en/Rezolute-Announces-Further-Evidence-of-RZ358-s-Efficacy-in-Tumor-Mediated-Hyperinsulinism.html","2023-10-11 08:00:00",-1.2531416987592416
"FARON.HE","Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients","Health","https://www.globenewswire.com/news-release/2023/10/11/2758195/0/en/Inside-information-Faron-Announces-Positive-BEXMAB-Study-Update-in-Relapsed-Refractory-AML-and-HMA-Refractory-MDS-Patients.html","2023-10-11 07:00:00",5.898687169624417
"CCCC","C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma","Health","https://www.globenewswire.com/news-release/2023/10/11/2758207/0/en/C4-Therapeutics-Announces-Upcoming-Data-Presentations-for-CFT8634-an-Orally-Bioavailable-BiDAC-Degrader-in-Development-for-Synovial-Sarcoma-and-SMARCB1-Null-Tumors-and-CFT7455-an-O.html","2023-10-11 07:00:00",1.3341574331132997
"PYPD","PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/10/11/2758188/0/en/PolyPid-Regains-Compliance-with-Nasdaq-Minimum-Closing-Bid-Price-Rule.html","2023-10-11 07:00:00",-2.566771191271545
"TLSA","Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/11/2758192/0/en/Tiziana-Announces-Presentation-of-Six-Month-Safety-and-Biomarker-Data-for-Intranasal-Foralumab-in-Patients-with-Non-Active-Secondary-Progressive-Multiple-Sclerosis-na-SPMS-at-the-E.html","2023-10-11 07:00:00",-4.3627358319640495
"OXUR.BR","Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas","Press releases","https://www.globenewswire.com/news-release/2023/10/10/2757856/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-Atlas.html","2023-10-10 14:00:00",-8.06187118856591
"CAPR","Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society","Health","https://www.globenewswire.com/news-release/2023/10/10/2757546/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentations-at-28th-Annual-Congress-of-the-World-Muscle-Society.html","2023-10-10 09:00:00",-0.8697843923559259
"PCRX","Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/10/10/2757436/0/en/Pacira-BioSciences-Appoints-Four-New-Independent-Directors-to-its-Board-of-Directors.html","2023-10-10 08:00:00",0.21315759665180012
"OVID","Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/10/10/2757419/0/en/Ovid-Therapeutics-to-Present-at-the-Jefferies-Biotech-CNS-Neuro-Summit.html","2023-10-10 08:00:00",-0.4289118836626514
"ECOR","Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress","Clinical Study","https://www.globenewswire.com/news-release/2023/10/10/2757401/0/en/Data-Highlighting-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Acute-Neurological-Injury-Presented-at-2023-World-Stroke-Congress.html","2023-10-10 08:00:00",-1.9109223651024267
"TSHA","Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/10/2757443/0/en/Taysha-Gene-Therapies-Announces-Two-Poster-Presentations-on-TSHA-102-in-Rett-Syndrome-at-Upcoming-European-Society-of-Gene-Cell-Therapy-ESGCT-30th-Annual-Congress.html","2023-10-10 08:00:00",-2.0160304266921827
"RENB","Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/10/10/2757407/0/en/Renovaro-Biosciences-Appoints-Two-Finance-Industry-Experts-to-Board-of-Directors.html","2023-10-10 08:00:00",-5.897487173396
"BCAB","BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/10/10/2757357/0/en/BioAtla-Provides-Guidance-on-Near-Term-Milestones-and-Plans-to-Announce-Third-Quarter-2023-Financial-Results-and-Business-Update-on-November-7-2023.html","2023-10-10 07:30:00",-0.1503606106169882
"WINT","Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/10/10/2757356/0/en/Windtree-to-Participate-in-the-Lytham-Partners-Fall-2023-Investor-Conference-on-October-17th.html","2023-10-10 07:30:00",-2.629706862952899
"BTAI","BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer","Clinical Study","https://www.globenewswire.com/news-release/2023/10/10/2757315/0/en/BioXcel-Therapeutics-Reports-Positive-Overall-Survival-Results-from-Single-Arm-Open-Label-Phase-2-Trial-of-BXCL701-in-Patients-with-Small-Cell-Neuroendocrine-Prostate-Cancer.html","2023-10-10 07:00:00",1.674455160998201
"AKRO","Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins","Clinical Study","https://www.globenewswire.com/news-release/2023/10/10/2757329/0/en/Akero-Therapeutics-Reports-Encouraging-36-Week-Analysis-of-96-Week-Phase-2b-SYMMETRY-Study-with-a-Trend-on-Fibrosis-Improvement-and-Statistically-Significant-Results-for-NASH-Resol.html","2023-10-10 07:00:00",-59.21504857011549
"FBIO","Fortress Biotech Announces Reverse Stock Split","Changes in share capital and votes","https://www.globenewswire.com/news-release/2023/10/09/2756959/28889/en/Fortress-Biotech-Announces-Reverse-Stock-Split.html","2023-10-09 12:50:00",-13.222764083370627
"KA","Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/09/2756914/0/en/Kineta-to-Present-Preclinical-Data-on-VISTA-Blocking-KVA12123-at-Immuno-US-2023.html","2023-10-09 12:10:00",7.7509051077174025
"QGEN","QIAGEN N.V. to release results for Q3 2023 and hold webcast","Company Announcement","https://www.globenewswire.com/news-release/2023/10/09/2756849/8690/en/QIAGEN-N-V-to-release-results-for-Q3-2023-and-hold-webcast.html","2023-10-09 11:14:00",-1.897968783571243
"DYAI","Dyadic Appoints Doug Pace to Its Executive Leadership Team","Health","https://www.globenewswire.com/news-release/2023/10/09/2756672/0/en/Dyadic-Appoints-Doug-Pace-to-Its-Executive-Leadership-Team.html","2023-10-09 08:30:00",-1.9946709036283792
"ANAB","Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/09/2756658/0/en/Anaptys-to-Provide-Overview-of-Rosnilimab-a-PD-1-Agonist-at-Virtual-R-D-Event-on-Wednesday-Oct-25.html","2023-10-09 08:15:00",6.5342296711777506
"ANAB","Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/09/2756638/0/en/Anaptys-Announces-Positive-Top-Line-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html","2023-10-09 08:00:00",6.5342296711777506
"ELOX","Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria","Health","https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html","2023-10-09 08:00:00",-0.006655306127109281
"ECOR","electroCore to Announce Third Quarter Financial Results on Wednesday, November 8","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/10/09/2756628/0/en/electroCore-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-November-8.html","2023-10-09 08:00:00",-1.1537133778742599
"MDWD","MediWound Deploys NexoBrid® for Emergency Supply","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/09/2756602/30505/en/MediWound-Deploys-NexoBrid-for-Emergency-Supply.html","2023-10-09 07:34:00",-1.4924064480334416
"RAD.AX","RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer","Clinical Study","https://www.globenewswire.com/news-release/2023/10/09/2756594/0/en/RAD-receives-approval-for-Phase-1-therapeutic-study-of-PDL1-nanobody-in-Non-Small-Cell-Lung-Cancer.html","2023-10-09 07:27:00",0.4563071969234895
"PYPD","PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/09/2756567/0/en/PolyPid-Announces-Presentation-at-the-American-College-of-Surgeons-Clinical-Congress-2023.html","2023-10-09 07:00:00",5.60066683277008
"EYEN","Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®","Clinical Study","https://www.globenewswire.com/news-release/2023/10/09/2756566/0/en/Eyenovia-to-Present-Data-on-Preservative-Free-Microbial-Integrity-of-the-Optejet.html","2023-10-09 07:00:00",0.4563071969234895
"SPRY","ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)","Clinical Study","https://www.globenewswire.com/news-release/2023/10/06/2756120/0/en/ARS-Pharmaceuticals-Announces-Scheduling-of-a-Type-A-Meeting-with-the-U-S-FDA-for-neffy-epinephrine-nasal-spray.html","2023-10-06 09:03:00",-0.15588397939042983
"IMNN","IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board","Press releases","https://www.globenewswire.com/news-release/2023/10/06/2756080/0/en/IMUNON-Appoints-Dr-Patrick-Ott-to-its-Scientific-Advisory-Board.html","2023-10-06 08:30:00",0.5959950010122202
"ARQT","FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/06/2756044/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-Treatment-of-Psoriasis-in-Children-Ages-6-to-11.html","2023-10-06 08:00:00",1.7246675218329441
"OCUP","Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/10/06/2756040/0/en/Ocuphire-Pharma-to-Present-at-Euretina-and-Retina-Society-Conferences-in-October.html","2023-10-06 08:00:00",0.3061402089819797
"ADTX","Aditxt, Inc. to Present at 8th Annual Dawson James Conference","Advisory","https://www.globenewswire.com/news-release/2023/10/06/2756039/0/en/Aditxt-Inc-to-Present-at-8th-Annual-Dawson-James-Conference.html","2023-10-06 08:00:00",-1.7809128030473722
"IMCR","Immunocore announces upcoming presentation and posters at ESMO 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/10/06/2756007/0/en/Immunocore-announces-upcoming-presentation-and-posters-at-ESMO-2023.html","2023-10-06 07:01:00",-0.320654554678416
"ALVO","Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/05/2755706/0/is/Alvotech-og-%C3%8Dslandsbanki-gera-samning-um-vi%C3%B0skiptavakt-me%C3%B0-hlutabr%C3%A9f-%C3%AD-Kauph%C3%B6llinni.html","2023-10-05 13:21:00",-2.183529849238415
"ALVO","Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland","European Regulatory News","https://www.globenewswire.com/news-release/2023/10/05/2755706/0/en/Alvotech-and-Islandsbanki-enter-into-Market-Making-Agreement-for-Shares-Trading-on-Nasdaq-Iceland.html","2023-10-05 13:21:00",-2.183529849238415
"DYAI","Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases","Health","https://www.globenewswire.com/news-release/2023/10/05/2755390/0/en/Dyadic-s-C1-Platform-Selected-by-the-Vaccine-and-Immunotherapy-Center-VIC-at-Massachusetts-General-Hospital-as-Part-of-VIC-s-5-88-Million-Award-by-U-S-DoD-to-Develop-a-Self-Assembl.html","2023-10-05 08:30:00",6.01124931530613
"CHRS","Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/05/2755393/33333/en/Coherus-Announces-Resubmission-of-Biologics-License-Application-BLA-Supplement-for-UDENYCA-ONBODY.html","2023-10-05 08:30:00",2.5943059008057037
"FBIO","Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/05/2755404/28889/en/Fortress-Biotech-to-Present-at-ROTH-MKM-2023-Healthcare-Opportunities-Conference.html","2023-10-05 08:30:00",0.07064906229916382
"EVAX","Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/10/05/2755383/0/en/Evaxion-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html","2023-10-05 08:30:00",-3.338438614101799
"MYNZ","Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/05/2755334/0/en/Mainz-Biomed-to-Attend-the-JonesTrading-2023-Healthcare-Summit.html","2023-10-05 08:01:00",-1.6242645481444427
"ECOR","electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/05/2755341/0/en/electroCore-to-Participate-in-the-Lytham-Partners-Fall-2023-Virtual-Investor-Conference.html","2023-10-05 08:00:00",0.5453283685705305
"BIOR","Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes","Health","https://www.globenewswire.com/news-release/2023/10/05/2755345/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html","2023-10-05 08:00:00",0.5293642071171197
"SCPH","scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","Health","https://www.globenewswire.com/news-release/2023/10/05/2755310/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","2023-10-05 08:00:00",-0.40328037423750085
"MDAI","Spectral AI CEO, Wensheng Fan, to Participate in AI Healthcare Panel at Accelerate Health Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/05/2755344/0/en/Spectral-AI-CEO-Wensheng-Fan-to-Participate-in-AI-Healthcare-Panel-at-Accelerate-Health-Conference.html","2023-10-05 08:00:00",-2.461001569083767
"LGVN","Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease","Clinical Study","https://www.globenewswire.com/news-release/2023/10/05/2755238/0/en/Longeveron-Announces-Positive-Top-Line-Results-for-Lomecel-B-in-its-CLEAR-MIND-Phase-2a-Clinical-Trial-in-the-Treatment-of-Mild-Alzheimer-s-Disease.html","2023-10-05 07:00:00",6.046748502034498
"SCLX","Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company","Dividend Reports and Estimates","https://www.globenewswire.com/news-release/2023/10/04/2754860/0/en/Scilex-Holding-Company-Provides-Notice-to-All-Lenders-of-Short-Positions-in-the-Restricted-Dividend-Shares-of-Scilex-Holding-Company.html","2023-10-04 12:59:00",13.09603244447857
"CHRS","CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html","2023-10-04 08:30:00",1.0801785631306062
"KA","Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy","Clinical Study","https://www.globenewswire.com/news-release/2023/10/04/2754567/0/en/Kineta-Presents-New-Preclinical-Data-on-Lead-Anti-CD27-Agonist-Antibody-at-AACR-Special-Conference-on-Tumor-Immunology-and-Immunotherapy.html","2023-10-04 08:30:00",-28.21512616352691
"MYNZ","Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/04/2754535/0/en/Mainz-Biomed-Announces-Live-Launch-of-ColoAlert-with-Bioclinica-in-Romania.html","2023-10-04 08:01:00",0.9314462194599477
"AKRO","Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology","Clinical Study","https://www.globenewswire.com/news-release/2023/10/04/2754507/0/en/Akero-Therapeutics-Announces-Publication-of-the-Harmony-Phase-2b-Trial-Results-in-The-Lancet-Gastroenterology-Hepatology.html","2023-10-04 08:00:00",0.6446775026982334
"VBLT","VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting","Annual Meetings & Shareholder Rights","https://www.globenewswire.com/news-release/2023/10/04/2754511/0/en/VBL-Therapeutics-Reminds-Shareholders-to-Vote-in-the-Upcoming-Annual-and-Special-Shareholder-Meeting.html","2023-10-04 08:00:00",-2.837592437695356
"KA","Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/10/04/2754501/0/en/Kineta-Inc-Announces-3-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html","2023-10-04 08:00:00",-28.21512616352691
"MLTX","Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress","Company Announcement","https://www.globenewswire.com/news-release/2023/10/04/2754446/0/en/Phase-2-MIRA-primary-analysis-trial-results-12-week-for-MoonLake-s-Nanobody-sonelokimab-in-hidradenitis-suppurativa-to-be-presented-at-a-late-breaking-session-at-the-European-Acade.html","2023-10-04 07:01:00",0.024386751511750664
"OCGN","Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa","Trade Show","https://www.globenewswire.com/news-release/2023/10/04/2754419/0/en/Ocugen-to-Present-at-the-2023-Cell-Gene-Meeting-on-the-Mesa.html","2023-10-04 07:00:00",-0.11385729986425291
"PYPD","PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform","Clinical Study","https://www.globenewswire.com/news-release/2023/10/04/2754436/0/en/PolyPid-Announces-Publication-of-Preclinical-Data-Further-Supporting-the-Good-Safety-Profile-of-D-PLEX-and-PLEX-Technology-Platform.html","2023-10-04 07:00:00",-1.987391821255425
"BTAI","BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film","Clinical Study","https://www.globenewswire.com/news-release/2023/10/04/2754431/0/en/BioXcel-Therapeutics-Provides-Update-on-Recent-Developments-for-Late-Stage-Clinical-Programs-and-Expansion-of-IP-Portfolio-for-IGALMI-dexmedetomidine-Sublingual-Film.html","2023-10-04 07:00:00",-2.6779575126986925
"OXUR.BR","Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/10/03/2754019/0/en/Oxurion-Receives-Transparency-Notification-from-Atlas-Special-Opportunities-LLC.html","2023-10-03 13:00:00",-6.875947929276832
"SPRY","Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology","Clinical Study","https://www.globenewswire.com/news-release/2023/10/03/2753749/0/en/Single-and-Repeat-Dose-Clinical-Study-of-neffy-epinephrine-nasal-spray-Published-in-the-Journal-of-Allergy-and-Clinical-Immunology.html","2023-10-03 09:03:00",5.214051657863221
"SCLX","Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company","Changes in share capital and votes","https://www.globenewswire.com/news-release/2023/10/03/2753697/0/en/Scilex-Holding-Company-Provides-Notice-to-All-Record-Holders-and-Beneficial-Owners-of-Restricted-Shares-of-Scilex-Holding-Company.html","2023-10-03 09:00:00",-0.2253291433181667
"YTEN","Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/03/2753651/34378/en/Yield10-Bioscience-Completes-Harvest-of-a-Majority-of-the-2023-Winter-and-Spring-Camelina-Grain-Grown-Under-Contract-Generating-Revenue-from-Biofuel-Production.html","2023-10-03 08:31:00",3.5568498345881396
"KA","Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial","Clinical Study","https://www.globenewswire.com/news-release/2023/10/03/2753627/0/en/Kineta-Announces-Positive-KVA12123-Monotherapy-Safety-and-Biomarker-Data-from-its-Ongoing-Phase-1-2-VISTA-101-Clinical-Trial.html","2023-10-03 08:30:00",10.548828412426156
"WINT","Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th","Calendar of Events","https://www.globenewswire.com/news-release/2023/10/03/2753555/0/en/Windtree-to-Present-at-the-Dawson-James-Small-Cap-Growth-Conference-on-October-12th.html","2023-10-03 08:00:00",-2.4146239060416583
"VIR","Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats","Contests/Awards","https://www.globenewswire.com/news-release/2023/10/03/2753536/0/en/Vir-Biotechnology-Awarded-BARDA-Funding-to-Support-Development-of-Antibody-Platform-Technologies-for-Global-Infectious-Disease-Threats.html","2023-10-03 07:59:00",0.5265498146205847
"NSPR","InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives","Management Changes","https://www.globenewswire.com/news-release/2023/10/03/2753471/0/en/InspireMD-Announces-Senior-Leadership-Changes-to-Support-Commercial-Growth-Initiatives.html","2023-10-03 07:00:00",1.43563986987084
"NTLA","Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/10/03/2753456/0/en/Regeneron-and-Intellia-Announce-Expanded-Research-Collaboration-to-Develop-CRISPR-Based-Therapies-for-the-Treatment-of-Neurological-and-Muscular-Diseases.html","2023-10-03 07:00:00",0.42454135898930156
"RENB","Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/10/02/2753011/0/en/Message-from-Renovaro-Biosciences-CEO-The-Hon-Mark-Dybul-MD.html","2023-10-02 12:05:00",3.3624887294936943
"CHRS","Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day","Health","https://www.globenewswire.com/news-release/2023/10/02/2752800/33333/en/Coherus-Applauds-Congressional-Designation-of-September-30th-as-Rare-Cancer-Day.html","2023-10-02 09:00:00",1.805459250426065
"MDAI","Spectral AI Adds Healthcare Services Leader and Population Health Expert Deepak Sadagopan to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/10/02/2752696/0/en/Spectral-AI-Adds-Healthcare-Services-Leader-and-Population-Health-Expert-Deepak-Sadagopan-to-Board-of-Directors.html","2023-10-02 08:00:00",4.213655150296802
"PCRX","American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care","Partnerships","https://www.globenewswire.com/news-release/2023/10/02/2752709/0/en/American-Society-of-Anesthesiologists-and-Pacira-BioSciences-Inc-Announce-New-Grant-to-Advance-Education-and-Enhance-Patient-Care.html","2023-10-02 08:00:00",0.4293433814735169
"TGTX","TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/10/02/2752664/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-at-the-2023-European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-Annual-Meeting.html","2023-10-02 07:30:00",1.277739602958095
"KBLB","Kraig Biocraft Laboratories Announces Management Changes and Recalibration at Its Vietnam subsidiary, Prodigy Textiles, to Support Production of Spider Silk","Management Changes","https://www.globenewswire.com/news-release/2023/10/02/2752635/0/en/Kraig-Biocraft-Laboratories-Announces-Management-Changes-and-Recalibration-at-Its-Vietnam-subsidiary-Prodigy-Textiles-to-Support-Production-of-Spider-Silk.html","2023-10-02 07:05:00",0.20118270960934603
"OXUR.BR","Oxurion Publishes First Half 2023 Results","Press releases","https://www.globenewswire.com/news-release/2023/09/29/2752222/0/en/Oxurion-Publishes-First-Half-2023-Results.html","2023-09-29 13:00:00",-6.7216541485422105
"RENB","Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/09/29/2752032/0/en/Renovaro-Biosciences-and-AI-Health-Company-GEDi-Cube-Sign-Definitive-Agreement-to-Combine.html","2023-09-29 09:15:00",-5.403399804046233
"DYAI","Dyadic to Present at Industry and Investor Events in October","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/29/2751979/0/en/Dyadic-to-Present-at-Industry-and-Investor-Events-in-October.html","2023-09-29 08:30:00",-0.7350939267297514
"INAB","IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/09/29/2751940/0/en/IN8bio-Announces-Presentations-at-the-Society-for-Immunology-of-Cancer-SITC-38th-Annual-Meeting.html","2023-09-29 08:00:00",-2.53689398697877
"CAPR","Capricor Therapeutics Announces $23 Million Registered Direct Offering","Partnerships","https://www.globenewswire.com/news-release/2023/09/29/2751922/0/en/Capricor-Therapeutics-Announces-23-Million-Registered-Direct-Offering.html","2023-09-29 07:35:00",-34.583894767339565
"OCGN","Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/29/2751917/0/en/Ocugen-CSO-to-Participate-in-4th-Annual-Gene-Therapy-for-Ophthalmic-Disorders-Conference.html","2023-09-29 07:30:00",0.49947279349524504
"CAPR","Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/29/2751919/0/en/Capricor-Therapeutics-Announces-Positive-Type-B-Meeting-with-the-FDA-to-Discuss-Pathway-to-BLA-for-CAP-1002-in-Duchenne-Muscular-Dystrophy.html","2023-09-29 07:30:00",-34.583894767339565
"MDAI","Spectral MD Awarded BARDA Project BioShield Contract Valued at $149 Million for AI-Driven DeepView® Burn Wound Imaging Technology","Financing Agreements","https://www.globenewswire.com/news-release/2023/09/28/2751374/0/en/Spectral-MD-Awarded-BARDA-Project-BioShield-Contract-Valued-at-149-Million-for-AI-Driven-DeepView-Burn-Wound-Imaging-Technology.html","2023-09-28 10:01:00",-8.655657671640885
"KA","Kineta Announces Participation at October Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/28/2751321/0/en/Kineta-Announces-Participation-at-October-Investor-Conferences.html","2023-09-28 09:30:00",10.714087254231492
"IMNN","IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer","Press releases","https://www.globenewswire.com/news-release/2023/09/28/2751209/0/en/IMUNON-Reports-Interim-Progression-Free-Survival-and-Overall-Survival-Data-in-Phase-1-2-OVATION-2-Study-in-Advanced-Ovarian-Cancer.html","2023-09-28 08:30:00",-2.8073920464523154
"QGEN","Les spécialistes du rein en Tunisie recommandent l'utilisation des solutions QuantiFERON de QIAGEN","Health","https://www.globenewswire.com/news-release/2023/09/28/2751121/0/fr/Les-sp%C3%A9cialistes-du-rein-en-Tunisie-recommandent-l-utilisation-des-solutions-QuantiFERON-de-QIAGEN.html","2023-09-28 07:52:00",0.3111307815302027
"QGEN","QIAGEN’s QuantiFERON solutions recommended for use by kidney specialists in Tunisia","Health","https://www.globenewswire.com/news-release/2023/09/28/2751121/0/en/QIAGEN-s-QuantiFERON-solutions-recommended-for-use-by-kidney-specialists-in-Tunisia.html","2023-09-28 07:52:00",0.3111307815302027
"OXUR.BR","Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/09/27/2750673/0/en/Oxurion-Receives-Transparency-Notification-from-Atlas-Special-Opportunities-LLC.html","2023-09-27 13:00:00",-6.899343182288402
"CHRS","Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","Health","https://www.globenewswire.com/news-release/2023/09/27/2750480/33333/en/Coherus-Announces-Three-Presentations-at-the-38th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html","2023-09-27 09:10:00",0.4696585300382859
"SCLX","Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)","Regulatory information","https://www.globenewswire.com/news-release/2023/09/27/2750433/0/en/Scilex-Holding-Company-Submits-a-Request-to-the-Securities-and-Exchange-Commission-to-Withdraw-its-Registration-Statement-on-Form-S-1-File-No-333-271401.html","2023-09-27 09:00:00",-2.2071907417628855
"MYNZ","Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/27/2750324/0/en/Mainz-Biomed-to-Present-Detailed-Results-of-ColoFuture-Study-at-International-Conference-on-Gastroenterology.html","2023-09-27 08:01:00",-3.776183207029408
"ECOR","gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/27/2750322/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Working-Memory-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html","2023-09-27 08:00:00",0.789228624334281
"OCUP","Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/27/2750331/0/en/Ocuphire-Pharma-and-Viatris-Announce-FDA-Approval-of-RYZUMVI-Phentolamine-Ophthalmic-Solution-0-75-Eye-Drops-for-the-Treatment-of-Pharmacologically-Induced-Mydriasis-Produced-by-Ad.html","2023-09-27 08:00:00",0.4621582972333435
"CDTX","Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/27/2750330/0/en/Cidara-Therapeutics-to-Present-New-Data-on-Novel-drug-Fc-conjugate-CD388-at-IDWeek-2023.html","2023-09-27 08:00:00",-0.9984042505887802
"ARQT","Arcutis Appoints L. Todd Edwards as Chief Commercial Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/09/27/2750305/0/en/Arcutis-Appoints-L-Todd-Edwards-as-Chief-Commercial-Officer.html","2023-09-27 08:00:00",-1.4847964696201703
"DYAI","Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells","Partnerships","https://www.globenewswire.com/news-release/2023/09/26/2749502/0/en/Dyadic-and-bYoRNA-Announce-a-Collaboration-Targeting-the-Production-of-Abundant-Low-Cost-mRNA-From-C1-Cells.html","2023-09-26 08:30:00",1.6880060268492827
"IMNN","IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies","Press releases","https://www.globenewswire.com/news-release/2023/09/26/2749511/0/en/IMUNON-Releases-Enterprise-Video-Highlighting-the-Company-s-Mission-Vision-Values-Breakthroughs-and-Technologies.html","2023-09-26 08:30:00",0.7264684470363678
"BMRA","Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test","Clinical Study","https://www.globenewswire.com/news-release/2023/09/26/2749488/0/en/Dubai-Government-Grants-Insurance-Reimbursement-for-Biomerica-s-EZ-Detect-Colorectal-Disease-Screening-Test.html","2023-09-26 08:19:00",5.580844458145285
"INAB","IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/09/26/2749460/0/en/IN8bio-to-Host-Research-Development-Day-on-its-Gamma-Delta-T-cell-Therapies-on-Thursday-October-12-2023-in-New-York-City.html","2023-09-26 08:00:00",4.0878096175954015
"ECOR","electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology","Patents","https://www.globenewswire.com/news-release/2023/09/26/2749414/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html","2023-09-26 08:00:00",1.1959538228655495
"TSHA","Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/09/26/2749398/0/en/Taysha-Gene-Therapies-Announces-Second-Patient-Dosed-with-TSHA-102-in-the-REVEAL-Phase-1-2-Adult-Trial-for-the-Treatment-of-Rett-Syndrome.html","2023-09-26 08:00:00",-4.34110227709562
"OVID","Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/26/2749357/0/en/Ovid-Therapeutics-to-Host-Investor-Event-R-D-Day-on-Monday-October-2-2023.html","2023-09-26 07:30:00",0.7264684470363678
"TLSA","Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis","Clinical Study","https://www.globenewswire.com/news-release/2023/09/26/2749323/0/en/Tiziana-Life-Sciences-Initiates-Multi-Center-Phase-2a-Clinical-Trial-of-Intranasal-Foralumab-for-Non-Active-Secondary-Progressive-Multiple-Sclerosis.html","2023-09-26 07:00:00",3.7567684670039228
"MDWD","MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/26/2749330/30505/en/MediWound-Secures-Additional-U-S-Department-of-Defense-Funding-to-Advance-NexoBrid-Development-for-the-U-S-Army.html","2023-09-26 07:00:00",2.579392779578288
"KA","Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy","Health","https://www.globenewswire.com/news-release/2023/09/25/2748721/0/en/Kineta-to-Present-New-Preclinical-Data-on-Lead-Anti-CD27-Agonist-Antibody-at-AACR-Special-Conference-on-Tumor-Immunology-and-Immunotherapy.html","2023-09-25 09:30:00",5.697257141248417
"ARQT","New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis","Health","https://www.globenewswire.com/news-release/2023/09/25/2748693/0/en/New-Campaign-from-Arcutis-Aims-to-Educate-Raise-Awareness-and-Provide-Encouragement-for-Those-Living-with-Seborrheic-Dermatitis.html","2023-09-25 09:00:00",2.892641951396264
"SCLX","Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/25/2748673/0/en/Scilex-Holding-Company-announces-the-State-of-Indiana-Medicaid-will-add-Elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-PDL-effective-October-1-2023.html","2023-09-25 09:00:00",-0.9754150829785577
"CHRS","FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/25/2748635/33333/en/FDA-Issues-Complete-Response-Letter-CRL-for-UDENYCA-ONBODY-Biologics-License-Application-Solely-Due-to-an-Ongoing-Review-of-Inspection-Findings-at-a-Third-Party-Filler-Coherus-Also.html","2023-09-25 08:30:00",-1.9517363037484057
"BIOR","Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program","Health","https://www.globenewswire.com/news-release/2023/09/25/2748572/0/en/Biora-Therapeutics-Announces-Submission-of-IND-Application-to-the-U-S-FDA-for-BT-600-Program.html","2023-09-25 08:00:00",0.2904140051586773
"ECOR","electroCore to Participate in the LD Micro Main Event XVI Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/25/2748582/0/en/electroCore-to-Participate-in-the-LD-Micro-Main-Event-XVI-Conference.html","2023-09-25 08:00:00",-1.4013181317556074
"FARON.HE","Faron Pharmaceuticals Announces Board Changes","Directors and Officers","https://www.globenewswire.com/news-release/2023/09/22/2748072/0/en/Faron-Pharmaceuticals-Announces-Board-Changes.html","2023-09-22 11:00:00",-0.6963808060218474
"TGTX","TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/22/2747901/8790/en/TG-Therapeutics-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html","2023-09-22 07:30:00",-0.029495593048501755
"PYPD","PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/22/2747883/0/en/PolyPid-to-Present-at-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html","2023-09-22 07:00:00",5.76353373618901
"EYEN","Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/21/2747224/0/en/Eyenovia-to-Participate-in-Panel-Discussion-at-Cantor-Global-Healthcare-Conference.html","2023-09-21 08:00:00",-0.5345641072753061
"ECOR","electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/21/2747197/0/en/electroCore-to-Present-at-iAccess-Alpha-s-Top-10-Best-Ideas-from-the-Buyside-Virtual-Conference.html","2023-09-21 08:00:00",-2.6385662940141126
"PYPD","PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/21/2747174/0/en/PolyPid-Announces-Successful-Commercial-Good-Manufacturing-Practice-GMP-Audit-by-Israeli-Ministry-of-Health.html","2023-09-21 07:34:00",0.3981454574890655
"OCGN","Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board","Management Changes","https://www.globenewswire.com/news-release/2023/09/21/2747171/0/en/Ocugen-Inc-Announces-Connie-Collingsworth-Joins-Business-Advisory-Board.html","2023-09-21 07:30:00",-0.5923710202797723
"ORPHA.CO","New CEO appointed","European Regulatory News","https://www.globenewswire.com/news-release/2023/09/20/2746819/0/da/New-CEO-appointed.html","2023-09-20 14:52:00",3.3046763685142326
"MYCO.CN","Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/09/20/2746742/0/en/Mydecine-Innovations-Announces-Amended-Press-Release-Relating-to-the-Closing-of-Prospectus-Supplement-Financing.html","2023-09-20 12:12:00",-4.6729249411562686
"MYCOF","Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/09/20/2746742/0/en/Mydecine-Innovations-Announces-Amended-Press-Release-Relating-to-the-Closing-of-Prospectus-Supplement-Financing.html","2023-09-20 12:12:00",-21.37121212936707
"PYPD","PolyPid Announces Reverse Share Split","Stock Market News","https://www.globenewswire.com/news-release/2023/09/20/2746559/0/en/PolyPid-Announces-Reverse-Share-Split.html","2023-09-20 09:15:00",24.084455030099026
"EVAX","Evaxion s'associe à la société pharmaceutique Afrigen Biologics pour développer un nouveau vaccin à ARN messager contre la gonorrhée","Partnerships","https://www.globenewswire.com/news-release/2023/09/20/2755536/0/fr/Evaxion-s-associe-%C3%A0-la-soci%C3%A9t%C3%A9-pharmaceutique-Afrigen-Biologics-pour-d%C3%A9velopper-un-nouveau-vaccin-%C3%A0-ARN-messager-contre-la-gonorrh%C3%A9e.html","2023-09-20 08:26:00",14.914680250325427
"EVAX","Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea","Partnerships","https://www.globenewswire.com/news-release/2023/09/20/2746452/0/en/Evaxion-Partners-With-Pharmaceutical-Company-Afrigen-Biologics-to-Develop-Novel-mRNA-Vaccine-Against-Gonorrhea.html","2023-09-20 08:26:00",14.914680250325427
"EVAX","Evaxion geht Partnerschaft mit dem Pharmaunternehmen Afrigen Biologics zur Entwicklung eines neuartigen mRNA-Impfstoffs gegen Gonorrhoe ein","Partnerships","https://www.globenewswire.com/news-release/2023/09/20/2755536/0/de/Evaxion-geht-Partnerschaft-mit-dem-Pharmaunternehmen-Afrigen-Biologics-zur-Entwicklung-eines-neuartigen-mRNA-Impfstoffs-gegen-Gonorrhoe-ein.html","2023-09-20 08:26:00",14.914680250325427
"INAB","IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/20/2746419/0/en/IN8bio-to-Participate-at-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html","2023-09-20 08:00:00",5.53159880357257
"OCGN","Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023","Trade Show","https://www.globenewswire.com/news-release/2023/09/20/2746430/0/en/Ocugen-to-Participate-in-Panel-at-Cantor-Fitzgerald-Global-Healthcare-Conference-2023.html","2023-09-20 08:00:00",-0.04489708494302604
"VIR","Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV","Clinical Study","https://www.globenewswire.com/news-release/2023/09/20/2746429/0/en/Vir-Biotechnology-Announces-First-Participant-Dosed-in-New-Phase-1-Trial-Evaluating-VIR-1388-an-Investigational-T-Cell-Vaccine-for-the-Prevention-of-HIV.html","2023-09-20 08:00:00",-0.5982255821581791
"SNCE","Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List","Contests/Awards","https://www.globenewswire.com/news-release/2023/09/20/2746374/0/en/Science-37-Chief-Delivery-Officer-Darcy-Forman-Named-to-Prestigious-PharmaVoice-100-List.html","2023-09-20 07:59:00",1.4505307634915354
"OVID","Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/20/2746343/0/en/Ovid-Therapeutics-to-Present-at-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html","2023-09-20 07:30:00",-0.033910076547976654
"TTOO","T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/19/2745682/32489/en/T2-Biosystems-Receives-FDA-510-k-Clearance-for-the-T2Biothreat-Panel.html","2023-09-19 09:00:00",-12.639888232885877
"CERT","Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software","Management statements","https://www.globenewswire.com/news-release/2023/09/19/2745582/0/en/Certara-Announces-300th-Regulatory-Submission-Milestone-Using-its-Technology-enabled-Services-and-Software.html","2023-09-19 08:15:00",0.28567756302210706
"INAB","IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/19/2745569/0/en/IN8bio-Strengthens-Intellectual-Property-Portfolio-with-Newly-Granted-Global-Patents.html","2023-09-19 08:03:00",2.7246105815189114
"BIOR","Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure","Interim information","https://www.globenewswire.com/news-release/2023/09/19/2745527/0/en/Biora-Therapeutics-Reduces-Debt-and-Largest-Shareholder-Increases-Equity-Exposure.html","2023-09-19 08:00:00",5.955778127242005
"AKYA","Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/19/2745518/0/en/Akoya-Biosciences-Sets-a-New-Standard-for-Scaling-Spatial-Biology-with-the-Launch-of-2-0-Platforms.html","2023-09-19 08:00:00",1.1575517890529736
"SCPH","scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/19/2745542/0/en/scPharmaceuticals-Announces-Positive-Feedback-from-Two-FDA-Meetings-on-Key-Long-Term-Growth-Initiatives.html","2023-09-19 08:00:00",0.21414516524467306
"ELOX","Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","Prospectus/Announcement of Prospectus","https://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","2023-09-19 08:00:00",0.030990791399103684
"DYAI","Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™","Licensing Agreements","https://www.globenewswire.com/news-release/2023/09/19/2745544/0/en/Dyadic-Announces-Development-and-License-Agreement-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html","2023-09-19 08:00:00",-1.4162945116489194
"ARQT","Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5","Clinical Study","https://www.globenewswire.com/news-release/2023/09/19/2745482/0/en/Arcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html","2023-09-19 07:30:00",-0.8744970850352184
"PYPD","PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/19/2745456/0/en/PolyPid-Announces-Successful-Completion-of-Manufacturing-Process-Validation-for-D-PLEX.html","2023-09-19 07:00:00",23.532529760710357
"KA","Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression","Health","https://www.globenewswire.com/news-release/2023/09/18/2744896/0/en/Kineta-Announces-New-Research-Agreement-to-Evaluate-VISTA-Biomarker-Expression.html","2023-09-18 09:30:00",-0.5813646084094017
"EVAX","Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company","Partnerships","https://www.globenewswire.com/news-release/2023/09/18/2744760/0/en/Evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company.html","2023-09-18 08:23:00",-2.85334992005454
"ELOX","Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html","2023-09-18 07:00:00",1.9429185586350448
"HARP","Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort","Clinical Study","https://www.globenewswire.com/news-release/2023/09/15/2743899/0/en/Harpoon-Therapeutics-Announces-First-Patients-with-Small-Cell-Lung-Cancer-Dosed-in-HPN328-Combination-Cohort.html","2023-09-15 07:15:00",1.0853470973601786
"SCLX","Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)","Clinical Study","https://www.globenewswire.com/news-release/2023/09/14/2743321/0/en/Scilex-Holding-Company-Announces-the-Completion-of-its-SP-103-lidocaine-topical-system-5-4-Triple-Strength-Formulation-of-ZTlido-Phase-2-trial-which-achieved-its-objectives-to-Eval.html","2023-09-14 09:00:00",0.3235252592587823
"SCLX","Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/09/13/2742513/0/en/Scilex-Holding-Company-Enters-into-Non-Binding-Term-Sheets-for-the-Purchase-of-all-of-the-Scilex-Common-Shares-Preferred-Shares-and-Warrants-Currently-Owned-by-Sorrento-Therapeutic.html","2023-09-13 09:00:00",1.1779338678316202
"IMNN","IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET","Press releases","https://www.globenewswire.com/news-release/2023/09/13/2742458/0/en/IMUNON-Reminds-Investors-of-its-Virtual-R-D-Day-Tomorrow-at-4-00-p-m-ET.html","2023-09-13 08:30:00",-0.9287652844131575
"OCGN","Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/13/2742453/0/en/Ocugen-Announces-Positive-Clinical-Study-Update-from-the-Phase-1-2-Trial-of-OCU400-a-Modifier-Gene-Therapy-Product-Candidate-for-the-Treatment-of-Retinitis-Pigmentosa-RP-and-Leber-.html","2023-09-13 08:15:00",4.2341428814717545
"SNCE","Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023","Contests/Awards","https://www.globenewswire.com/news-release/2023/09/13/2742398/0/en/Science-37-Recognized-in-the-Gartner-Hype-Cycle-for-Life-Science-Clinical-Development-2023.html","2023-09-13 07:59:00",1.0595346722359642
"ANAB","AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/12/2741776/0/en/AnaptysBio-to-Present-at-the-Stifel-2023-Immunology-and-Inflammation-Virtual-Summit.html","2023-09-12 09:15:00",0.23290871542919486
"SCLX","Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/09/12/2741736/0/en/Scilex-Holding-Company-Presented-Oral-and-Poster-Presentations-on-ZTlido-lidocaine-topical-system-at-the-2023-Annual-PAINWeek-Conference-Held-in-Las-Vegas-NV.html","2023-09-12 09:00:00",2.824109533835312
"SCLX","Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/12/2741728/0/en/Scilex-Holding-Company-Presented-Oral-and-Poster-Presentations-on-Elyxyb-at-the-2023-Annual-Brain-Week-Conference-Held-in-Las-Vegas-NV.html","2023-09-12 09:00:00",2.824109533835312
"EVAX","Révolutionner la découverte de vaccins : De nouvelles données valident la plateforme d'intelligence artificielle d'Evaxion, promettant de réduire les risques et les coûts dans le développement de vaccins contre les maladies infectieuses","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/09/12/2741564/0/fr/R%C3%A9volutionner-la-d%C3%A9couverte-de-vaccins-De-nouvelles-donn%C3%A9es-valident-la-plateforme-d-intelligence-artificielle-d-Evaxion-promettant-de-r%C3%A9duire-les-risques-et-les-co%C3%BBts-dans-le-d%C3%A9ve.html","2023-09-12 07:59:00",2.7672630797412214
"EVAX","Revolution in der Entdeckung von Impfstoffen: Neue Daten validieren die KI-Plattform von Evaxion und versprechen Senkung der Risiken und Kosten bei der Entwicklung von Impfstoffen gegen Infektionskrankheiten","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/09/12/2741564/0/de/Revolution-in-der-Entdeckung-von-Impfstoffen-Neue-Daten-validieren-die-KI-Plattform-von-Evaxion-und-versprechen-Senkung-der-Risiken-und-Kosten-bei-der-Entwicklung-von-Impfstoffen-g.html","2023-09-12 07:59:00",2.7672630797412214
"SNCE","Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan","Other News","https://www.globenewswire.com/news-release/2023/09/12/2741563/0/en/Science-37-Named-Market-Leader-for-Global-Decentralized-Clinical-Trials-by-Frost-Sullivan.html","2023-09-12 07:59:00",-0.03865519459853063
"ARQT","Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older","Regulatory information","https://www.globenewswire.com/news-release/2023/09/12/2741541/0/en/Arcutis-Submits-Roflumilast-Cream-0-15-Supplemental-New-Drug-Application-to-the-FDA-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Ages-6-Years-and-Older.html","2023-09-12 07:30:00",0.46285808430574993
"MDAI","Artificial Intelligence-Driven Predictive Medical Diagnostics Company Spectral MD Announces Closing of Business Combination","Stock Market News","https://www.globenewswire.com/news-release/2023/09/11/2741116/0/en/Artificial-Intelligence-Driven-Predictive-Medical-Diagnostics-Company-Spectral-MD-Announces-Closing-of-Business-Combination.html","2023-09-11 13:29:00",-5.132990218308586
"OCUP","Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/11/2740925/0/en/Ocuphire-Pharma-to-Participate-in-Three-Upcoming-Investment-Bank-Conferences.html","2023-09-11 09:41:00",0.9506504213387057
"SCLX","Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information","Pre-Release Comments","https://www.globenewswire.com/news-release/2023/09/11/2740873/0/en/Scilex-Holding-Company-Generates-Record-Monthly-Revenue-In-August-2023-And-Provides-Certain-Preliminary-Unaudited-Financial-Results-For-Gross-And-Net-Sales-For-The-One-Month-Ended-.html","2023-09-11 09:00:00",1.7516796825976584
"CNTG","CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/11/2740822/0/en/CENTOGENE-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-11 08:30:00",-5.155983773773755
"EVAX","Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/09/11/2740790/0/en/Revolutionizing-Vaccine-Discovery-New-Data-Validates-Evaxion-AI-Platform-Offering-Promise-to-Reduce-Risk-and-Cost-in-Infectious-Disease-Vaccine-Development.html","2023-09-11 08:17:00",2.02877441398122
"BIOR","Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/11/2740775/0/en/Biora-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-11 08:01:00",1.1316441695138666
"MDWD","MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/11/2740747/30505/en/MediWound-s-NexoBrid-Highlighted-in-20-Oral-and-Poster-Presentations-at-the-20th-European-Burns-Association-Congress.html","2023-09-11 08:00:00",0.9632988414389771
"LGVN","Longeveron Issues Letter to Stockholders","Management statements","https://www.globenewswire.com/news-release/2023/09/11/2740742/0/en/Longeveron-Issues-Letter-to-Stockholders.html","2023-09-11 08:00:00",-1.0254601733574107
"CHRS","Coherus Completes Surface Oncology Acquisition","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/09/08/2740124/33333/en/Coherus-Completes-Surface-Oncology-Acquisition.html","2023-09-08 09:05:00",1.215755728877801
"TLSA","Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/08/2739983/0/en/Tiziana-Life-Sciences-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-08 07:00:00",-2.750968507528474
"OXUR.BR","Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas","Press releases","https://www.globenewswire.com/news-release/2023/09/07/2739686/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-Atlas.html","2023-09-07 13:00:00",-7.059354520864229
"ELOX","Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013","Clinical Study","https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html","2023-09-07 09:00:00",7.921296573522307
"ONCT","Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board","Directors and Officers","https://www.globenewswire.com/news-release/2023/09/07/2739424/0/en/Oncternal-Therapeutics-Announces-its-Prostate-Cancer-Scientific-Advisory-Board.html","2023-09-07 09:00:00",4.145252126204005
"OCUP","Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739442/0/en/Ocuphire-Pharma-to-Present-at-ESCRS-2023-and-MODLive-Conferences-in-September.html","2023-09-07 09:00:00",2.791214295176228
"YTEN","Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/07/2739369/34378/en/Yield10-Bioscience-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-07 08:31:00",-4.431231248887761
"FBIO","Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739367/28889/en/Fortress-Biotech-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-07 08:30:00",-1.8671350593343017
"ARQT","Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)","Clinical Study","https://www.globenewswire.com/news-release/2023/09/07/2739327/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-15-Showing-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Mild-to-Moderate.html","2023-09-07 08:15:00",5.213103131229201
"ELTX","Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/09/07/2739266/0/en/Elicio-Therapeutics-Receives-2-6-Million-Grant-from-the-Gastro-Intestinal-GI-Research-Foundation-to-Fund-Research-for-Two-Therapeutic-Cancer-Vaccines.html","2023-09-07 08:00:00",3.6450825434720606
"EYEN","Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739251/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-07 08:00:00",1.2317280237200234
"ECOR","electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739252/0/en/electroCore-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-07 08:00:00",0.6132852517480597
"LGVN","Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739261/0/en/Long-term-Survival-Data-from-Longeveron-s-ELPIS-1-Trial-Accepted-for-Presentation-at-the-2023-Scientific-Sessions-of-the-American-Heart-Association.html","2023-09-07 08:00:00",-1.0124309651085093
"CDTX","Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739260/0/en/Cidara-Therapeutics-to-Host-Virtual-Research-Development-Day-on-its-Cloudbreak-Development-Pipeline-on-September-21-2023.html","2023-09-07 08:00:00",-1.7030297264934193
"TGTX","TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/07/2739207/8790/en/TG-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-07 07:30:00",-0.4795024268114302
"CAPR","Capricor Therapeutics Appoints Michael Kelliher to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/09/06/2738485/0/en/Capricor-Therapeutics-Appoints-Michael-Kelliher-to-Board-of-Directors.html","2023-09-06 09:00:00",0.6755844243833076
"CDTX","Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza","Business Contracts","https://www.globenewswire.com/news-release/2023/09/06/2738348/0/en/Cidara-Therapeutics-Announces-Janssen-s-Election-to-Proceed-Under-its-License-Agreement-Relating-to-Novel-Drug-Fc-Conjugates-Targeting-Influenza.html","2023-09-06 08:00:00",18.724184417894804
"ELTX","Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738299/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-06 08:00:00",7.083532590235425
"VBLT","VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/09/06/2738347/0/en/VBL-Therapeutics-Announces-that-S-4-Registration-Statement-for-Proposed-Merger-with-Notable-Labs-Is-Declared-Effective-by-SEC.html","2023-09-06 08:00:00",4.9263207851682775
"PEPG","PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences","Clinical Study","https://www.globenewswire.com/news-release/2023/09/06/2738306/0/en/PepGen-Inc-Presents-PGN-EDODM1-Preclinical-Data-Supporting-the-Company-s-Enhanced-Delivery-Oligonucleotide-Platform-and-PGN-EDODM1-Program-at-Two-Medical-Conferences.html","2023-09-06 08:00:00",1.0431411103302877
"BCAB","BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/06/2738343/0/en/BioAtla-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-06 08:00:00",0.9806316909237608
"PCRX","Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738334/0/en/Pacira-BioSciences-Announces-Fireside-Chat-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-06 08:00:00",0.7335939915938207
"INAB","IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738317/0/en/IN8bio-to-Participate-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html","2023-09-06 08:00:00",-0.7838912393279008
"IMRX","Immuneering to Present at the Morgan Stanley Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738329/0/en/Immuneering-to-Present-at-the-Morgan-Stanley-Healthcare-Conference.html","2023-09-06 08:00:00",-0.9584872297299722
"HARP","Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738263/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Poster-Presentation-at-the-20th-International-Myeloma-Society-Annual-Meeting.html","2023-09-06 07:30:00",3.2458078702895783
"BCDA","BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs","Clinical Study","https://www.globenewswire.com/news-release/2023/09/06/2738243/0/en/BioCardia-Announces-Clarification-and-Next-Steps-on-its-Autologous-CardiAMP-Cell-Therapy-Programs.html","2023-09-06 07:15:00",-4.985427360989219
"TLSA","Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance","Clinical Study","https://www.globenewswire.com/news-release/2023/09/06/2738217/0/en/Study-Validating-MoA-of-Intranasal-Foralumab-in-Alzheimer-s-Disease-Published-in-the-Prestigious-Journal-PNAS-Following-FDA-IND-Clearance.html","2023-09-06 07:00:00",1.502769883510882
"MLTX","MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11","Company Announcement","https://www.globenewswire.com/news-release/2023/09/06/2738194/0/en/MoonLake-Immunotherapeutics-to-host-a-Capital-Markets-Day-on-Monday-September-11.html","2023-09-06 07:00:00",0.4048046389455053
"RZLT","Rezolute to Participate in Upcoming Investor Conferences in September","Calendar of Events","https://www.globenewswire.com/news-release/2023/09/06/2738189/0/en/Rezolute-to-Participate-in-Upcoming-Investor-Conferences-in-September.html","2023-09-06 07:00:00",-0.5123184098954242
"ALVO","Alvotech Announces Changes to the Leadership Team","Management Changes","https://www.globenewswire.com/news-release/2023/09/05/2737492/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html","2023-09-05 09:30:00",-0.07305287425934913
"ALVO","Alvotech Announces Changes to the Leadership Team","European Regulatory News","https://www.globenewswire.com/news-release/2023/09/05/2737491/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html","2023-09-05 09:30:00",-0.07305287425934913
"ALVO","Alvotech tilkynnir um breytingar í framkvæmdastjórn","European Regulatory News","https://www.globenewswire.com/news-release/2023/09/05/2737491/0/is/Alvotech-tilkynnir-um-breytingar-%C3%AD-framkv%C3%A6mdastj%C3%B3rn.html","2023-09-05 09:30:00",-0.07305287425934913
"OXUR.BR","Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas","Press releases","https://www.globenewswire.com/news-release/2023/09/01/2736244/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-Atlas.html","2023-09-01 13:00:00",-11.327781747437935
"OXUR.BR","Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/09/01/2736245/0/en/Oxurion-Receives-Transparency-Notification-from-Atlas-Special-Opportunities-LLC.html","2023-09-01 13:00:00",-11.327781747437935
"PEPG","PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/09/01/2735983/0/en/PepGen-Announces-Presentations-at-the-2023-Myotonic-Dystrophy-Foundation-Annual-Conference-Ottawa-Neuromuscular-Disease-Meeting-and-H-C-Wainwright-25th-Annual-Global-Investment-Con.html","2023-09-01 08:00:00",1.5960387797554214
"CNTG","CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients","Clinical Study","https://www.globenewswire.com/news-release/2023/09/01/2735986/0/en/CENTOGENE-Announces-Publication-Establishing-Lyso-Gb1-as-a-Predictive-Biomarker-for-Gaucher-Disease-Patients.html","2023-09-01 08:00:00",0.2141540367277611
"VALN","Valneva participera à différentes conférences investisseurs aux Etats-Unis et en Europe en septembre 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/08/31/2735615/0/fr/Valneva-participera-%C3%A0-diff%C3%A9rentes-conf%C3%A9rences-investisseurs-aux-Etats-Unis-et-en-Europe-en-septembre-2023.html","2023-08-31 13:00:00",0.1449703879196797
"VALN","Valneva to Participate in Investor Conferences in the United States and Europe in September 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/08/31/2735615/0/en/Valneva-to-Participate-in-Investor-Conferences-in-the-United-States-and-Europe-in-September-2023.html","2023-08-31 13:00:00",0.1449703879196797
"KA","Kineta to Participate in Upcoming Investor Conferences","Trade Show","https://www.globenewswire.com/news-release/2023/08/31/2735375/0/en/Kineta-to-Participate-in-Upcoming-Investor-Conferences.html","2023-08-31 09:30:00",-1.0018528537487659
"ARQT","Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report","Environmental, Social, and Governance Criteria","https://www.globenewswire.com/news-release/2023/08/31/2735212/0/en/Arcutis-Biotherapeutics-Publishes-Annual-Environmental-Social-and-Governance-ESG-Report.html","2023-08-31 08:00:00",-0.029926242876150852
"NSPR","InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23","Health","https://www.globenewswire.com/news-release/2023/08/31/2735175/0/en/InspireMD-Announces-Abstract-of-30-Day-Results-from-the-C-Guardians-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial-Accepted-for-Presentation-at-VIVA23.html","2023-08-31 08:00:00",-0.44040739204464496
"ADAG","Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/31/2735151/0/en/Adagene-Reports-Six-Month-Financial-Results-for-2023-and-Provides-Corporate-Update.html","2023-08-31 07:32:00",0.705566753533815
"AKRO","Akero Therapeutics to Present at Upcoming Healthcare Conferences in September","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/31/2735089/0/en/Akero-Therapeutics-to-Present-at-Upcoming-Healthcare-Conferences-in-September.html","2023-08-31 07:00:00",-0.30282963187339684
"RENB","Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort","Clinical Study","https://www.globenewswire.com/news-release/2023/08/30/2734438/0/en/Renovaro-BioSciences-Welcomes-GEDiCube-Announcement-of-New-Joint-Effort.html","2023-08-30 09:15:00",2.614389800701672
"OVID","Ovid Therapeutics to Participate in Upcoming September Investor Conferences","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/30/2734267/0/en/Ovid-Therapeutics-to-Participate-in-Upcoming-September-Investor-Conferences.html","2023-08-30 08:00:00",-0.0779245927201757
"EVAX","Evaxion announces Executive Management Changes to strengthen the AI-strategy","Management Changes","https://www.globenewswire.com/news-release/2023/08/29/2733405/0/en/Evaxion-announces-Executive-Management-Changes-to-strengthen-the-AI-strategy.html","2023-08-29 08:30:00",2.297572860557117
"CERT","Certara Simcyp™ Group Awarded Two New Grants from US FDA","Health","https://www.globenewswire.com/news-release/2023/08/29/2733376/0/en/Certara-Simcyp-Group-Awarded-Two-New-Grants-from-US-FDA.html","2023-08-29 08:15:00",-0.10078327254492611
"ARQT","Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/29/2733332/0/en/Arcutis-Launches-First-Television-Ad-for-ZORYVE-Roflumilast-Cream-0-3.html","2023-08-29 08:00:00",1.645784817102865
"ICCC","ImmuCell Announces Submission of CMC Technical Section to the FDA","Government News","https://www.globenewswire.com/news-release/2023/08/29/2733350/0/en/ImmuCell-Announces-Submission-of-CMC-Technical-Section-to-the-FDA.html","2023-08-29 08:00:00",0.4663484052127312
"LGVN","Longeveron to Participate in the 149th Annual National Investment Banking Association Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/29/2733333/0/en/Longeveron-to-Participate-in-the-149th-Annual-National-Investment-Banking-Association-Conference.html","2023-08-29 08:00:00",-0.8447166631806684
"TTOO","T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs","Other News","https://www.globenewswire.com/news-release/2023/08/28/2732593/32489/en/T2-Biosystems-Praises-CDC-s-Actions-Aimed-at-Optimizing-U-S-Hospital-Sepsis-Programs.html","2023-08-28 08:30:00",2.47319494593572
"BMRA","Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/08/28/2732577/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Joins-Biomerica-s-Board-of-Directors.html","2023-08-28 08:19:00",-0.515941770432929
"OCUP","Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium","Clinical Study","https://www.globenewswire.com/news-release/2023/08/28/2732556/0/en/Abstract-on-ZETA-1-Study-of-APX3330-Receives-Award-at-Women-in-Ophthalmology-WIO-Summer-Symposium.html","2023-08-28 08:00:00",-0.007036411990621241
"ELTX","Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics","Directors and Officers","https://www.globenewswire.com/news-release/2023/08/28/2732545/0/en/Elicio-Therapeutics-Announces-Appointment-of-Megan-Filoon-as-General-Counsel-and-Dr-Thian-Kheoh-as-Senior-Vice-President-of-Biometrics.html","2023-08-28 08:00:00",-1.1376979187665486
"AKRO","Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/28/2732469/0/en/Akero-Therapeutics-to-Report-Results-of-Phase-2b-SYMMETRY-Study-in-October-2023.html","2023-08-28 07:00:00",3.278095437218286
"NZYM-B.CO","Trading by management and close relations of management","European Regulatory News","https://www.globenewswire.com/news-release/2023/08/25/2731838/0/en/Trading-by-management-and-close-relations-of-management.html","2023-08-25 08:36:00",-0.47591635595711096
"PCIB.OL","PCI Biotech: Invitation to first half interim 2023 results presentation","European Regulatory News","https://www.globenewswire.com/news-release/2023/08/25/2731830/0/en/PCI-Biotech-Invitation-to-first-half-interim-2023-results-presentation.html","2023-08-25 08:30:00",0.7879017447405748
"TSHA","Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/08/24/2731098/0/en/Taysha-Gene-Therapies-Announces-Fast-Track-Designation-Granted-by-U-S-FDA-for-TSHA-102-in-Rett-Syndrome.html","2023-08-24 08:00:00",17.643318055678016
"RAD.AX","Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer","Business Contracts","https://www.globenewswire.com/news-release/2023/08/24/2731100/0/en/Radiopharm-Theranostics-Expands-Supply-Agreement-With-TerThera-for-Terbium-161-Isotope-Use-in-Prostate-Cancer.html","2023-08-24 08:00:00",5.307127974182848
"OXUR.BR","Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas","Press releases","https://www.globenewswire.com/news-release/2023/08/23/2730682/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-Atlas.html","2023-08-23 14:05:00",-6.416110172121186
"OXUR.BR","Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/08/23/2730679/0/en/Oxurion-Receives-Transparency-Notifications-from-Atlas-Special-Opportunities-LLC.html","2023-08-23 14:00:00",-6.416110172121186
"TLSA","Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/08/23/2730575/0/en/Tiziana-Life-Sciences-Announces-Appointment-of-William-A-Clementi-as-Chief-Development-Officer.html","2023-08-23 10:30:00",6.9519445462501075
"WINT","Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators  by the US Patent and Trademark Office","Patents","https://www.globenewswire.com/news-release/2023/08/23/2730379/0/en/Windtree-Announces-Issuance-of-Composition-of-Matter-Patent-for-Dual-Mechanism-SERCA2a-Activators-by-the-US-Patent-and-Trademark-Office.html","2023-08-23 08:00:00",9.918435410474476
"ECOR","electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering","Initial Public Offerings","https://www.globenewswire.com/news-release/2023/08/23/2730348/0/en/electroCore-Announces-Dismissal-of-All-Litigation-Related-to-Its-2018-Initial-Public-Offering.html","2023-08-23 08:00:00",-2.338737668982355
"TLSA","Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/23/2730275/0/en/Tiziana-Life-Sciences-Announces-Foralumab-Presentation-by-Dr-Howard-Weiner-at-the-Annual-Meeting-of-the-International-Society-of-Neuroimmunology.html","2023-08-23 07:00:00",-4.72867342588773
"LGVN","Longeveron Rights Offering Subscription Period Begins","Management statements","https://www.globenewswire.com/news-release/2023/08/22/2729442/0/en/Longeveron-Rights-Offering-Subscription-Period-Begins.html","2023-08-22 08:00:00",1.924938614037933
"OXUR.BR","Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas","Press releases","https://www.globenewswire.com/news-release/2023/08/21/2728929/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-Atlas.html","2023-08-21 13:05:00",-14.045459779760982
"OXUR.BR","Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/08/21/2728925/0/en/Oxurion-Receives-Transparency-Notification-from-Atlas-Special-Opportunities-LLC.html","2023-08-21 13:00:00",-14.045459779760982
"RENB","Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/08/21/2728734/0/en/Renovaro-BioSciences-Congratulates-GEDi-Cube-on-Appointment-of-its-Chief-Medical-Officer.html","2023-08-21 09:15:00",1.555865625278071
"EVAX","Evaxion Announces Business Update and Second Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/18/2728141/0/en/Evaxion-Announces-Business-Update-and-Second-Quarter-2023-Financial-Results.html","2023-08-18 11:57:00",-4.888910500136631
"KRON","Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development","Directors and Officers","https://www.globenewswire.com/news-release/2023/08/17/2727193/0/en/Kronos-Bio-Announces-Departure-of-Chief-Financial-Officer-and-Head-of-Corporate-Development.html","2023-08-17 08:00:00",-4.693564217288735
"TLSA","Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease","Management statements","https://www.globenewswire.com/news-release/2023/08/17/2727113/0/en/Tiziana-Life-Sciences-Announces-Live-Bloomberg-TV-Interview-of-Renowned-Scientist-Dr-Howard-L-Weiner-to-Discuss-FDA-IND-Clearance-for-Intranasal-Foralumab-in-Alzheimer-s-Disease.html","2023-08-17 07:00:00",-0.3457349110697645
"OXUR.BR","Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC","Press releases","https://www.globenewswire.com/news-release/2023/08/16/2726727/0/en/Oxurion-Receives-Transparency-Notification-from-Atlas-Special-Opportunities-LLC.html","2023-08-16 13:00:00",6.192899667786877
"LGVN","Longeveron Rights Offering Declared Effective and Calendar Finalized","Changes in share capital and votes","https://www.globenewswire.com/news-release/2023/08/16/2726461/0/en/Longeveron-Rights-Offering-Declared-Effective-and-Calendar-Finalized.html","2023-08-16 09:13:00",0.09709480438404644
"CDTX","Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development","Company Announcement","https://www.globenewswire.com/news-release/2023/08/16/2726300/0/en/Cidara-Therapeutics-Announces-Appointment-of-Nicole-Davarpanah-M-D-J-D-as-Senior-Vice-President-of-Translational-Research-Development.html","2023-08-16 08:00:00",-0.5636962096511408
"YTEN","Yield10 Bioscience Announces Closing of $3.7 Million Public Offering","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/15/2725798/34378/en/Yield10-Bioscience-Announces-Closing-of-3-7-Million-Public-Offering.html","2023-08-15 13:00:00",0.757383298999034
"NZYM-B.CO","Trading by management and close relations of management","European Regulatory News","https://www.globenewswire.com/news-release/2023/08/15/2725604/0/en/Trading-by-management-and-close-relations-of-management.html","2023-08-15 09:55:00",-0.992071870241002
"INAB","IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/15/2725402/0/en/IN8bio-to-Present-at-the-H-C-Wainwright-Immune-Cell-Engager-Virtual-Conference.html","2023-08-15 08:00:00",2.1200229923501244
"SNCE","Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards","Contests/Awards","https://www.globenewswire.com/news-release/2023/08/15/2725393/0/en/Science-37-Recognized-as-Best-Digital-Health-Solution-Nominee-at-2023-Prix-Galien-USA-Awards.html","2023-08-15 07:59:00",-3.4891084168534965
"TLSA","Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease","Regulatory information","https://www.globenewswire.com/news-release/2023/08/15/2725322/0/en/Tiziana-Life-Sciences-Announces-FDA-IND-Clearance-of-Intranasal-Foralumab-for-the-Treatment-of-Alzheimer-s-Disease.html","2023-08-15 07:00:00",52.077277672614116
"ELOX","Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html","2023-08-14 08:30:00",5.26579442614339
"IMNN","IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla","Press releases","https://www.globenewswire.com/news-release/2023/08/14/2724408/0/en/IMUNON-Expands-Scientific-Advisory-Board-with-the-Addition-of-Dr-Sachet-Shukla.html","2023-08-14 08:30:00",3.661450615183877
"ELOX","Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html","2023-08-14 08:00:00",5.26579442614339
"LGVN","Longeveron Announces Pricing for Rights Offering and Expected Calendar","Management statements","https://www.globenewswire.com/news-release/2023/08/14/2724319/0/en/Longeveron-Announces-Pricing-for-Rights-Offering-and-Expected-Calendar.html","2023-08-14 08:00:00",-2.5391233034827225
"VBLT","VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/14/2724325/0/en/VBL-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-08-14 08:00:00",-3.2650937108380593
"TSHA","Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/14/2724266/0/en/Taysha-Gene-Therapies-Reports-Initial-Clinical-Data-from-First-Adult-Rett-Syndrome-Patient-Dosed-in-REVEAL-Phase-1-2-Trial-and-Provides-Corporate-Update-with-Second-Quarter-2023-Fi.html","2023-08-14 07:02:00",105.89651473343436
"TSHA","Taysha Gene Therapies Announces $150 Million Private Placement Financing","Financing Agreements","https://www.globenewswire.com/news-release/2023/08/14/2724228/0/en/Taysha-Gene-Therapies-Announces-150-Million-Private-Placement-Financing.html","2023-08-14 07:00:00",105.89651473343436
"MDAI","Spectral MD Holdings, Ltd. (“Spectral MD” or the “Company”) ISO 13485 Certification Received for AI-Driven DeepView® Wound Imaging System","Stock Market News","https://www.globenewswire.com/news-release/2023/08/14/2724227/0/en/Spectral-MD-Holdings-Ltd-Spectral-MD-or-the-Company-ISO-13485-Certification-Received-for-AI-Driven-DeepView-Wound-Imaging-System.html","2023-08-14 07:00:00",1.1556783604412928
"BTAI","BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/14/2724260/0/en/BioXcel-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Announces-Strategic-Reprioritization.html","2023-08-14 07:00:00",-32.48953564648519
"YTEN","Yield10 Bioscience to Announce Second Quarter 2023 Financial Results and Host a Conference Call on Monday, August 14, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/11/2723596/34378/en/Yield10-Bioscience-to-Announce-Second-Quarter-2023-Financial-Results-and-Host-a-Conference-Call-on-Monday-August-14-2023.html","2023-08-11 09:15:00",-56.00057747319186
"ELTX","Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/11/2723550/0/en/Elicio-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Updates.html","2023-08-11 08:30:00",-1.7649367544141068
"YTEN","Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/08/11/2723546/34378/en/Yield10-Bioscience-Announces-Pricing-of-3-7-Million-Public-Offering.html","2023-08-11 08:30:00",-56.00057747319186
"OCUP","Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/11/2723507/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Second-Quarter-2023-and-Provides-Corporate-Update.html","2023-08-11 08:00:00",4.299808172136181
"LGVN","Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/11/2723467/0/en/Longeveron-Reports-Second-Quarter-2023-Results-and-Provides-Corporate-Update.html","2023-08-11 07:30:00",-3.872629619639092
"LGVN","Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/08/11/2723443/0/en/Longeveron-Announces-Achievement-of-Surpassing-50-Enrollment-Threshold-in-Phase-2-ELPIS-II-Study-of-Lomecel-B-in-Hypoplastic-Left-Heart-Syndrome.html","2023-08-11 07:00:00",-3.872629619639092
"ARQT","Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for  Topical Roflumilast in Greater China and Southeast Asia","Licensing Agreements","https://www.globenewswire.com/news-release/2023/08/10/2722655/0/en/Arcutis-and-Huadong-Announce-Strategic-Collaboration-and-Licensing-Agreement-for-Topical-Roflumilast-in-Greater-China-and-Southeast-Asia.html","2023-08-10 08:16:00",-0.44090403363487485
"IMNN","IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update","Press releases","https://www.globenewswire.com/news-release/2023/08/10/2722608/0/en/IMUNON-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-08-10 08:00:00",-1.347391820662622
"IMCR","Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/10/2722471/0/en/Immunocore-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-08-10 07:00:00",0.6399132771577248
"MLTX","MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update","Press releases","https://www.globenewswire.com/news-release/2023/08/10/2722470/0/en/MoonLake-Immunotherapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html","2023-08-10 07:00:00",-0.5473925836020752
"RENB","AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/08/09/2721707/0/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer.html","2023-08-09 09:00:00",118.76112968573229
"TTOO","T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/08/09/2721642/32489/en/T2-Biosystems-Regains-Compliance-with-Nasdaq-s-Market-Value-of-Listed-Securities-Requirement.html","2023-08-09 08:30:00",-8.44949327589356
"EYEN","Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/09/2721562/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-3rd-Annual-Ophthalmology-Virtual-Conference.html","2023-08-09 08:00:00",0.42304117258660945
"ELTX","Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model","Clinical Study","https://www.globenewswire.com/news-release/2023/08/09/2721581/0/en/Elicio-Therapeutics-Announces-Publication-of-Preclinical-Data-Demonstrating-AMP-CpG-Adjuvant-Can-Induce-Potent-and-Durable-Immune-Response-in-Epstein-Barr-Virus-EBV-Infectious-Dise.html","2023-08-09 08:00:00",-0.5623971785011397
"PYPD","PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/09/2721475/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Second-Quarter-2023-Financial-Results.html","2023-08-09 07:00:00",-4.737719538992802
"PEPG","PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/08/2720622/0/en/PepGen-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html","2023-08-08 08:15:00",0.3835202903880076
"INAB","IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/08/2720555/0/en/IN8bio-Expands-Capabilities-with-the-Grand-Opening-of-its-Advanced-Research-and-Development-Facility.html","2023-08-08 08:00:00",2.292935198742893
"OCUP","Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/08/2720577/0/en/Ocuphire-Pharma-to-Present-at-the-Canaccord-43rd-Annual-Growth-Conference-and-the-H-C-Wainwright-Ophthalmology-Conference-in-August.html","2023-08-08 08:00:00",-0.6069445645549242
"NSPR","InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/08/2720437/0/en/InspireMD-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-08-08 07:00:00",1.5512736012913946
"CCCC","C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/08/2720434/0/en/C4-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html","2023-08-08 07:00:00",0.015343588624565797
"ICCC","ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023","Health","https://www.globenewswire.com/news-release/2023/08/07/2719984/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2023.html","2023-08-07 12:00:00",-2.206977576082536
"IMNN","Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv","Press releases","https://www.globenewswire.com/news-release/2023/08/07/2719692/0/en/Preclinical-Data-Showing-Strong-Immunogenicity-and-Protection-with-IMUNON-s-PlaCCine-DNA-Based-Vaccines-Modality-Available-Online-on-bioRxiv.html","2023-08-07 08:30:00",2.8267940544307693
"DYAI","Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/07/2719707/0/en/Dyadic-Announces-Continued-Progress-Towards-Commercialization-of-Animal-Free-Recombinant-Serum-Albumin.html","2023-08-07 08:30:00",-1.5880248834947732
"AKYA","Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/07/2719672/0/en/Akoya-Biosciences-Announces-Milestone-of-1-000-Peer-Reviewed-Publications-Citing-Use-of-its-Spatial-Biology-Technologies.html","2023-08-07 08:05:00",-0.7353125469219154
"MDWD","MediWound to Report Second Quarter 2023 Financial Results","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/07/2719647/30505/en/MediWound-to-Report-Second-Quarter-2023-Financial-Results.html","2023-08-07 08:00:00",2.1274787413375384
"EYEN","Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/07/2719644/0/en/Eyenovia-to-Report-Second-Quarter-2023-Results-on-Thursday-August-10.html","2023-08-07 08:00:00",0.9701121305219533
"LGVN","Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023","Pre-Release Comments","https://www.globenewswire.com/news-release/2023/08/07/2719643/0/en/Longeveron-to-Report-Second-Quarter-2023-Results-and-Provide-Corporate-Update-on-August-11-2023.html","2023-08-07 08:00:00",-0.7228540871651554
"OPGN","OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/07/2719601/35690/en/OpGen-s-Subsidiary-Ares-Genetics-Releases-New-Features-to-its-AREScloud-Offering.html","2023-08-07 07:30:00",1.7894173553392794
"FARON.HE","Faron Pharmaceuticals Notice of Half-Year Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/04/2718898/0/en/Faron-Pharmaceuticals-Notice-of-Half-Year-Financial-Results.html","2023-08-04 08:00:00",2.0027949244176018
"OVID","Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/04/2718899/0/en/Ovid-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Updates.html","2023-08-04 08:00:00",0.4847550236240768
"FBIO","Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/03/2718058/28889/en/Fortress-Biotech-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2023.html","2023-08-03 08:30:00",2.1884540376492065
"IMNN","IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023","Press releases","https://www.globenewswire.com/news-release/2023/08/03/2718025/0/en/IMUNON-to-Hold-Second-Quarter-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-August-10-2023.html","2023-08-03 08:30:00",-0.3230913439529569
"BMRA","CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/03/2718011/0/en/CVS-Health-to-Begin-Nationwide-In-Store-Sales-of-Biomerica-s-EZ-Detect-Colorectal-Disease-Screening-Test.html","2023-08-03 08:19:00",17.587596715585647
"OPGN","OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement","Partnerships","https://www.globenewswire.com/news-release/2023/08/03/2717968/35690/en/OpGen-s-Subsidiary-Curetis-and-FIND-Extend-R-D-Collaboration-Agreement.html","2023-08-03 08:00:00",3.8541470205949584
"EYEN","Eyenovia Announces First Commercial Sale of Mydcombi™","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/03/2717937/0/en/Eyenovia-Announces-First-Commercial-Sale-of-Mydcombi.html","2023-08-03 08:00:00",0.46430949175110814
"BIOR","Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform","Patents","https://www.globenewswire.com/news-release/2023/08/03/2717952/0/en/Biora-Therapeutics-Announces-New-Patents-Covering-its-BioJet-Systemic-Oral-Delivery-Platform.html","2023-08-03 08:00:00",-0.05517054518209812
"SCPH","scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/03/2717942/0/en/scPharmaceuticals-to-Announce-Second-Quarter-2023-Financial-Results-on-Thursday-August-10-2023.html","2023-08-03 08:00:00",-0.5112993566254881
"IMCR","Immunocore to report second quarter 2023 financial results and host call on August 10, 2023","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/03/2717932/0/en/Immunocore-to-report-second-quarter-2023-financial-results-and-host-call-on-August-10-2023.html","2023-08-03 08:00:00",-0.7462862005162616
"OPGN","OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/03/2717888/35690/en/OpGen-to-Provide-Business-Update-and-Financial-Results-for-the-Second-Quarter-2023-on-August-10th-at-4-30-p-m-Eastern-Time.html","2023-08-03 07:30:00",3.8541470205949584
"HARP","Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/03/2717893/0/en/Harpoon-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-in-August.html","2023-08-03 07:30:00",0.7316889152205612
"NTLA","Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/03/2717889/0/en/Intellia-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html","2023-08-03 07:30:00",-3.010878836715948
"YTEN","Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market","Advisory","https://www.globenewswire.com/news-release/2023/08/02/2716870/34378/en/Yield10-Bioscience-Announces-Positive-Results-in-the-First-Field-Test-of-Stacked-Herbicide-Tolerance-Traits-in-Camelina-Supporting-Large-Acreage-Production-of-Low-carbon-Intensity-.html","2023-08-02 08:35:00",-2.3761066325442823
"FARON.HE","Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/02/2716788/0/en/Faron-to-Participate-in-Fireside-Chat-at-the-Canaccord-Genuity-43rd-Annual-Growth-Conference.html","2023-08-02 08:00:00",0.7075908930489545
"BIOR","Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/02/2716792/0/en/Biora-Therapeutics-to-Participate-in-Canaccord-Genuity-43rd-Annual-Growth-Conference.html","2023-08-02 08:00:00",0.7075908930489545
"PCRX","Pacira BioSciences Reports Second Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/02/2716806/0/en/Pacira-BioSciences-Reports-Second-Quarter-2023-Financial-Results.html","2023-08-02 08:00:00",-2.764631329173268
"BCDA","BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/02/2716675/0/en/BioCardia-to-Host-Q2-2023-Financial-Results-and-Corporate-Update-Conference-Call-on-August-9-2023.html","2023-08-02 07:00:00",4.831298178948462
"OVID","Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/08/01/2715784/0/en/Ovid-Therapeutics-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2023.html","2023-08-01 08:00:00",0.6105855033429468
"SCPH","scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion","Health","https://www.globenewswire.com/news-release/2023/08/01/2715773/0/en/scPharmaceuticals-Announces-Positive-Type-C-Meeting-Feedback-from-FDA-on-Potential-Heart-Failure-Class-IV-Indication-Expansion.html","2023-08-01 08:00:00",0.3320342302972836
"ECOR","electroCore to Announce Second Quarter Financial Results on Wednesday, August 9","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/08/01/2715804/0/en/electroCore-to-Announce-Second-Quarter-Financial-Results-on-Wednesday-August-9.html","2023-08-01 08:00:00",-0.5568538108811018
"MDWD","MediWound Announces Commercial Launch of NexoBrid® in Japan","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/08/01/2715699/30505/en/MediWound-Announces-Commercial-Launch-of-NexoBrid-in-Japan.html","2023-08-01 07:30:00",0.3320342302972836
"HARP","Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development","Management Changes","https://www.globenewswire.com/news-release/2023/08/01/2715708/0/en/Harpoon-Therapeutics-Appoints-Haibo-Wang-as-Senior-Vice-President-of-Business-Development.html","2023-08-01 07:30:00",-0.051104125558435125
"TGTX","TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/08/01/2715675/8790/en/TG-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2023-Financial-Results.html","2023-08-01 07:15:00",-42.24892368275177
"EVAX","Evaxion announces financing commitments totaling up to USD 20 million with Negma Group","Financing Agreements","https://www.globenewswire.com/news-release/2023/08/01/2715621/0/en/Evaxion-announces-financing-commitments-totaling-up-to-USD-20-million-with-Negma-Group.html","2023-08-01 07:00:00",-0.4744166073114012
"TGTX","TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)","Clinical Study","https://www.globenewswire.com/news-release/2023/08/01/2715625/8790/en/TG-Therapeutics-and-Neuraxpharm-Announce-Ex-US-Commercialization-Agreement-for-BRIUMVI-ublituximab-xiiy.html","2023-08-01 07:00:00",-42.24892368275177
"ANAB","AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer","Health","https://www.globenewswire.com/news-release/2023/07/31/2715235/0/en/AnaptysBio-and-GSK-Partnered-Immuno-Oncology-Agent-JEMPERLI-dostarlimab-gxly-plus-Chemotherapy-Approved-in-the-U-S-for-dMMR-MSI-H-Primary-Advanced-or-Recurrent-Endometrial-Cancer.html","2023-07-31 13:34:00",14.443361371117943
"TTOO","T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements","Stock Market News","https://www.globenewswire.com/news-release/2023/07/31/2714891/32489/en/T2-Biosystems-Receives-Extension-to-Comply-with-Nasdaq-Listing-Requirements.html","2023-07-31 08:30:00",6.7893072813099655
"TGTX","TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update","Calendar of Events","https://www.globenewswire.com/news-release/2023/07/31/2714890/8790/en/TG-Therapeutics-to-Host-Conference-Call-on-Second-Quarter-2023-Financial-Results-and-Business-Update.html","2023-07-31 08:30:00",1.111035263688637
"TSHA","Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/07/31/2714841/0/en/Taysha-Gene-Therapies-Announces-Positive-Recommendation-from-Independent-Data-Monitoring-Committee-of-REVEAL-Phase-1-2-Trial-in-Rett-Syndrome.html","2023-07-31 08:00:00",1.66267752199206
"BTAI","BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/07/31/2714718/0/en/BioXcel-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-on-August-14-2023.html","2023-07-31 07:00:00",0.936607687400038
"EVAX","Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus","Clinical Study","https://www.globenewswire.com/news-release/2023/07/31/2714741/0/en/Evaxion-presents-promising-results-on-EVX-B1-an-AI-designed-vaccine-against-Staphylococcus-aureus.html","2023-07-31 07:00:00",-2.4694401460808146
"TTOO","T2 Biosystems to Attend Upcoming Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/07/28/2713129/32489/en/T2-Biosystems-to-Attend-Upcoming-Investor-Conferences.html","2023-07-28 08:30:00",0.10551304823974324
"RVVTF","Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents","Patents","https://www.globenewswire.com/news-release/2023/07/28/2713021/0/en/Revive-Therapeutics-Announces-Filing-of-Patent-for-Bucillamine-in-the-Treatment-of-Exposure-to-Chemical-Warfare-Agents.html","2023-07-28 07:00:00",-19.267712154406862
"BIOR","Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform","Clinical Study","https://www.globenewswire.com/news-release/2023/07/27/2712117/0/en/Biora-Therapeutics-Announces-Clinical-Device-Performance-Study-Results-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html","2023-07-27 08:00:00",-1.5902316193070376
"NTLA","Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/07/27/2712072/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Second-Quarter-2023-Earnings-and-Company-Updates.html","2023-07-27 07:30:00",1.0398307173921155
"YTEN","Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/26/2711325/34378/en/Yield10-Bioscience-Files-Request-for-Regulatory-Status-Review-under-USDA-APHIS-s-SECURE-Rule-Covering-Elite-Camelina-Designed-to-Produce-the-EPA-Component-of-Omega-3-Oil.html","2023-07-26 08:40:00",1.8434143186934469
"OCUP","Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit","Health","https://www.globenewswire.com/news-release/2023/07/26/2711269/0/en/Ocuphire-to-Present-at-American-Society-of-Retina-Specialists-Annual-Meeting-and-OIS-Retina-Innovation-Summit.html","2023-07-26 08:00:00",1.7205173640830937
"PCRX","Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/07/26/2711252/0/en/Pacira-to-Report-Second-Quarter-2023-Financial-Results-on-Wednesday-August-2-2023.html","2023-07-26 08:00:00",0.21298112056547308
"PYPD","PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/07/26/2711169/0/en/PolyPid-to-Report-Second-Quarter-2023-Financial-Results-and-Operational-Highlights-on-August-9-2023.html","2023-07-26 07:00:00",1.7055146099534506
"MLTX","MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts","Press releases","https://www.globenewswire.com/news-release/2023/07/25/2710350/0/en/MoonLake-completes-patient-randomization-ahead-of-schedule-for-its-Phase-2-trial-in-active-psoriatic-arthritis-PsA-and-provides-calendar-of-next-readouts.html","2023-07-25 08:00:00",0.08017591856695985
"NSPR","InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th","Company Announcement","https://www.globenewswire.com/news-release/2023/07/25/2710361/0/en/InspireMD-to-Report-Second-Quarter-2023-Financial-Results-and-Provide-Corporate-Business-Update-on-Tuesday-August-8th.html","2023-07-25 08:00:00",-0.2528185211144648
"BCAB","BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/07/25/2710360/0/en/BioAtla-to-Announce-Second-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-August-1-2023.html","2023-07-25 08:00:00",-0.9800273290949334
"ECOR","gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/07/25/2710362/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Memory-in-Patients-with-Posttraumatic-Stress-Disorder-PTSD.html","2023-07-25 08:00:00",-2.7985177841801696
"ALERS.PA","EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/07/24/2709830/0/en/EUROBIO-ACCELERATION-OF-STRATEGIC-DEPLOYMENT-IN-THE-FIRST-HALF-OF-2023.html","2023-07-24 13:45:00",-0.7121772278854642
"ALERS.PA","EUROBIO : ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/07/24/2709736/0/fr/EUROBIO-ACC%C3%89L%C3%89RATION-DU-D%C3%89PLOIEMENT-STRAT%C3%89GIQUE-AU-PREMIER-SEMESTRE-2023.html","2023-07-24 11:46:00",-0.7121772278854642
"DYAI","Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate","Clinical Study","https://www.globenewswire.com/news-release/2023/07/24/2709514/0/en/Dyadic-Provides-Phase-1-Clinical-Trial-Update-for-its-Recombinant-Protein-RBD-Vaccine-Candidate.html","2023-07-24 08:30:00",4.575541356315547
"CAPR","Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors","Management Changes","https://www.globenewswire.com/news-release/2023/07/24/2709506/0/en/Capricor-Therapeutics-Announces-Appointment-of-Philip-J-Gotwals-Ph-D-to-its-Board-of-Directors.html","2023-07-24 08:30:00",1.2752846883717712
"QGEN","QIAGEN N.V. to release results for Q2 2023 and hold webcast","Company Announcement","https://www.globenewswire.com/news-release/2023/07/24/2709438/8690/en/QIAGEN-N-V-to-release-results-for-Q2-2023-and-hold-webcast.html","2023-07-24 07:41:00",-0.606296485787712
"BCDA","BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/24/2709400/0/en/BioCardia-Announces-DSMB-Recommendation-to-Pause-New-Enrollment-in-Phase-III-Pivotal-CardiAMP-Cell-Therapy-Heart-Failure-Trial-While-Additional-Blinded-Data-is-Collected.html","2023-07-24 07:00:00",-33.59650140488106
"TTOO","T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/20/2708188/32489/en/T2-Biosystems-Receives-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html","2023-07-20 08:30:00",37.48117841834753
"LGVN","Longeveron Appoints Lisa Locklear as Chief Financial Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/07/20/2708128/0/en/Longeveron-Appoints-Lisa-Locklear-as-Chief-Financial-Officer.html","2023-07-20 08:00:00",0.5178187967565815
"VIR","Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness","Clinical Study","https://www.globenewswire.com/news-release/2023/07/20/2708142/0/en/Vir-Biotechnology-Announces-Topline-Data-from-Phase-2-PENINSULA-Trial-Evaluating-VIR-2482-for-the-Prevention-of-Seasonal-Influenza-A-Illness.html","2023-07-20 08:00:00",-40.337716292436085
"SCPH","scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/07/19/2707252/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","2023-07-19 08:00:00",-0.6451184446267672
"OPGN","OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/19/2707193/35690/en/OpGen-s-Subsidiary-Curetis-Meets-Milestones-of-Extended-and-Expanded-R-D-Collaboration-with-FIND.html","2023-07-19 07:30:00",-0.026689446097349585
"KBLB","New Sericulture Experts Join Kraig Biocraft Laboratories, Bringing Extensive Experience Supporting Acceleration of Production Ramp-Up","Directors and Officers","https://www.globenewswire.com/news-release/2023/07/19/2707180/0/en/New-Sericulture-Experts-Join-Kraig-Biocraft-Laboratories-Bringing-Extensive-Experience-Supporting-Acceleration-of-Production-Ramp-Up.html","2023-07-19 07:05:00",-0.18054279482396507
"ECOR","electroCore Expands Intellectual Patent Portfolio for nVNS Technology","Patents","https://www.globenewswire.com/news-release/2023/07/18/2706335/0/en/electroCore-Expands-Intellectual-Patent-Portfolio-for-nVNS-Technology.html","2023-07-18 08:00:00",-0.034117561115284314
"ARQT","Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/17/2705601/0/en/Arcutis-Announces-ZORYVE-Roflumilast-Cream-0-3-Has-Been-Included-in-a-Preferred-Position-on-National-Formularies-for-CVS-Caremark.html","2023-07-17 08:00:00",3.8469513508560436
"CCCC","C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","Management statements","https://www.globenewswire.com/news-release/2023/07/17/2705168/0/en/C4-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","2023-07-17 07:00:00",0.03338539371703871
"SCLX","Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/13/2704383/0/en/Scilex-Holding-Company-Announces-Results-From-Independent-Market-Research-Study-Conducted-with-Pain-Specialists-and-HCPs-Treating-Post-Herpetic-Neuralgia-PHN-Pain-on-ZTlido.html","2023-07-13 09:00:00",3.853586333183011
"CAPR","Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/07/13/2704319/0/en/Capricor-Therapeutics-Announces-Appointment-of-Paul-Auwaerter-M-D-to-its-Board-of-Directors.html","2023-07-13 08:30:00",1.3884461265742407
"CHRS","Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/13/2704318/33333/en/Coherus-and-Superior-Biologics-Announce-National-Distribution-Agreement-for-YUSIMRY.html","2023-07-13 08:30:00",0.36149818630615016
"ECOR","electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC","Partnerships","https://www.globenewswire.com/news-release/2023/07/13/2704254/0/en/electroCore-Inc-Announces-Distribution-Agreement-with-Reliefband-Technologies-LLC.html","2023-07-13 08:00:00",-2.879328729550438
"TTOO","T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results","Pre-Release Comments","https://www.globenewswire.com/news-release/2023/07/12/2703505/32489/en/T2-Biosystems-Announces-Preliminary-Second-Quarter-2023-Financial-Results.html","2023-07-12 08:30:00",-15.55488653808721
"AKYA","Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/07/12/2703488/0/en/Akoya-to-Report-Second-Quarter-2023-Financial-Results-on-August-7th-2023.html","2023-07-12 08:05:00",-3.7847733932893703
"CNTG","CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort","Clinical Study","https://www.globenewswire.com/news-release/2023/07/12/2703428/0/en/CENTOGENE-Biodatabank-Reveals-Unique-Genetic-Variants-in-World-s-Largest-Niemann-Pick-Type-C1-Disease-Cohort.html","2023-07-12 07:30:00",0.40210793772854464
"LGVN","Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/07/11/2702588/0/en/Longeveron-Appoints-Dr-Nataliya-Agafonova-as-Chief-Medical-Officer.html","2023-07-11 08:00:00",0.7726937717474911
"ECOR","electroCore Provides Select Second Quarter 2023 Financial Guidance","Pre-Release Comments","https://www.globenewswire.com/news-release/2023/07/11/2702564/0/en/electroCore-Provides-Select-Second-Quarter-2023-Financial-Guidance.html","2023-07-11 08:00:00",0.6433582164232744
"SNCE","Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)","Partnerships","https://www.globenewswire.com/news-release/2023/07/11/2702540/0/en/Synlogic-Partners-with-Science-37-on-Pivotal-Study-for-Investigational-Drug-for-Phenylketonuria-PKU.html","2023-07-11 07:59:00",2.5230151892819195
"ELOX","Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html","2023-07-10 09:00:00",1.1893457750447376
"LGVN","Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors","Contests/Awards","https://www.globenewswire.com/news-release/2023/07/10/2701736/0/en/Longeveron-Congratulates-Co-Founder-and-Chairman-Dr-Joshua-Hare-on-Induction-as-Fellow-of-National-Academy-of-Inventors.html","2023-07-10 08:00:00",1.3746969127719195
"MDWD","MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma","Clinical Study","https://www.globenewswire.com/news-release/2023/07/10/2701666/30505/en/MediWound-Announces-Positive-Results-in-Its-U-S-Phase-I-II-Study-of-MW005-for-the-Treatment-of-Basal-Cell-Carcinoma.html","2023-07-10 07:30:00",-0.5816706738810208
"ALERS.PA","Eurobio Scientific : bilan semestriel du contrat de liquidité","European Regulatory News","https://www.globenewswire.com/news-release/2023/07/06/2700601/0/fr/Eurobio-Scientific-bilan-semestriel-du-contrat-de-liquidit%C3%A9.html","2023-07-06 11:45:00",1.5056635496875648
"TTOO","T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity","Prospectus/Announcement of Prospectus","https://www.globenewswire.com/news-release/2023/07/06/2700253/32489/en/T2-Biosystems-Announces-Conversion-of-Approximately-Twenty-Percent-of-CRG-Term-Loan-into-Equity.html","2023-07-06 08:00:00",2.1885742038305116
"ECOR","gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/06/2700272/0/en/gammaCore-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Study-Funded-by-the-National-Football-League-NFL-and-National-Football-League-Players-Association-NFLPA-on-Alleviating-C.html","2023-07-06 08:00:00",0.5142991522457121
"CHRS","Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/07/03/2698528/33333/en/Coherus-Launches-YUSIMRY-a-Biosimilar-of-Humira-at-995-per-Carton-in-U-S.html","2023-07-03 08:30:00",2.4231276248832136
"MDWD","MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","Health","https://www.globenewswire.com/news-release/2023/07/03/2698438/30505/en/MediWound-Receives-Positive-Scientific-Advice-from-European-Medicine-Agency-EMA-on-EscharEx-Phase-III-Study-Design.html","2023-07-03 07:00:00",1.2069119804310007
"OCGN","Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/30/2697720/0/en/Ocugen-CEO-CSO-to-Present-at-41st-Annual-AAPI-Convention-and-Scientific-Assembly.html","2023-06-30 08:00:00",0.19411057287709327
"VIR","Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer","Management Changes","https://www.globenewswire.com/news-release/2023/06/29/2697070/0/en/Vir-Biotechnology-Appoints-Sasha-Damouni-Ellis-as-Executive-Vice-President-and-Chief-Corporate-Affairs-Officer.html","2023-06-29 09:00:00",-0.26318826872654344
"PYPD","PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections","Health","https://www.globenewswire.com/news-release/2023/06/29/2696940/0/en/PolyPid-Announces-New-Publication-Highlighting-Potent-Antibacterial-Activity-of-D-PLEX-against-Susceptible-and-Resistant-Bacteria-for-the-Prevention-of-Surgical-Site-Infections.html","2023-06-29 08:00:00",2.5916200616014073
"FBIO","Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States","Clinical Study","https://www.globenewswire.com/news-release/2023/06/29/2696949/28889/en/Urica-Therapeutics-Announces-Topline-Data-from-the-Phase-1-Clinical-Trial-Evaluating-Dotinurad-in-Healthy-Volunteers-in-the-United-States.html","2023-06-29 08:00:00",0.09854102498330726
"ELOX","Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02","Clinical Study","https://www.globenewswire.com/news-release/2023/06/28/2696256/0/en/Eloxx-Pharmaceuticals-Key-Opinion-Leader-Event-Highlights-Significant-Unmet-Need-in-Treatment-of-Alport-Syndrome-Patients-with-Nonsense-Mutations-and-Additional-Positive-Results-fr.html","2023-06-28 09:00:00",-0.7284342667814395
"BIOR","Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform","Patents","https://www.globenewswire.com/news-release/2023/06/28/2696172/0/en/Biora-Therapeutics-Announces-New-Patents-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html","2023-06-28 08:30:00",0.2567864824002151
"OVID","Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer","Management statements","https://www.globenewswire.com/news-release/2023/06/28/2696116/0/en/Ovid-Therapeutics-Expands-Its-Scientific-Leadership-Team-Appoints-Chief-Strategy-Officer.html","2023-06-28 08:00:00",-1.2313073829973078
"TSHA","Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/28/2696132/0/en/Taysha-Gene-Therapies-Provides-Clinical-Updates-for-Investigational-Programs-TSHA-120-in-Giant-Axonal-Neuropathy-GAN-and-TSHA-102-in-Rett-Syndrome-at-R-D-Day.html","2023-06-28 08:00:00",-2.9690168680345237
"IMNN","IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus","Press releases","https://www.globenewswire.com/news-release/2023/06/27/2695606/0/en/IMUNON-Unveils-New-Manufacturing-Capabilities-at-Huntsville-s-HudsonAlpha-Biotech-Campus.html","2023-06-27 12:00:00",-3.1562791530230156
"SANN.SW","Santhera’s Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltungsrats zu","Press releases","https://www.globenewswire.com/news-release/2023/06/27/2695295/0/de/Santhera-s-Aktion%C3%A4re-stimmen-an-heutiger-Generalversammlung-allen-Antr%C3%A4gen-des-Verwaltungsrats-zu.html","2023-06-27 08:30:00",1.5478758619115076
"SANN.SW","Shareholders Approve all Board Proposals at Today’s Annual General Meeting","Press releases","https://www.globenewswire.com/news-release/2023/06/27/2695295/0/en/Shareholders-Approve-all-Board-Proposals-at-Today-s-Annual-General-Meeting.html","2023-06-27 08:30:00",1.5478758619115076
"WINT","Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/06/27/2695240/0/en/Windtree-Therapeutics-Appoints-Mark-Strobeck-Ph-D-to-Board-of-Directors.html","2023-06-27 08:00:00",1.3515761321995299
"OCUP","Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference","Clinical Study","https://www.globenewswire.com/news-release/2023/06/27/2695238/0/en/Ocuphire-Presents-APX3330-ZETA-1-Clinical-Data-in-Late-Breaker-Session-at-the-American-Diabetes-Association-s-Annual-Conference.html","2023-06-27 08:00:00",0.8226745241989474
"ECOR","TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/06/27/2695227/0/en/TAC-STIM-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Inclusion-in-the-Air-Force-Research-Laboratories-Real-Time-Assessing-and-Augmenting-Cognitive-Performance-in-Extreme-Envi.html","2023-06-27 08:00:00",-1.2703511099267242
"CNTG","CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment","Financing Agreements","https://www.globenewswire.com/news-release/2023/06/27/2695202/0/en/CENTOGENE-and-Lifera-a-Biopharma-Company-Owned-by-the-PIF-Enter-Strategic-Collaboration-Forming-Saudi-Arabian-Joint-Venture-to-Increase-Access-to-Leading-Data-Driven-Multiomic-Test.html","2023-06-27 07:30:00",41.73281247995752
"HARP","Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma","Clinical Study","https://www.globenewswire.com/news-release/2023/06/27/2695191/0/en/Harpoon-Therapeutics-Announces-Completion-of-Planned-Patient-Enrollment-in-Phase-1-Study-of-HPN217-in-Relapsed-Refractory-Multiple-Myeloma.html","2023-06-27 07:30:00",-0.2109224126089148
"ORIC","ORIC Pharmaceuticals Announces $85 Million Private Placement Financing","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/06/26/2694439/0/en/ORIC-Pharmaceuticals-Announces-85-Million-Private-Placement-Financing.html","2023-06-26 08:30:00",12.462851534088449
"NSPR","InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial","Clinical Study","https://www.globenewswire.com/news-release/2023/06/26/2694383/0/en/InspireMD-Announces-Completion-of-Enrollment-in-C-Guardians-U-S-Investigational-Device-Exemption-IDE-Clinical-Trial.html","2023-06-26 08:00:00",6.678241281089149
"CDTX","Cidara Therapeutics Added to Russell Microcap® Index","Stock Market News","https://www.globenewswire.com/news-release/2023/06/26/2694379/0/en/Cidara-Therapeutics-Added-to-Russell-Microcap-Index.html","2023-06-26 08:00:00",0.9982599341990441
"EYEN","Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes","Trading information","https://www.globenewswire.com/news-release/2023/06/26/2694372/0/en/Eyenovia-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html","2023-06-26 08:00:00",0.5581423721154518
"BCAB","BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index","Trading information","https://www.globenewswire.com/news-release/2023/06/26/2694369/0/en/BioAtla-Added-to-Membership-of-U-S-Small-Cap-Russell-2000-Index.html","2023-06-26 08:00:00",-1.292378300170429
"OVID","Ovid Therapeutics Added to Russell 3000® Index","Stock Market News","https://www.globenewswire.com/news-release/2023/06/26/2694370/0/en/Ovid-Therapeutics-Added-to-Russell-3000-Index.html","2023-06-26 08:00:00",-3.617162233676654
"OPGN","OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe","Patents","https://www.globenewswire.com/news-release/2023/06/26/2694329/35690/en/OpGen-Subsidiary-Ares-Genetics-Successfully-Maintains-Key-Patent-under-Opposition-in-Europe.html","2023-06-26 07:30:00",0.13619176600911914
"SCPH","scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes","Stock Market News","https://www.globenewswire.com/news-release/2023/06/23/2693627/0/en/scPharmaceuticals-Inc-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html","2023-06-23 08:00:00",0.9165796979205592
"AKRO","Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/23/2693588/0/en/Akero-Therapeutics-Presents-Analyses-of-Phase-2b-HARMONY-Study-at-the-2023-International-Liver-Congress-Reinforcing-and-Characterizing-EFX-Related-Improvements-in-Liver-Histopathol.html","2023-06-23 07:00:00",0.031835801818960556
"CDTX","Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/06/22/2692856/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-CD388-a-Novel-Drug-Fc-Conjugate-Targeting-Influenza-A-and-B.html","2023-06-22 08:00:00",10.227616439590102
"TALS","Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/06/22/2692800/0/en/Talaris-Therapeutics-and-Tourmaline-Bio-Announce-Merger-Agreement.html","2023-06-22 07:30:00",23.40943260174681
"OPGN","OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/06/22/2692799/35690/en/OpGen-s-Subsidiary-Curetis-Receives-Batch-of-Ten-New-C-Series-Unyvero-A30-Instruments.html","2023-06-22 07:30:00",-1.3596847296775458
"PYPD","PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections","Clinical Study","https://www.globenewswire.com/news-release/2023/06/22/2692776/0/en/PolyPid-Announces-Recruitment-of-First-Patient-in-Revised-SHIELD-II-Phase-3-Trial-Evaluating-D-PLEX-for-Prevention-of-Abdominal-Colorectal-Surgical-Site-Infections.html","2023-06-22 07:00:00",8.62870235509121
"ELOX","Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome","Health","https://www.globenewswire.com/news-release/2023/06/21/2692434/0/en/Eloxx-Pharmaceuticals-to-Host-Investor-and-Analyst-Call-on-Alport-Syndrome.html","2023-06-21 13:30:00",-11.64872236580108
"ELOX","Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress","Clinical Study","https://www.globenewswire.com/news-release/2023/06/21/2692112/0/en/Eloxx-Pharmaceuticals-Highlights-Recent-Alport-Syndrome-Natural-History-Data-Presented-at-60th-ERA-Congress.html","2023-06-21 09:00:00",1.6446047728609612
"DYAI","Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity","Business Contracts","https://www.globenewswire.com/news-release/2023/06/21/2692028/0/en/Dyadic-Announced-an-MoU-with-Bangladesh-s-State-Owned-Pharmaceutical-Company-to-Facilitate-Biopharmaceutical-Research-and-Biomanufacturing-Capacity.html","2023-06-21 08:33:00",3.1459296626543063
"BMRA","Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients","Patents","https://www.globenewswire.com/news-release/2023/06/21/2691993/0/en/Biomerica-Receives-Notice-of-Patent-Allowance-in-China-for-a-Potential-Innovative-Technology-That-Includes-an-Artificial-Intelligence-AI-Claim-for-Predicting-Foods-That-Contain-Ing.html","2023-06-21 08:19:00",6.368281806010781
"OCUP","Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference","Health","https://www.globenewswire.com/news-release/2023/06/21/2691963/0/en/Ocuphire-Announces-Late-Breaking-Presentation-on-APX3330-ZETA-1-Clinical-Data-at-American-Diabetes-Association-Annual-Conference.html","2023-06-21 08:00:00",0.485199926949856
"CDTX","Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit","Clinical Study","https://www.globenewswire.com/news-release/2023/06/20/2691268/0/en/Cidara-Therapeutics-to-Present-Ongoing-Development-of-Drug-Fc-Conjugates-DFC-Including-CD73-Targeting-DFC-From-Its-Cloudbreak-Platform-at-Adenosine-Pathway-Targeted-Cancer-Immunoth.html","2023-06-20 09:55:00",2.7889958698859725
"ALERS.PA","Eurobio Scientific: all resolutions approved at the Annual General Meeting","European Regulatory News","https://www.globenewswire.com/news-release/2023/06/16/2689837/0/en/Eurobio-Scientific-all-resolutions-approved-at-the-Annual-General-Meeting.html","2023-06-16 11:45:00",0.39485273221552003
"ALERS.PA","Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions","European Regulatory News","https://www.globenewswire.com/news-release/2023/06/16/2689837/0/fr/Eurobio-Scientific-l-assembl%C3%A9e-g%C3%A9n%C3%A9rale-approuve-l-ensemble-des-r%C3%A9solutions.html","2023-06-16 11:45:00",0.39485273221552003
"SCLX","Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/16/2689744/0/en/Scilex-Holding-Company-to-Present-Data-on-ELYXYB-celecoxib-oral-solution-at-the-65th-Annual-Scientific-Meeting-of-the-American-Headache-Society-in-Austin-TX.html","2023-06-16 09:00:00",1.704594149770106
"CHRS","Coherus to Acquire Surface Oncology","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/06/16/2689648/33333/en/Coherus-to-Acquire-Surface-Oncology.html","2023-06-16 07:01:00",-12.15426121704736
"SCLX","Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/06/15/2688968/0/en/Scilex-Holding-Company-Announces-that-Sorrento-Therapeutics-Inc-s-Bankruptcy-Court-Issues-Temporary-Restraining-Order-Against-Brokerage-Firms-and-Suspends-Short-Sales-of-Dividended.html","2023-06-15 09:03:00",7.576982408570565
"TSHA","Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/06/15/2688822/0/en/Taysha-Gene-Therapies-to-Host-Virtual-R-D-Day-on-Lead-Clinical-Investigational-Programs-TSHA-120-in-Giant-Axonal-Neuropathy-GAN-and-TSHA-102-in-Rett-Syndrome.html","2023-06-15 08:00:00",4.9563294517113645
"FBIO","Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program","Clinical Study","https://www.globenewswire.com/news-release/2023/06/15/2688861/28889/en/Helocyte-Announces-3-22-Million-Grant-from-the-National-Cancer-Institute-for-Triplex-Phase-2-Clinical-Trial-Program.html","2023-06-15 08:00:00",1.8073284146947861
"ECOR","electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/06/14/2688000/0/en/electroCore-to-Participate-in-the-Healthcare-Virtual-Conference-Presented-by-Maxim-Group-LLC.html","2023-06-14 08:00:00",5.86950685137148
"MDWD","MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/06/14/2688003/30505/en/MediWound-to-Participate-in-Fireside-Chat-at-Maxim-Group-Healthcare-Virtual-Conference-2023.html","2023-06-14 08:00:00",0.42604083171912993
"CAPR","Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/06/13/2687234/0/en/Capricor-Therapeutics-to-Present-24-Month-Results-from-Ongoing-HOPE-2-Open-Label-Extension-Study-of-CAP-1002-in-Duchenne-Muscular-Dystrophy.html","2023-06-13 09:15:00",0.2947591366514731
"LGVN","Longeveron Welcomes Three New Prominent Board Members","Directors and Officers","https://www.globenewswire.com/news-release/2023/06/13/2687120/0/en/Longeveron-Welcomes-Three-New-Prominent-Board-Members.html","2023-06-13 08:30:00",2.1086175927909805
"CDTX","Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit","Health","https://www.globenewswire.com/news-release/2023/06/13/2687061/0/en/Cidara-Therapeutics-to-Present-at-Adenosine-Pathway-Targeted-Cancer-Immunotherapy-Summit.html","2023-06-13 08:00:00",-1.1634037400136137
"BIOR","Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","Initial Public Offerings","https://www.globenewswire.com/news-release/2023/06/13/2687091/0/en/Biora-Therapeutics-Announces-8-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html","2023-06-13 08:00:00",-20.09357481373963
"TLSA","Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/06/13/2687009/0/en/Tiziana-Life-Sciences-Promotes-Matthew-W-Davis-MD-RPh-to-Chief-Operating-Officer.html","2023-06-13 07:00:00",-0.3503963978845085
"IMNN","IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023","Press releases","https://www.globenewswire.com/news-release/2023/06/12/2686298/0/en/IMUNON-CEO-to-Discuss-Company-s-Novel-Non-viral-DNA-Therapy-Option-at-the-Mass-General-Brigham-World-Medical-Innovation-Forum-2023.html","2023-06-12 08:30:00",4.048449759785244
"WINT","Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism","Patents","https://www.globenewswire.com/news-release/2023/06/12/2686229/0/en/Windtree-Announces-Notice-of-Allowance-from-the-US-Patent-and-Trademark-Office-for-a-Group-of-SERCA2a-Activators-with-a-Dual-Mechanism.html","2023-06-12 08:00:00",1.4576446294164895
"OCUP","Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/06/12/2686261/0/en/Ocuphire-Presents-APX3330-ZETA-1-Data-at-Clinical-Trials-at-the-Summit-CTS-2023.html","2023-06-12 08:00:00",0.5606025548508596
"TTOO","T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use","Clinical Study","https://www.globenewswire.com/news-release/2023/06/09/2685564/32489/en/T2-Biosystems-Announces-Clinical-Collaboration-with-Vanderbilt-University-Medical-Center-to-Implement-and-Evaluate-the-T2Bacteria-Panel-for-Clinical-Use.html","2023-06-09 09:15:00",2.216224749099803
"BIOR","Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/08/2684790/0/en/Biora-Therapeutics-to-Present-Preclinical-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html","2023-06-08 09:00:00",0.7679005373126375
"RENB","Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/06/08/2684768/0/en/Enochian-BioSciences-Announces-that-its-Cancer-Platform-Remains-on-Track-for-Trials-in-Humans-Following-FDA-Review.html","2023-06-08 08:45:00",-1.9127443805430726
"IMNN","IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention","Press releases","https://www.globenewswire.com/news-release/2023/06/08/2684743/0/en/IMUNON-s-CEO-Presents-Business-Overview-to-Investors-and-Senior-Biopharmaceutical-Professionals-at-the-BIO-2023-International-Convention.html","2023-06-08 08:30:00",-0.016412454863960497
"BCDA","BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan","Patents","https://www.globenewswire.com/news-release/2023/06/08/2684599/0/en/BioCardia-Announces-Helix-Biotherapeutic-Delivery-Patent-Issuance-in-Japan.html","2023-06-08 07:00:00",2.998660032171281
"CAPR","Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/07/2683850/0/en/Capricor-Therapeutics-Announces-Follow-up-Type-B-Clinical-Meeting-with-the-FDA-for-CAP-1002-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html","2023-06-07 09:15:00",1.6395676780649966
"TLSA","Tiziana Life Sciences meldet Verringerung der mikroglialen Aktivierung bei insgesamt 5 von 6 an nicht-aktiver sekundär progredienter Multipler Sklerose erkrankten Patienten mit erweitertem Zugang zu intranasalem Foralumab","Clinical Study","https://www.globenewswire.com/news-release/2023/06/06/2682912/0/de/Tiziana-Life-Sciences-meldet-Verringerung-der-mikroglialen-Aktivierung-bei-insgesamt-5-von-6-an-nicht-aktiver-sekund%C3%A4r-progredienter-Multipler-Sklerose-erkrankten-Patienten-mit-erw.html","2023-06-06 09:03:00",-5.334106524276941
"ELOX","Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement","Exchange Members","https://www.globenewswire.com/news-release/2023/06/06/2682826/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html","2023-06-06 08:30:00",2.488741890598929
"KRON","Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance","Directors and Officers","https://www.globenewswire.com/news-release/2023/06/06/2682751/0/en/Kronos-Bio-Names-Marc-Besman-Ph-D-as-Senior-Vice-President-of-Regulatory-Affairs-and-Clinical-Quality-Assurance.html","2023-06-06 08:00:00",-0.4875574350512918
"TLSA","Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis","Clinical Study","https://www.globenewswire.com/news-release/2023/06/05/2682101/0/en/Tiziana-Life-Sciences-Announces-Reduction-in-Microglial-Activation-in-a-Total-of-5-Out-of-6-Intranasal-Foralumab-Expanded-Access-Patients-with-Non-Active-Secondary-Progressive-Mult.html","2023-06-05 10:00:00",-24.92773285749349
"TTOO","T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test","Company Announcement","https://www.globenewswire.com/news-release/2023/06/05/2682027/32489/en/T2-Biosystems-Announces-Submission-for-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html","2023-06-05 09:00:00",36.19038416372965
"WINT","Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones","Health","https://www.globenewswire.com/news-release/2023/06/05/2681890/0/en/Windtree-Therapeutics-to-Host-Virtual-R-D-and-Investor-Day-Focusing-on-the-Cardiogenic-Shock-Market-Istaroxime-Company-Strategy-and-Planned-Near-Term-Milestones.html","2023-06-05 08:00:00",0.6352993331816157
"IMRX","Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors","Clinical Study","https://www.globenewswire.com/news-release/2023/06/05/2681894/0/en/Immuneering-Completes-Dose-Escalation-in-the-IMM-1-104-Phase-1-Clinical-Trial-for-RAS-Mutant-Advanced-Solid-Tumors.html","2023-06-05 08:00:00",0.4873063026982583
"TSHA","Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome","Clinical Study","https://www.globenewswire.com/news-release/2023/06/05/2681911/0/en/Taysha-Gene-Therapies-Announces-First-Patient-Dosed-with-TSHA-102-in-the-REVEAL-Phase-1-2-Trial-Under-Investigation-for-the-Treatment-of-Rett-Syndrome.html","2023-06-05 08:00:00",0.16903684213520165
"INAB","IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/06/05/2681908/0/en/IN8bio-Announces-Positive-INB-200-Phase-1-Data-Update-in-Glioblastoma-at-the-2023-ASCO-Annual-Meeting.html","2023-06-05 08:00:00",-3.2587320683543286
"TGTX","TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/06/05/2681853/8790/en/TG-Therapeutics-to-Participate-in-the-2023-Jefferies-Healthcare-Conference.html","2023-06-05 07:30:00",-1.4018969956484035
"OCGN","Ocugen, Inc. Announces Business Advisory Board","Management Changes","https://www.globenewswire.com/news-release/2023/06/05/2681833/0/en/Ocugen-Inc-Announces-Business-Advisory-Board.html","2023-06-05 07:02:00",0.33960522114455116
"AKRO","Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease","Clinical Study","https://www.globenewswire.com/news-release/2023/06/05/2681816/0/en/Akero-Therapeutics-Phase-2b-SYMMETRY-Cohort-D-Study-Met-Safety-Tolerability-Endpoints-and-Showed-Adding-EFX-to-GLP-1-Therapy-Significantly-Improved-Non-Invasive-Markers-of-NASH-Rel.html","2023-06-05 07:00:00",-1.9244852847997058
"TGTX","TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/06/02/2681185/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-from-the-ULTIMATE-I-II-Phase-3-Trials-of-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-2023-Consortium-of-Multiple-Sclerosis-.html","2023-06-02 09:15:00",0.039470746286661765
"SCLX","Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information","Pre-Release Comments","https://www.globenewswire.com/news-release/2023/06/01/2680682/0/en/Scilex-Holding-Company-provides-certain-preliminary-unaudited-financial-results-for-gross-and-net-Sales-for-the-one-month-ended-May-2023-and-year-to-date-May-2023-based-on-currentl.html","2023-06-01 12:28:00",-2.3946538607910477
"TGTX","TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/06/01/2680448/8790/en/TG-Therapeutics-Announces-European-Commission-Approval-for-BRIUMVI-ublituximab-xiiy-for-the-Treatment-of-Relapsing-Forms-of-Multiple-Sclerosis-in-Adults.html","2023-06-01 09:15:00",0.3931882263010245
"CHRS","Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html","2023-06-01 08:33:00",1.8985537403867783
"DYAI","Dyadic to Participate at Upcoming Events in June","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/01/2680321/0/en/Dyadic-to-Participate-at-Upcoming-Events-in-June.html","2023-06-01 08:30:00",-1.3732227766718996
"ELTX","Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/06/01/2680276/0/en/Angion-Biomedia-Corp-Announces-1-for-10-Reverse-Stock-Split.html","2023-06-01 08:00:00",8.10583255220566
"EYEN","Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/01/2680264/0/en/Eyenovia-Announces-Presentation-at-the-OCTANE-Ophthalmology-Tech-Forum-2023.html","2023-06-01 08:00:00",-0.7616592431055249
"BTAI","BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/06/01/2680145/0/en/BioXcel-Therapeutics-to-Participate-at-Two-Upcoming-Investor-Conferences.html","2023-06-01 07:00:00",-0.1689198098078729
"SCLX","Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/31/2679753/0/en/Scilex-Holding-Company-Enters-Master-Distributor-Agreement-Among-CH-Trading-Group-LLC-CHT-or-Territories-Distributor-and-Farouk-Maamoun-Tamer-Co-Master-Distributor-For-the-Distribu.html","2023-05-31 15:16:00",-1.8741414638498413
"MLYS","Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/31/2679313/0/en/Mineralys-Therapeutics-to-Participate-in-the-Jefferies-Healthcare-Conference.html","2023-05-31 08:00:00",2.3389746451914504
"AKRO","Akero Therapeutics to Present at the Jefferies Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/31/2679310/0/en/Akero-Therapeutics-to-Present-at-the-Jefferies-Healthcare-Conference.html","2023-05-31 08:00:00",0.2699163637297946
"SCPH","scPharmaceuticals to Present at the Jefferies Healthcare Conference","Health","https://www.globenewswire.com/news-release/2023/05/31/2679300/0/en/scPharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference.html","2023-05-31 08:00:00",0.060413316466390206
"PCRX","Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/31/2679343/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-2023-Jefferies-Healthcare-Conference.html","2023-05-31 08:00:00",-0.006287282686587639
"BCAB","BioAtla to Participate in the Jefferies Healthcare Conference","Trade Show","https://www.globenewswire.com/news-release/2023/05/31/2679301/0/en/BioAtla-to-Participate-in-the-Jefferies-Healthcare-Conference.html","2023-05-31 08:00:00",-0.20787967017384495
"TGTX","TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/31/2679264/8790/en/TG-Therapeutics-Announces-Data-from-the-ULTIMATE-I-II-Phase-3-Trials-of-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-to-be-Presented-at-the-2023-Consortium-of-Multiple-Sclerosis-.html","2023-05-31 07:30:00",0.17756941088511424
"NTLA","Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/31/2679272/0/en/Intellia-Therapeutics-to-Present-Updated-Interim-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-HAE-at-the-EAACI-Hybrid-Congress-2023.html","2023-05-31 07:30:00",-0.2934834878562758
"ORPHA.CO","Change in management","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/30/2678759/0/en/Change-in-management.html","2023-05-30 13:41:00",19.907388072942105
"TALS","Talaris Therapeutics Announces Leadership Transition","Directors and Officers","https://www.globenewswire.com/news-release/2023/05/26/2676996/0/en/Talaris-Therapeutics-Announces-Leadership-Transition.html","2023-05-26 07:00:00",-2.411189699173556
"TLSA","Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/25/2675985/0/en/Tiziana-Life-Sciences-to-Host-KOL-Webinar-on-Foralumab-in-Non-Active-Secondary-Progressive-Multiple-Sclerosis-SPMS.html","2023-05-25 07:00:00",-0.8878819550462389
"BTAI","BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia","Health","https://www.globenewswire.com/news-release/2023/05/25/2675983/0/en/BioXcel-Therapeutics-Announces-Promising-Topline-Results-from-Part-1-of-Pivotal-SERENITY-III-Trial-of-BXCL501-for-At-Home-Use-in-Acute-Treatment-of-Agitation-in-Bipolar-Disorders-o.html","2023-05-25 07:00:00",-0.9264482055828416
"OCGN","Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/05/24/2675253/0/en/Ocugen-Inc-Announces-Pricing-of-16-5-Million-Public-Offering-of-Common-Stock.html","2023-05-24 08:36:00",-22.823413897293634
"ELOX","Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study","Clinical Study","https://www.globenewswire.com/news-release/2023/05/24/2675190/0/en/Eloxx-Pharmaceuticals-Intends-to-Advance-ELX-02-into-Pivotal-Trial-for-the-Treatment-of-Alport-Syndrome-with-Nonsense-Mutations-Following-Achievement-of-Remission-in-Patient-in-Pha.html","2023-05-24 08:00:00",-3.0891453736990244
"ALERS.PA","Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/23/2674617/0/fr/Eurobio-Scientific-devient-une-des-premi%C3%A8res-soci%C3%A9t%C3%A9s-europ%C3%A9ennes-%C3%A0-obtenir-le-marquage-CE-IVDR1-de-tests-PCR.html","2023-05-23 11:45:00",1.9073673137629323
"ALERS.PA","Eurobio Scientific becomes one of the first European companies to obtain IVDR1 CE marking of PCR tests","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/23/2674617/0/en/Eurobio-Scientific-becomes-one-of-the-first-European-companies-to-obtain-IVDR1-CE-marking-of-PCR-tests.html","2023-05-23 11:45:00",1.9073673137629323
"OCGN","Ocugen to Present at BIO International Convention 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/23/2674248/0/en/Ocugen-to-Present-at-BIO-International-Convention-2023.html","2023-05-23 08:00:00",0.8267374072847056
"TLSA","Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/23/2674142/0/en/Tiziana-Life-Sciences-Announces-Participation-on-the-Webull-Corporate-Communications-Service-Platform.html","2023-05-23 07:00:00",1.724112679059121
"BCDA","BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/23/2674138/0/en/BioCardia-Announces-Timing-of-the-Next-Data-Safety-Monitoring-Board-Meeting-for-the-CardiAMP-Cell-Therapy-in-Heart-Failure-Pivotal-Study.html","2023-05-23 07:00:00",1.0000398356911493
"PYPD","PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections","Business Contracts","https://www.globenewswire.com/news-release/2023/05/22/2673448/0/en/PolyPid-Announces-FDA-Agreement-on-the-Design-of-SHIELD-II-Phase-3-Trial-Evaluating-D-PLEX-for-Prevention-of-Abdominal-Colorectal-Surgical-Site-Infections.html","2023-05-22 09:00:00",5.258379148797437
"SCLX","Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023","Health","https://www.globenewswire.com/news-release/2023/05/22/2673437/0/en/Scilex-Holding-Company-Added-to-the-Preliminary-List-of-the-Russell-3000-Index-and-the-Small-Cap-Russell-2000-Index-as-part-of-the-2023-Russell-Indexes-Annual-Reconstitution-in-Jun.html","2023-05-22 09:00:00",0.8355530804783061
"TSHA","Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting","Trade Show","https://www.globenewswire.com/news-release/2023/05/19/2672510/0/en/Taysha-Gene-Therapies-Presents-Preclinical-Data-on-TSHA-102-for-Rett-Syndrome-Demonstrating-Cellular-Regulation-of-MeCP2-Expression-in-Key-Mouse-Models-at-the-American-Society-of-G.html","2023-05-19 08:00:00",8.77578231975016
"BMRA","inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology","Clinical Study","https://www.globenewswire.com/news-release/2023/05/18/2671867/0/en/inFoods-IBS-Test-Now-Validated-for-Use-with-Simple-Finger-Stick-Whole-Blood-Collection-Technology.html","2023-05-18 08:19:00",-4.920526826959605
"NSPR","InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","Regulatory information","https://www.globenewswire.com/news-release/2023/05/18/2671815/0/en/InspireMD-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html","2023-05-18 08:00:00",-2.193246977506713
"SNCE","Science 37 Wins 2023 MedTech Breakthrough Award for ""Best Overall Clinical Trial Platform""","Contests/Awards","https://www.globenewswire.com/news-release/2023/05/18/2671805/0/en/Science-37-Wins-2023-MedTech-Breakthrough-Award-for-Best-Overall-Clinical-Trial-Platform.html","2023-05-18 07:59:00",3.0206494545713047
"PEPG","PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy","Clinical Study","https://www.globenewswire.com/news-release/2023/05/18/2671748/0/en/PepGen-Announces-Clearance-by-Health-Canada-of-CTA-for-PGN-EDO51-to-Begin-the-Phase-2-Clinical-Trial-CONNECT1-EDO51-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html","2023-05-18 07:00:00",0.14834366965507315
"ORPHA.CO","Major shareholder announcement","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/17/2671372/0/en/Major-shareholder-announcement.html","2023-05-17 12:51:00",6.253440938946721
"INAB","IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer","Health","https://www.globenewswire.com/news-release/2023/05/17/2670958/0/en/IN8bio-s-DeltEx-Gamma-Delta-T-Cells-Show-Promise-in-Targeting-Ovarian-Cancer.html","2023-05-17 08:00:00",-0.13735301860447924
"TLSA","Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/17/2670851/0/en/Tiziana-Life-Sciences-Announces-Chief-Medical-Officer-Invited-to-Give-Presentation-on-Intranasal-Foralumab-on-May-17.html","2023-05-17 07:00:00",-1.777713574064261
"ICCC","ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/16/2669999/0/en/ImmuCell-to-Hold-Virtual-Only-Annual-Meeting-of-Stockholders.html","2023-05-16 09:00:00",-0.32516685716285226
"BTAI","BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program","Health","https://www.globenewswire.com/news-release/2023/05/16/2669821/0/en/BioXcel-Therapeutics-Announces-Positive-Top-Line-Data-from-Repeat-Dosing-of-BXCL501-in-Phase-1b-Multiple-Ascending-Dose-Trial-in-Healthy-Volunteers-for-Major-Depressive-Disorder-MD.html","2023-05-16 07:00:00",0.3886246531368373
"NSPR","InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/16/2669829/0/en/InspireMD-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-05-16 07:00:00",-8.417207154992397
"SPRY","ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/15/2668855/0/en/ARS-Pharmaceuticals-Highlights-Progress-and-Reports-First-Quarter-2023-Financial-Results.html","2023-05-15 09:00:00",0.7175768436214531
"NSPR","InspireMD Announces Private Placement of Up to $113.6 Million","Financing Agreements","https://www.globenewswire.com/news-release/2023/05/15/2668728/0/en/InspireMD-Announces-Private-Placement-of-Up-to-113-6-Million.html","2023-05-15 08:00:00",6.053824297290802
"OCUP","Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/15/2668732/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-First-Quarter-2023-and-Provides-Corporate-Update.html","2023-05-15 08:00:00",0.8419577611113502
"VIR","Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/05/15/2668713/0/en/Vir-Biotechnology-Appoints-Jeff-Calcagno-M-D-as-Executive-Vice-President-and-Chief-Business-Officer.html","2023-05-15 08:00:00",0.0494419126975785
"AKRO","Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/15/2668591/0/en/Akero-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-05-15 07:00:00",-1.1675301977152293
"ORPHA.CO","Major shareholder announcement","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/12/2668022/0/en/Major-shareholder-announcement.html","2023-05-12 12:02:00",-2.7240222004406394
"INAB","IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/12/2667745/0/en/IN8bio-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","2023-05-12 08:00:00",2.439280767813863
"MDWD","MediWound to Report First Quarter 2023 Financial Results","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/12/2667732/30505/en/MediWound-to-Report-First-Quarter-2023-Financial-Results.html","2023-05-12 08:00:00",0.8430581478085057
"LGVN","Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/12/2667754/0/en/Longeveron-Inc-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results.html","2023-05-12 08:00:00",0.2666994829666082
"MLTX","MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update","Company Announcement","https://www.globenewswire.com/news-release/2023/05/12/2667716/0/en/MoonLake-Immunotherapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html","2023-05-12 07:45:00",-1.661326955268859
"RVVTF","Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","Health","https://www.globenewswire.com/news-release/2023/05/12/2667677/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html","2023-05-12 07:00:00",-34.275273191078824
"VIR","Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html","2023-05-11 08:30:00",-0.5185034080397616
"IMNN","IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update","Press releases","https://www.globenewswire.com/news-release/2023/05/11/2666666/0/en/IMUNON-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-05-11 08:00:00",0.21799536954801832
"PEPG","PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/11/2666505/0/en/PepGen-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html","2023-05-11 07:00:00",0.013498213343707093
"DYAI","Dyadic to Participate at Two Industry Events in May","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/10/2665543/0/en/Dyadic-to-Participate-at-Two-Industry-Events-in-May.html","2023-05-10 08:30:00",-1.2734418483311343
"PYPD","PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/10/2665398/0/en/PolyPid-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results.html","2023-05-10 07:00:00",4.282106380163342
"IMCR","Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update","Press releases","https://www.globenewswire.com/news-release/2023/05/10/2665365/0/en/Immunocore-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html","2023-05-10 07:00:00",-1.1028232802395164
"PCIB.OL","PCI Biotech: Invitation to Q1 2023 results presentation","European Regulatory News","https://www.globenewswire.com/news-release/2023/05/09/2664612/0/en/PCI-Biotech-Invitation-to-Q1-2023-results-presentation.html","2023-05-09 09:52:00",14.643236313869174
"SPRY","ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/09/2664565/0/en/ARS-Pharmaceuticals-Announces-Availability-of-Briefing-Documents-for-FDA-Advisory-Committee-Meeting-on-neffy-for-the-Treatment-of-Type-I-Allergic-Reactions-Including-Anaphylaxis.html","2023-05-09 09:10:00",-1.2738272575911842
"PCRX","Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/09/2664354/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-2023-RBC-Capital-Markets-Global-Healthcare-Conference.html","2023-05-09 08:00:00",-0.08318102698571724
"RAD.AX","Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer","Health","https://www.globenewswire.com/news-release/2023/05/09/2664296/0/en/Radiopharm-Theranostics-Receives-FDA-Orphan-Drug-Designation-for-Trivehexin-RAD-301-in-Pancreatic-Cancer.html","2023-05-09 07:30:00",6.272428571950144
"MDWD","MediWound Announces an Additional $10 Million Award from BARDA","Financing Agreements","https://www.globenewswire.com/news-release/2023/05/09/2664300/30505/en/MediWound-Announces-an-Additional-10-Million-Award-from-BARDA.html","2023-05-09 07:30:00",0.39007253710702167
"BCDA","BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications","Patents","https://www.globenewswire.com/news-release/2023/05/09/2664254/0/en/BioCardia-Announces-US-Patent-on-Bone-Marrow-Derived-Neurokinin-1-Receptor-Positive-NK1R-Mesenchymal-Stem-Cells-for-Therapeutic-Applications.html","2023-05-09 07:00:00",-1.0805143232240997
"BIOR","Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/08/2663346/0/en/Biora-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html","2023-05-08 09:00:00",-0.47150208339723265
"DYAI","Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™","Health","https://www.globenewswire.com/news-release/2023/05/08/2663306/0/en/Dyadic-Announces-Collaboration-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html","2023-05-08 08:30:00",2.341849986135786
"EYEN","Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/08/2663251/0/en/Eyenovia-Announces-FDA-Approval-of-Mydcombi-the-First-Ophthalmic-Spray-for-Mydriasis-Which-Also-Leverages-the-Company-s-Proprietary-Optejet-Device-Platform.html","2023-05-08 08:00:00",2.091513629339098
"OPGN","OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/08/2663183/35690/en/OpGen-to-Provide-Business-Update-and-Financial-Results-for-the-First-Quarter-2023-on-May-15th-at-4-30-p-m-Eastern-Time.html","2023-05-08 07:30:00",3.320746977460371
"BTAI","BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/08/2663157/0/en/BioXcel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Operational-Highlights.html","2023-05-08 07:00:00",-9.447956596830652
"NSPR","InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/05/2662473/0/en/InspireMD-Announces-May-15th-as-New-Date-for-First-Quarter-2023-Financial-Results-and-Corporate-Business-Update.html","2023-05-05 08:00:00",1.3226033453837518
"OVID","Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/05/2662457/0/en/Ovid-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Corporate-Updates.html","2023-05-05 07:30:00",-4.768652740658346
"OCGN","Ocugen Provides Business Update with First Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/05/2662425/0/en/Ocugen-Provides-Business-Update-with-First-Quarter-2023-Financial-Results.html","2023-05-05 07:00:00",3.6712838204214804
"ADAG","Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/05/04/2661611/0/en/Adagene-Achieves-3-Million-Milestone-in-Collaboration-with-Exelixis-for-Successful-Nomination-of-Second-SAFEbody-Novel-Masked-Antibody-Drug-Conjugate.html","2023-05-04 09:00:00",0.2671428771236258
"SCLX","Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain","Clinical Study","https://www.globenewswire.com/news-release/2023/05/04/2661612/0/en/Scilex-Holding-Company-Announces-Complete-Enrollment-of-a-Phase-2-Study-to-Evaluate-the-Safety-and-Efficacy-of-SP-103-lidocaine-topical-system-5-4-Triple-Strength-Formulation-of-ZT.html","2023-05-04 09:00:00",0.2671428771236258
"CAPR","Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/04/2661614/0/en/Capricor-Therapeutics-to-Present-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Update-on-May-11.html","2023-05-04 09:00:00",-0.5141063952805964
"YTEN","Yield10 Bioscience to Announce First Quarter 2023 Financial Results and Host a Conference Call on Wednesday, May 10, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/04/2661544/34378/en/Yield10-Bioscience-to-Announce-First-Quarter-2023-Financial-Results-and-Host-a-Conference-Call-on-Wednesday-May-10-2023.html","2023-05-04 08:31:00",3.2671400161006767
"IMNN","IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023","Press releases","https://www.globenewswire.com/news-release/2023/05/04/2661505/0/en/IMUNON-to-Hold-First-Quarter-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-May-11-2023.html","2023-05-04 08:30:00",1.8544429626704835
"BCAB","BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/04/2661440/0/en/BioAtla-to-Announce-First-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-May-11-2023.html","2023-05-04 08:00:00",0.8019017240625321
"EYEN","Eyenovia to Report First Quarter 2023 Results on Thursday, May 11","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/04/2661428/0/en/Eyenovia-to-Report-First-Quarter-2023-Results-on-Thursday-May-11.html","2023-05-04 08:00:00",-0.08068287812009024
"TSHA","Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/04/2661426/0/en/Taysha-Gene-Therapies-to-Release-First-Quarter-2023-Financial-Results-and-Host-Conference-Call-and-Webcast-on-May-11.html","2023-05-04 08:00:00",-0.4735971441097559
"PEPG","PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/04/2661445/0/en/PepGen-to-Participate-in-the-Bank-of-America-Securities-2023-Healthcare-Conference.html","2023-05-04 08:00:00",-3.724739147554085
"NTLA","Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/04/2661383/0/en/Intellia-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html","2023-05-04 07:30:00",0.7336967442456039
"TGTX","TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/04/2661396/8790/en/TG-Therapeutics-to-Participate-in-the-Bank-of-America-Securities-2023-Health-Care-Conference.html","2023-05-04 07:30:00",0.20978566927644213
"CCCC","C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/04/2661295/0/en/C4-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html","2023-05-04 07:00:00",0.5856139003455187
"YTEN","Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/05/03/2660489/34378/en/Yield10-Bioscience-Announces-Pricing-of-3-0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html","2023-05-03 09:40:00",2.1632900628907583
"PCRX","Pacira BioSciences Reports First Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/03/2660310/0/en/Pacira-BioSciences-Reports-First-Quarter-2023-Financial-Results.html","2023-05-03 08:00:00",-4.582971287335573
"ANAB","AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)","Clinical Study","https://www.globenewswire.com/news-release/2023/05/02/2659323/0/en/AnaptysBio-Announces-British-Journal-of-Dermatology-Publication-of-Imsidolimab-IL-36R-Previously-Reported-Phase-2-GALLOP-Data-in-Generalized-Pustular-Psoriasis-GPP.html","2023-05-02 09:15:00",-0.05808029332800965
"VIR","Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention","Health","https://www.globenewswire.com/news-release/2023/05/02/2659283/0/en/Vir-Biotechnology-Receives-Expanded-Support-to-Develop-Its-Novel-T-Cell-Vaccine-Platform-with-New-10-Million-Grant-for-HIV-Prevention.html","2023-05-02 09:00:00",-0.4180835269802105
"OCUP","Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/02/2659176/0/en/Ocuphire-Announces-APX3330-and-Nyxol-Data-Presentations-at-ASCRS-2023-and-Eyecelerator.html","2023-05-02 08:30:00",0.510324978012458
"SCPH","scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/02/2659075/0/en/scPharmaceuticals-to-Announce-First-Quarter-2023-Financial-Results-on-Wednesday-May-10-2023.html","2023-05-02 08:00:00",1.1030752981810448
"MLYS","Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension","Health","https://www.globenewswire.com/news-release/2023/05/02/2659083/0/en/Mineralys-Therapeutics-Announces-First-Patient-Dosed-in-the-ADVANCE-HTN-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-and-Resistant-Hypertension.html","2023-05-02 08:00:00",0.10489126162674411
"ELOX","Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013","Clinical Study","https://www.globenewswire.com/news-release/2023/05/02/2659091/0/en/Eloxx-Pharmaceuticals-Announces-FDA-Clearance-to-Begin-Single-Ascending-Dose-Study-of-ZKN-013.html","2023-05-02 08:00:00",-1.1150062533693383
"SNCE","Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot","Partnerships","https://www.globenewswire.com/news-release/2023/05/02/2659048/0/en/Science-37-Joins-Partnership-in-Support-of-White-House-CancerX-and-Cancer-Moonshot.html","2023-05-02 07:59:00",-1.2303541322447924
"BTAI","BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference","Trade Show","https://www.globenewswire.com/news-release/2023/05/02/2658961/0/en/BioXcel-Therapeutics-to-Present-at-the-BofA-Securities-2023-Health-Care-Conference.html","2023-05-02 07:00:00",0.17809938017390856
"YTEN","Yield10 Bioscience and Marathon Petroleum Corporation Sign LOI for Potential Investment and Offtake Agreement for Camelina Feedstock Oil for Renewable Fuels","Partnerships","https://www.globenewswire.com/news-release/2023/05/01/2658369/34378/en/Yield10-Bioscience-and-Marathon-Petroleum-Corporation-Sign-LOI-for-Potential-Investment-and-Offtake-Agreement-for-Camelina-Feedstock-Oil-for-Renewable-Fuels.html","2023-05-01 09:17:00",9.233400468627188
"BIOR","Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer","Management Changes","https://www.globenewswire.com/news-release/2023/05/01/2658330/0/en/Biora-Therapeutics-Appoints-Dr-Ariella-Kelman-as-Chief-Medical-Officer.html","2023-05-01 09:00:00",-1.1239732095065422
"MLYS","Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/05/01/2658230/0/en/Mineralys-Therapeutics-to-Announce-First-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-Monday-May-15-2023.html","2023-05-01 08:00:00",0.5566932608641948
"NSPR","InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform","Clinical Study","https://www.globenewswire.com/news-release/2023/05/01/2658242/0/en/InspireMD-Announces-Successful-First-in-Human-Procedure-Utilizing-CGuard-Prime-its-Next-Generation-Carotid-Artery-Stent-CAS-Platform.html","2023-05-01 08:00:00",0.1105934804361872
"INAB","IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/05/01/2658240/0/en/IN8bio-Appoints-Jeremy-Graff-Ph-D-to-Board-of-Directors.html","2023-05-01 08:00:00",-1.259268191067437
"TGTX","TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/05/01/2658199/8790/en/TG-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2023-Financial-Results.html","2023-05-01 07:30:00",2.8089425676396598
"NTLA","Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities","Environmental, Social, and Governance Criteria","https://www.globenewswire.com/news-release/2023/05/01/2658192/0/en/Intellia-Therapeutics-Releases-2023-Corporate-Responsibility-Report-Highlighting-the-Advancement-of-its-Environmental-Social-Governance-ESG-Priorities.html","2023-05-01 07:30:00",-0.5781437951484568
"SNCE","Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/05/01/2658148/0/en/Science-37-to-Report-First-Quarter-2023-Financial-Results-on-May-15-2023.html","2023-05-01 07:00:00",4.688051655134247
"ALERS.PA","Eurobio Scientific : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022","European Regulatory News","https://www.globenewswire.com/news-release/2023/04/28/2657647/0/fr/Eurobio-Scientific-MISE-%C3%80-DISPOSITION-DU-RAPPORT-FINANCIER-ANNUEL-2022.html","2023-04-28 11:45:00",-1.5674062317062223
"ALERS.PA","EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022","European Regulatory News","https://www.globenewswire.com/news-release/2023/04/28/2657649/0/fr/EUROBIO-SCIENTIFIC-RAPPORT-FINANCIER-ANNUEL-2022.html","2023-04-28 11:45:00",-1.5674062317062223
"SCLX","Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/28/2657449/0/en/Scilex-Holding-Company-to-Participate-in-the-H-C-Wainwright-BioConnect-Investor-Conference-at-Nasdaq-on-May-2-2023.html","2023-04-28 09:00:00",-4.169678569769327
"BCDA","BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/28/2657312/0/en/BioCardia-Presentations-at-Next-Generation-Cardiovascular-Drug-Development-Summit-Now-Available.html","2023-04-28 07:00:00",1.2131803037622357
"ADAG","Adagene Announces Updates to its Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/04/28/2657314/0/en/Adagene-Announces-Updates-to-its-Board-of-Directors.html","2023-04-28 07:00:00",0.22308222874441933
"OCGN","Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/28/2657318/0/en/Ocugen-to-Host-Conference-Call-on-Friday-May-5-at-8-30-A-M-ET-to-Discuss-Business-Updates-and-First-Quarter-2023-Financial-Results.html","2023-04-28 07:00:00",0.08163290685472789
"OVID","Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/04/27/2656846/0/en/Long-term-Safety-Efficacy-Findings-from-Soticlestat-Open-Label-Extension-Study-Presented-by-Takeda-at-American-Academy-of-Neurology-Annual-Meeting.html","2023-04-27 14:30:00",6.43195473709716
"CAPR","Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/27/2656431/0/en/Capricor-Announces-Peer-Reviewed-Publication-Demonstrating-the-Therapeutic-Potential-of-Exosome-Based-Multivalent-Vaccine-Developed-from-its-StealthX-Platform.html","2023-04-27 09:00:00",0.10660572203672934
"WINT","Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime","Clinical Study","https://www.globenewswire.com/news-release/2023/04/27/2656271/0/en/Windtree-Therapeutics-Announces-Publication-from-Its-SEISMiC-Pre-Cardiogenic-Shock-Study-Comparing-Two-Doses-of-Istaroxime.html","2023-04-27 08:00:00",2.756207234284816
"CERT","Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year","Health","https://www.globenewswire.com/news-release/2023/04/27/2656261/0/en/Certara-Customers-Received-90-Percent-of-US-FDA-Novel-Drug-Approvals-for-9th-Consecutive-Year.html","2023-04-27 08:00:00",0.2239356563741502
"AKYA","Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument","Other News","https://www.globenewswire.com/news-release/2023/04/27/2656258/0/en/Akoya-Biosciences-Marks-Milestone-Achievement-with-Shipment-of-1-000th-Spatial-Biology-Instrument.html","2023-04-27 08:00:00",-0.35526844229176746
"NSPR","InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/27/2656294/0/en/InspireMD-to-Report-First-Quarter-2023-Financial-Results-on-May-9-2023-and-Provide-Corporate-Business-Update.html","2023-04-27 08:00:00",-0.652887215371272
"TGTX","TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services","Health","https://www.globenewswire.com/news-release/2023/04/27/2656215/8790/en/TG-Therapeutics-Announces-Issuance-of-Permanent-J-Code-for-BRIUMVI-ublituximab-xiiy-from-Centers-for-Medicare-and-Medicaid-Services.html","2023-04-27 07:30:00",0.25208496625146726
"NTLA","Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/27/2656209/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-First-Quarter-2023-Earnings-and-Company-Updates.html","2023-04-27 07:30:00",-0.4320706764104511
"OCGN","Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of  ABCA4-Associated Retinopathies","Health","https://www.globenewswire.com/news-release/2023/04/27/2656202/0/en/Ocugen-Announces-OCU410ST-Receives-Orphan-Drug-Designation-for-Treatment-of-ABCA4-Associated-Retinopathies.html","2023-04-27 07:25:00",0.45821782489663093
"TLSA","Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/27/2656161/0/en/Tiziana-Life-Sciences-Announces-Findings-from-Intranasal-Anti-CD3-mAb-Treatment-in-Intracerebral-Hemorrhage-at-the-Annual-American-Academy-of-Neurology-Conference.html","2023-04-27 07:00:00",3.944816375253616
"INAB","IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/04/26/2655295/0/en/IN8bio-Announces-Oral-Presentation-of-New-INB-200-Phase-1-Data-in-Glioblastoma-GBM-to-be-Presented-at-2023-ASCO-Annual-Meeting.html","2023-04-26 10:00:00",-1.919741945560121
"CNTG","CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/26/2655078/0/en/CENTOGENE-Accelerates-Global-Genetic-Data-Interpretation-Launching-FilterTool-Application-as-Accessory-to-CentoCloud-Bioinformatics-Pipeline.html","2023-04-26 08:30:00",1.06938467305368
"PCRX","Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/26/2654968/0/en/Pacira-to-Report-First-Quarter-2023-Financial-Results-on-Wednesday-May-3-2023.html","2023-04-26 08:00:00",-0.878815378417136
"MDWD","MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023","Health","https://www.globenewswire.com/news-release/2023/04/26/2654972/30505/en/MediWound-to-Present-Phase-2-EscharEx-Data-at-the-Symposium-on-Advanced-Wound-Care-SAWC-Spring-2023.html","2023-04-26 08:00:00",-1.7609880080401084
"PYPD","PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/26/2654861/0/en/PolyPid-to-Report-First-Quarter-2023-Financial-Results-and-Operational-Highlights-on-May-10-2023.html","2023-04-26 07:00:00",3.0534017509144937
"TGTX","TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/04/25/2653850/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-from-the-ULTIMATE-I-II-Phase-3-Trials-of-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-75th-Ann.html","2023-04-25 08:00:00",0.5851978422470528
"OCUP","Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs","Health","https://www.globenewswire.com/news-release/2023/04/25/2653839/0/en/Ocuphire-Provides-Corporate-Update-and-Reiterates-Previous-Guidance-on-Clinical-Programs.html","2023-04-25 08:00:00",-0.8115879768529344
"INAB","IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma","Clinical Study","https://www.globenewswire.com/news-release/2023/04/25/2653858/0/en/IN8bio-Receives-FDA-Orphan-Drug-Designation-for-INB-400-410-for-the-Treatment-of-Newly-Diagnosed-Glioblastoma.html","2023-04-25 08:00:00",-8.169848791571873
"SNCE","Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity","Management Changes","https://www.globenewswire.com/news-release/2023/04/25/2653799/0/en/Science-37-Appoints-SVP-Erica-Prowisor-to-Bolster-Patient-Recruitment-Velocity-Diversity.html","2023-04-25 07:59:00",-0.08797893650992336
"MYCO.CN","Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues","Clinical Study","https://www.globenewswire.com/news-release/2023/04/24/2652991/0/en/Mydecine-Reports-Positive-Preclinical-Results-on-the-MYCO-006-Series-of-its-Short-Acting-MDMA-Analogues.html","2023-04-24 11:16:00",-0.15534713551496848
"MYCOF","Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues","Clinical Study","https://www.globenewswire.com/news-release/2023/04/24/2652991/0/en/Mydecine-Reports-Positive-Preclinical-Results-on-the-MYCO-006-Series-of-its-Short-Acting-MDMA-Analogues.html","2023-04-24 11:16:00",-13.710900718966176
"INAB","IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/24/2652669/0/en/IN8bio-Presents-Positive-New-INB-100-Data-Showing-Long-term-Complete-Remissions-and-Elevated-Gamma-Delta-T-Cells-in-100-of-Evaluable-Treated-Leukemia-Patients-at-EBMT-2023.html","2023-04-24 08:00:00",141.00334064170477
"CDTX","Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/24/2652645/0/en/Cidara-Therapeutics-Receives-20-Million-Milestone-Payment-Following-FDA-Approval-of-REZZAYO.html","2023-04-24 08:00:00",0.05095147172163705
"EYEN","Eyenovia Announces Poster Presentation at ARVO 2023","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/24/2652646/0/en/Eyenovia-Announces-Poster-Presentation-at-ARVO-2023.html","2023-04-24 08:00:00",-0.5612976961245528
"FBIO","Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H","Health","https://www.globenewswire.com/news-release/2023/04/24/2652668/28889/en/Aevitas-Therapeutics-a-Fortress-Biotech-Subsidiary-Announces-Asset-Purchase-Agreement-with-4D-Molecular-Therapeutics-for-World-Wide-Rights-to-Aevitas-Short-Form-Human-Complement-Fa.html","2023-04-24 08:00:00",-1.3574957010771707
"PYPD","PolyPid to Participate in Upcoming Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/24/2652551/0/en/PolyPid-to-Participate-in-Upcoming-Investor-Conferences.html","2023-04-24 07:00:00",1.4463027158970154
"BTAI","BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/24/2652526/0/en/BioXcel-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-on-May-8-2023.html","2023-04-24 07:00:00",-0.7161968922879334
"OCUP","Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/04/21/2651886/0/en/Ocuphire-Appoints-Rick-Rodgers-as-Interim-Chief-Executive-Officer.html","2023-04-21 08:00:00",-8.354481005601784
"KA","Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/04/20/2651011/0/en/Kineta-Inc-Announces-6-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html","2023-04-20 08:38:00",-14.871446753815546
"WINT","Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering","Stock Market News","https://www.globenewswire.com/news-release/2023/04/20/2650991/0/en/Windtree-Therapeutics-Announces-Pricing-of-Upsized-10-8-Million-Underwritten-Public-Offering.html","2023-04-20 08:30:00",-56.43535891397392
"PCRX","Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/20/2650910/0/en/Pacira-BioSciences-Partners-with-The-Invited-Celebrity-Classic-a-PGA-TOUR-Champions-Event-to-Make-iovera-The-Official-Non-Opioid-Pain-Management-Partner.html","2023-04-20 08:00:00",0.2449343596709494
"SNCE","Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research","Partnerships","https://www.globenewswire.com/news-release/2023/04/20/2650902/0/en/Science-37-Collaborates-with-AWS-to-Enable-Faster-Patient-Friendly-Clinical-Research.html","2023-04-20 07:59:00",11.485943184232752
"IMNN","IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001","Press releases","https://www.globenewswire.com/news-release/2023/04/19/2650034/0/en/IMUNON-Presents-Poster-at-the-American-Association-for-Cancer-Research-Annual-Meeting-Demonstrating-Preclinical-Immune-Response-of-IMNN-001.html","2023-04-19 08:30:00",6.463340968493678
"MLTX","MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today","Press releases","https://www.globenewswire.com/news-release/2023/04/19/2650017/0/en/MoonLake-Immunotherapeutics-to-host-Capital-Markets-Day-in-New-York-and-virtually-today.html","2023-04-19 08:16:00",1.4905281086653153
"PCRX","Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/04/19/2649955/0/en/Pacira-BioSciences-Inc-Appoints-Christopher-Young-as-Chief-Manufacturing-Officer.html","2023-04-19 08:00:00",0.1123607111189113
"CCCC","C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/04/19/2649860/0/en/C4-Therapeutics-to-Participate-in-the-Stifel-2023-Virtual-Targeted-Oncology-Days.html","2023-04-19 07:00:00",-1.4063678282236012
"HARP","Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/04/18/2649471/0/en/Harpoon-Therapeutics-Presents-Preclinical-Results-for-Novel-T-Cell-Engagers-HPN217-and-HPN328-at-AACR-2023.html","2023-04-18 13:30:00",-6.813198554509969
"IMRX","Immuneering Announces $30 Million Underwritten Offering","Initial Public Offerings","https://www.globenewswire.com/news-release/2023/04/18/2649195/0/en/Immuneering-Announces-30-Million-Underwritten-Offering.html","2023-04-18 09:24:00",-6.548773146018521
"ADAG","Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors","Clinical Study","https://www.globenewswire.com/news-release/2023/04/18/2649190/0/en/Adagene-Presents-Clinical-Data-for-Anti-CTLA-4-SAFEbody-ADG126-Reinforcing-Best-in-Class-Safety-Profile-at-Repeat-Doses-and-Showing-Early-Efficacy-Profile-in-Advanced-Metastatic-So.html","2023-04-18 09:17:00",4.431392595282898
"IMRX","Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline","Clinical Study","https://www.globenewswire.com/news-release/2023/04/18/2649098/0/en/Immuneering-Announces-Positive-Initial-Phase-1-Pharmacokinetic-Pharmacodynamic-and-Safety-Data-for-IMM-1-104-Universal-RAS-Program-Accelerates-Study-Timeline.html","2023-04-18 09:00:00",-6.548773146018521
"DYAI","Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform","Patents","https://www.globenewswire.com/news-release/2023/04/18/2649016/0/en/Dyadic-Receives-U-S-Patent-for-Manufacturing-Seasonal-and-Pandemic-Influenza-Vaccines-from-its-Proprietary-C1-Protein-Production-Platform.html","2023-04-18 08:30:00",2.9005112087995926
"SNCE","Science 37 Adds New Head of Quality, Irena Lambridis","Directors and Officers","https://www.globenewswire.com/news-release/2023/04/18/2648887/0/en/Science-37-Adds-New-Head-of-Quality-Irena-Lambridis.html","2023-04-18 07:59:00",0.9195993864484383
"OPGN","OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel","Clinical Study","https://www.globenewswire.com/news-release/2023/04/18/2648851/35690/en/OpGen-Submits-De-Novo-request-to-the-U-S-FDA-for-Unyvero-Urinary-Tract-Infection-Panel.html","2023-04-18 07:30:00",3.1663614594814273
"IMCR","Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival","Press releases","https://www.globenewswire.com/news-release/2023/04/18/2648795/0/en/Immunocore-presents-new-KIMMTRAK-data-confirming-association-between-early-ctDNA-reduction-and-longer-overall-survival.html","2023-04-18 07:00:00",1.6167600215255338
"HARP","Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/04/17/2648353/0/en/Harpoon-Therapeutics-Presents-Data-for-New-ProTriTAC-Development-Candidates-in-TROP2-and-ITGB6-expressing-Solid-Tumors-at-AACR-2023.html","2023-04-17 13:30:00",-1.9454522974973076
"INAB","IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023","Health","https://www.globenewswire.com/news-release/2023/04/17/2648006/0/en/IN8bio-Announces-Positive-Preclinical-Data-for-Gamma-Delta-CAR-Platform-and-Launches-New-CD33-Program-at-AACR-Annual-Meeting-2023.html","2023-04-17 09:00:00",5.7242990422682265
"WINT","Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/17/2647851/0/en/Windtree-Therapeutics-Announces-Issuance-of-New-Dual-Mechanism-SERCA2a-Activator-Patent.html","2023-04-17 08:00:00",8.46930516125978
"PEPG","PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting","Health","https://www.globenewswire.com/news-release/2023/04/17/2647853/0/en/PepGen-Announces-Upcoming-Data-Presentations-at-the-2023-American-Academy-of-Neurology-Annual-Meeting.html","2023-04-17 08:00:00",3.214910158535621
"BMRA","Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/17/2647830/0/en/Biomerica-s-inFoods-IBS-test-is-now-available-at-Gastro-Health-providing-a-revolutionary-new-treatment-for-patients-suffering-from-Irritable-Bowel-Syndrome-IBS.html","2023-04-17 07:47:00",-1.1686556820103338
"RAD.AX","Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/17/2647815/0/en/Radiopharm-Theranostics-Enters-Into-Supply-Agreement-with-TerThera-for-Terbium-161-Isotope.html","2023-04-17 07:30:00",0.02181941030768476
"CNTG","CENTOGENE to Participate in Upcoming Conferences in April","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/14/2647012/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-April.html","2023-04-14 08:00:00",0.15962552547000294
"AKYA","Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data","Partnerships","https://www.globenewswire.com/news-release/2023/04/12/2645278/0/en/Akoya-Biosciences-and-Enable-Medicine-Introduce-Cloud-Platform-to-Power-Faster-Analysis-of-PhenoCycler-Fusion-Data.html","2023-04-12 08:00:00",2.233870941266558
"AKYA","Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/12/2645262/0/en/Akoya-Biosciences-Introduces-PhenoCode-Discovery-Panels-to-Simplify-PhenoCycler-Fusion-Workflow.html","2023-04-12 08:00:00",2.233870941266558
"DYAI","Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent","Licensing Agreements","https://www.globenewswire.com/news-release/2023/04/12/2645288/0/en/Dyadic-Announces-Expanded-Licensing-Agreement-to-Develop-and-Commercialize-Vaccines-and-Biologics-for-African-Continent.html","2023-04-12 08:00:00",1.0377576360628338
"PCRX","Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/12/2645255/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html","2023-04-12 08:00:00",0.29138383258880873
"INAB","IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/04/11/2644329/0/en/IN8bio-to-Present-New-Positive-Clinical-Data-from-Phase-1-Trial-of-INB-100-at-EBMT-2023-Annual-Meeting.html","2023-04-11 08:00:00",10.49704356614331
"IMCR","Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference","Press releases","https://www.globenewswire.com/news-release/2023/04/11/2644212/0/en/Immunocore-to-present-at-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html","2023-04-11 07:00:00",0.6231703156299817
"AKYA","Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/04/06/2642490/0/en/Akoya-to-Report-First-Quarter-2023-Financial-Results-on-May-8th-2023.html","2023-04-06 08:00:00",0.6063225908308343
"ALERS.PA","Eurobio Scientific : 2022 ANNUAL RESULTS - Very strong performance and strengthening of the Core Business","European Regulatory News","https://www.globenewswire.com/news-release/2023/04/05/2641992/0/en/Eurobio-Scientific-2022-ANNUAL-RESULTS-Very-strong-performance-and-strengthening-of-the-Core-Business.html","2023-04-05 11:41:00",-0.04746305297354475
"ALERS.PA","Eurobio Scientific: RESULTATS ANNUELS 2022 - Très solide performance et renforcement du Cœur d’Activité","European Regulatory News","https://www.globenewswire.com/news-release/2023/04/05/2641992/0/fr/Eurobio-Scientific-RESULTATS-ANNUELS-2022-Tr%C3%A8s-solide-performance-et-renforcement-du-C%C5%93ur-d-Activit%C3%A9.html","2023-04-05 11:41:00",-0.04746305297354475
"IMRX","Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023","Clinical Study","https://www.globenewswire.com/news-release/2023/04/05/2641610/0/en/Immuneering-to-Present-Initial-Phase-1-Pharmacokinetic-Pharmacodynamic-Modeling-and-Safety-Data-for-Universal-RAS-Program-IMM-1-104-at-American-Association-for-Cancer-Research-Annu.html","2023-04-05 08:00:00",-0.1767937327701669
"OPGN","OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/04/05/2641571/35690/en/OpGen-s-Subsidiary-Curetis-Signs-Expansion-of-R-D-Collaboration-with-FIND.html","2023-04-05 07:30:00",-0.5716125331590451
"KBLB","Kraig Biocraft Laboratories Preparing Response to U.S. Department of Defense Request for Information on Domestic Biomanufacturing of Spider Silk","Other News","https://www.globenewswire.com/news-release/2023/04/05/2641550/0/en/Kraig-Biocraft-Laboratories-Preparing-Response-to-U-S-Department-of-Defense-Request-for-Information-on-Domestic-Biomanufacturing-of-Spider-Silk.html","2023-04-05 07:05:00",0.185971502839269
"BCDA","BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies","Patents","https://www.globenewswire.com/news-release/2023/04/04/2640452/0/en/BioCardia-Announces-Issuance-of-Two-Patents-Related-to-Technology-That-Guides-Interventional-Therapies.html","2023-04-04 07:00:00",-2.163030794988585
"RENB","Enochian BioSciences’ CEO Letter to Shareholders","Management statements","https://www.globenewswire.com/news-release/2023/04/03/2639669/0/en/Enochian-BioSciences-CEO-Letter-to-Shareholders.html","2023-04-03 09:00:00",-2.8189150509599608
"ELOX","Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/04/03/2639530/0/en/Eloxx-Pharmaceuticals-Reports-Fourth-Quarter-2022-Financial-and-Operating-Results-and-Provides-Business-Update.html","2023-04-03 08:00:00",0.13190564635183047
"PCRX","Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources","Financing Agreements","https://www.globenewswire.com/news-release/2023/04/03/2639531/0/en/Pacira-BioSciences-Announces-Repayment-and-Termination-of-Term-Loan-B-Facility-Using-Proceeds-from-New-150-Million-5-Year-Term-Loan-A-Facility-and-Existing-Cash-Resources.html","2023-04-03 08:00:00",-0.08862890292361544
"WINT","Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/04/03/2639462/0/en/Windtree-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Provides-Key-Business-Updates.html","2023-04-03 07:35:00",-2.8740988708920923
"OPGN","OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics","Management statements","https://www.globenewswire.com/news-release/2023/04/03/2639437/35690/en/OpGen-s-Subsidiary-Curetis-Meets-Milestones-in-Collaborative-Research-Project-with-InfectoGnostics.html","2023-04-03 07:30:00",0.8837846042905818
"RVVTF","Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/04/03/2639397/0/en/Revive-Therapeutics-Advances-MDMA-Transdermal-Patch-Development-with-Purchase-of-MDMA-Supply-from-PharmAla-Biotech.html","2023-04-03 07:00:00",0.13190564635183047
"PYPD","PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds","Financing Agreements","https://www.globenewswire.com/news-release/2023/03/31/2638897/0/en/PolyPid-Announces-Closing-of-Underwritten-Public-Offering-Including-Full-Exercise-of-Overallotment-Option-and-Concurrent-Private-Placement-with-11-4-Million-in-Aggregate-Gross-Proc.html","2023-03-31 12:00:00",4.578241129751102
"CDTX","Cidara Therapeutics to Participate in Upcoming Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/31/2638585/0/en/Cidara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","2023-03-31 08:00:00",-1.8002967677586603
"TGTX","TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults","Health","https://www.globenewswire.com/news-release/2023/03/31/2638552/8790/en/TG-Therapeutics-Announces-Positive-CHMP-Opinion-for-BRIUMVI-ublituximab-xiiy-for-the-Treatment-of-Relapsing-Forms-of-Multiple-Sclerosis-in-Adults.html","2023-03-31 07:30:00",2.2228966086369635
"OPGN","CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/30/2638101/35690/en/CORRECTION-OpGen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html","2023-03-30 14:25:00",-3.1821858653988206
"NZYM-B.CO","Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner","Press releases","https://www.globenewswire.com/news-release/2023/03/30/2637989/0/en/Novozymes-and-Chr-Hansen-s-shareholders-approve-combination-to-create-a-leading-global-biosolutions-partner.html","2023-03-30 12:00:00",-0.274597778175187
"NZYM-B.CO","Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner","European Regulatory News","https://www.globenewswire.com/news-release/2023/03/30/2637980/0/en/Novozymes-and-Chr-Hansen-s-shareholders-approve-combination-to-create-a-leading-global-biosolutions-partner.html","2023-03-30 11:59:00",-0.274597778175187
"DYAI","Dyadic to Present at World Vaccine Congress Washington 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/30/2637625/0/en/Dyadic-to-Present-at-World-Vaccine-Congress-Washington-2023.html","2023-03-30 08:30:00",1.3307274279986725
"OCUP","Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/30/2637588/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Fourth-Quarter-and-Year-Ended-2022-and-Provides-Corporate-Update.html","2023-03-30 08:00:00",0.15064572566224846
"IMNN","IMUNON Reports 2022 Financial Results and Provides Business Update","Press releases","https://www.globenewswire.com/news-release/2023/03/30/2637567/0/en/IMUNON-Reports-2022-Financial-Results-and-Provides-Business-Update.html","2023-03-30 08:00:00",-0.6826934577567455
"NZYM-B.CO","Resolutions from Novozymes A/S’ Extraordinary Shareholders’ Meeting on 30 March 2023","European Regulatory News","https://www.globenewswire.com/news-release/2023/03/30/2637516/0/en/Resolutions-from-Novozymes-A-S-Extraordinary-Shareholders-Meeting-on-30-March-2023.html","2023-03-30 07:19:00",-0.1084758091506796
"NZYM-B.CO","Combination between Novozymes and Chr. Hansen approved by the Novozymes shareholders","European Regulatory News","https://www.globenewswire.com/news-release/2023/03/30/2637508/0/en/Combination-between-Novozymes-and-Chr-Hansen-approved-by-the-Novozymes-shareholders.html","2023-03-30 07:08:00",-0.1084758091506796
"NSPR","InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/30/2637494/0/en/InspireMD-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Provides-Business-Update.html","2023-03-30 07:00:00",-6.769644300716747
"RENB","Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/03/29/2636755/0/en/Enochian-BioSciences-Announces-a-Scientific-Presentation-of-Proof-of-Concept-Studies-for-a-Potential-Therapy-for-Cancers-with-a-Poor-Life-Expectancy-by-a-Leading-Researcher.html","2023-03-29 09:00:00",-1.0945365281750294
"BCDA","BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/29/2636648/0/en/BioCardia-Reports-Fourth-Quarter-and-Full-Year-2022-Business-Highlights-and-Financial-Results.html","2023-03-29 08:15:00",-1.0945365281750294
"PCRX","Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures","Health","https://www.globenewswire.com/news-release/2023/03/29/2636622/0/en/Pacira-Announces-FDA-Acceptance-of-sNDA-for-Exparel-Nerve-Blocks-to-Produce-Regional-Analgesia-in-Lower-Extremity-Procedures.html","2023-03-29 08:00:00",-0.09227762712709173
"PYPD","PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants","Initial Public Offerings","https://www.globenewswire.com/news-release/2023/03/29/2636582/0/en/PolyPid-Announces-Pricing-of-6-2-Million-Underwritten-Public-Offering-of-Ordinary-Shares-and-Concurrent-4-4-Million-Private-Placement-of-Pre-Funded-Warrants.html","2023-03-29 07:59:00",-16.884010212385554
"SPRY","ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/03/28/2635830/0/en/ARS-Pharmaceuticals-Announces-FDA-Advisory-Committee-for-neffy-for-the-Treatment-of-Allergic-Reactions-Type-1-Including-Anaphylaxis.html","2023-03-28 09:39:00",-0.9271930942466777
"IMRX","Immuneering Appoints Harold E. Brakewood as Chief Business Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/03/28/2635614/0/en/Immuneering-Appoints-Harold-E-Brakewood-as-Chief-Business-Officer.html","2023-03-28 08:00:00",2.1559255523749306
"RAD.AX","Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/28/2635541/0/en/Radiopharm-Theranostics-Invited-to-Participate-in-Jefferies-Radiopharma-Innovation-Summit.html","2023-03-28 07:30:00",-2.675546385854135
"RVVTF","Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder","Clinical Study","https://www.globenewswire.com/news-release/2023/03/28/2635528/0/en/Revive-Therapeutics-Provides-Update-on-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder.html","2023-03-28 07:00:00",0.18159379516176805
"ONCT","Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","Stock Market News","https://www.globenewswire.com/news-release/2023/03/27/2634811/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html","2023-03-27 09:00:00",0.5505625001823046
"PCRX","Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit","Press releases","https://www.globenewswire.com/news-release/2023/03/27/2634697/0/en/Third-Circuit-Court-Upholds-Decision-to-Dismiss-Pacira-BioSciences-Inc-Lawsuit.html","2023-03-27 08:00:00",1.0362926321878088
"EYEN","Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/23/2633055/0/en/Eyenovia-to-Report-Fourth-Quarter-and-Full-Year-2022-Results-on-Thursday-March-30.html","2023-03-23 08:00:00",1.437806437316305
"OCUP","Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/03/23/2633095/0/en/Ocuphire-Announces-APX3330-and-Nyxol-Data-Presentations-at-ARVO-2023-Annual-Meeting.html","2023-03-23 08:00:00",-1.0385449221888423
"CDTX","Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/23/2633001/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","2023-03-23 07:12:00",-11.286305806200792
"PEPG","PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference","Health","https://www.globenewswire.com/news-release/2023/03/22/2632136/0/en/PepGen-Presents-Clinical-and-Nonclinical-Data-at-the-2023-Annual-Muscular-Dystrophy-Association-Clinical-and-Scientific-Conference.html","2023-03-22 08:00:00",7.280412548513586
"PCRX","Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2023/03/22/2632141/0/en/Pacira-BioSciences-Announces-Yvonne-Greenstreet-to-Retire-from-Board-of-Directors.html","2023-03-22 08:00:00",0.020299073355165193
"NTLA","Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema","Health","https://www.globenewswire.com/news-release/2023/03/21/2631168/0/en/Intellia-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema.html","2023-03-21 07:30:00",0.4959820932509379
"NZYM-B.CO","Trading by management and close relations of management","European Regulatory News","https://www.globenewswire.com/news-release/2023/03/20/2630292/0/en/Trading-by-management-and-close-relations-of-management.html","2023-03-20 08:38:00",-0.20769701245587358
"RVVTF","Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","Clinical Study","https://www.globenewswire.com/news-release/2023/03/20/2630256/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html","2023-03-20 08:28:00",-37.888852755185376
"NSPR","InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/03/20/2630192/0/en/InspireMD-Announces-Promotion-of-Andrea-Tommasoli-to-Chief-Operating-Officer.html","2023-03-20 08:00:00",3.0709883084447784
"MLTX","MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update","Press releases","https://www.globenewswire.com/news-release/2023/03/20/2630167/0/en/MoonLake-Immunotherapeutics-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Provides-a-Business-Update.html","2023-03-20 07:45:00",-4.2699210898233435
"AKRO","Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/17/2629388/0/en/Akero-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","2023-03-17 07:00:00",1.3083521115191183
"BCAB","BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/16/2628593/0/en/BioAtla-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provide-Business-Highlights.html","2023-03-16 08:00:00",0.24130905234910116
"PEPG","PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/16/2628613/0/en/PepGen-to-Host-Fourth-Quarter-and-Full-Year-2022-Financial-Results-Call.html","2023-03-16 08:00:00",-1.8443897655586448
"MDWD","MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/16/2628508/30505/en/MediWound-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Company-Update.html","2023-03-16 07:10:00",-6.984548743502911
"BCDA","BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/16/2628490/0/en/BioCardia-to-Host-2022-Financial-Results-and-Corporate-Update-Conference-Call-on-March-29-2023.html","2023-03-16 07:00:00",2.1547748537330476
"MDWD","MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer","Directors and Officers","https://www.globenewswire.com/news-release/2023/03/16/2628474/30505/en/MediWound-Announces-the-Appointment-of-Hani-Luxenburg-as-Chief-Financial-Officer.html","2023-03-16 07:00:00",-6.984548743502911
"SCPH","scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/15/2627575/0/en/scPharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-Wednesday-March-22.html","2023-03-15 08:00:00",-0.639861400469847
"VBLT","VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/14/2626587/0/en/VBL-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html","2023-03-14 08:00:00",6.829440001570565
"RENB","Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements","Stock Market News","https://www.globenewswire.com/news-release/2023/03/13/2625713/0/en/Enochian-BioSciences-Achieves-Full-Compliance-with-NASDAQ-Filing-Requirements.html","2023-03-13 08:30:00",-0.8067426926388072
"PEPG","PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/13/2625653/0/en/PepGen-Announces-Upcoming-Data-Presentations-at-the-2023-Annual-Muscle-Dystrophy-Association-Clinical-and-Scientific-Conference.html","2023-03-13 08:00:00",-0.9556675477109674
"WINT","Windtree Regains Compliance with Nasdaq","Changes in company's own shares","https://www.globenewswire.com/news-release/2023/03/13/2625637/0/en/Windtree-Regains-Compliance-with-Nasdaq.html","2023-03-13 08:00:00",-2.617229969461319
"OVID","Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/13/2625656/0/en/Ovid-Therapeutics-Reports-Business-Update-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html","2023-03-13 08:00:00",-2.937576693042887
"VBLT","VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash","Company Announcement","https://www.globenewswire.com/news-release/2023/03/09/2624072/0/en/VBL-Therapeutics-Announces-Closing-of-Sale-of-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html","2023-03-09 08:00:00",1.7552391464948665
"CERT","A.I. Coming to Certara’s D360 Scientific Informatics Software","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/03/09/2624051/0/en/A-I-Coming-to-Certara-s-D360-Scientific-Informatics-Software.html","2023-03-09 08:00:00",0.358886055729103
"OVID","Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/09/2624046/0/en/Ovid-Therapeutics-to-Present-at-the-2nd-Annual-Needham-Virtual-Neuroscience-Forum.html","2023-03-09 08:00:00",-3.9555553863562807
"BTAI","BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/03/09/2623898/0/en/BioXcel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Operational-Highlights.html","2023-03-09 07:00:00",-5.283124999353728
"CAPR","Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/08/2623124/0/en/Capricor-Therapeutics-to-Present-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Corporate-Update-on-March-15.html","2023-03-08 09:00:00",1.0202773560391907
"YTEN","Yield10 Bioscience to Announce Fourth Quarter and Full Year 2022 Financial Results and Host a Conference Call on Tuesday, March 14, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/08/2623049/34378/en/Yield10-Bioscience-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Host-a-Conference-Call-on-Tuesday-March-14-2023.html","2023-03-08 08:32:00",-2.8079200476932185
"BMRA","Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed","Health","https://www.globenewswire.com/news-release/2023/03/08/2623008/0/en/Biomerica-announces-the-Launch-of-InFoods-IBS-as-a-Laboratory-Developed-Test-LDT-First-patient-samples-have-been-processed.html","2023-03-08 08:19:00",1.716586503152991
"PCRX","Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/03/08/2622954/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-2023-Barclays-Global-Healthcare-Conference.html","2023-03-08 08:00:00",0.48953433358034804
"OVID","Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures","Clinical Study","https://www.globenewswire.com/news-release/2023/03/08/2622968/0/en/Studies-Published-in-Cell-Reports-Medicine-Validate-the-Potential-of-Direct-KCC2-Activation-in-Resistant-Seizures.html","2023-03-08 08:00:00",-0.8464624871817319
"RVVTF","Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","Clinical Study","https://www.globenewswire.com/news-release/2023/03/08/2622940/0/en/Revive-Therapeutics-Provides-Update-From-Type-C-Meeting-with-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html","2023-03-08 07:45:00",-1.0202377328871666
"RZLT","Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/08/2622893/0/en/Rezolute-to-Highlight-RZ402-Phase-2-Clinical-Program-with-Leading-Clinical-Expert.html","2023-03-08 07:00:00",-2.096260269914844
"FBIO","Fortress Biotech to Participate in Two March 2023 Investor Conferences","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/07/2622003/28889/en/Fortress-Biotech-to-Participate-in-Two-March-2023-Investor-Conferences.html","2023-03-07 08:00:00",0.012358838187723509
"CERT","Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/03/07/2621986/0/en/Certara-announces-the-release-of-Simcyp-PBPK-Simulator-Version-22-expanding-ability-to-simulate-untested-scenarios-for-new-patient-and-therapeutic-types.html","2023-03-07 08:00:00",-0.6866142509528319
"WINT","Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime","Health","https://www.globenewswire.com/news-release/2023/03/06/2621027/0/en/Windtree-Finds-Cardiogenic-Shock-Has-High-Cost-of-US-Patient-Care-and-Plans-Innovation-with-the-Unique-Profile-of-Istaroxime.html","2023-03-06 08:00:00",-5.561226585091788
"BCDA","Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting","Law & Legal Issues","https://www.globenewswire.com/news-release/2023/03/06/2620928/0/en/Positive-Echocardiography-Data-from-BioCardia-Phase-III-CardiAMP-Cell-Therapy-Heart-Failure-Trial-Presented-at-American-College-of-Cardiology-Annual-Meeting.html","2023-03-06 07:00:00",-2.4349876989696106
"MYCOF","Mydecine Announces Debt Settlements","Stock Market News","https://www.globenewswire.com/news-release/2023/03/06/2620930/0/en/Mydecine-Announces-Debt-Settlements.html","2023-03-06 07:00:00",-3.8491318481377492
"MYCO.CN","Mydecine Announces Debt Settlements","Stock Market News","https://www.globenewswire.com/news-release/2023/03/06/2620930/0/en/Mydecine-Announces-Debt-Settlements.html","2023-03-06 07:00:00",-10.557595890965937
"RAD.AX","Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/03/03/2620252/0/en/Radiopharm-Theranostics-Partners-With-Next-Generation-Preclinical-Platform-for-Therapeutic-Radiopharmaceuticals.html","2023-03-03 08:41:00",-0.47761341045847483
"TGTX","TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting","Clinical Study","https://www.globenewswire.com/news-release/2023/03/03/2620225/8790/en/TG-Therapeutics-Announces-Data-Presentations-from-the-ULTIMATE-I-II-Phase-3-Trials-of-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-to-be-Presented-at-the-American-Academy-of-Neur.html","2023-03-03 08:30:00",0.4675697860523392
"RAD.AX","Dr Ken Herrmann Appointed to RAD Scientific Advisory Board","Directors and Officers","https://www.globenewswire.com/news-release/2023/03/03/2620158/0/en/Dr-Ken-Herrmann-Appointed-to-RAD-Scientific-Advisory-Board.html","2023-03-03 07:30:00",-0.47761341045847483
"BMRA","Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock","Prospectus/Announcement of Prospectus","https://www.globenewswire.com/news-release/2023/03/03/2620157/0/en/Biomerica-Announces-Pricing-of-8-Million-Underwritten-Public-Offering-of-Common-Stock.html","2023-03-03 07:30:00",-10.549554931011572
"CAPR","Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award","Contests/Awards","https://www.globenewswire.com/news-release/2023/03/02/2619446/0/en/Capricor-Therapeutics-Receives-Clinical-Research-Forum-s-2023-Top-Ten-Clinical-Research-Achievement-Award.html","2023-03-02 09:15:00",0.9194758045283545
"YTEN","Yield10 Bioscience and American Airlines Sign MOU to Form a Collaboration to Develop the Value Chain for Camelina as a Feedstock Oil for Sustainable Aviation Fuel","Partnerships","https://www.globenewswire.com/news-release/2023/03/02/2619337/34378/en/Yield10-Bioscience-and-American-Airlines-Sign-MOU-to-Form-a-Collaboration-to-Develop-the-Value-Chain-for-Camelina-as-a-Feedstock-Oil-for-Sustainable-Aviation-Fuel.html","2023-03-02 08:30:00",8.357684009923872
"NSPR","InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/03/02/2619253/0/en/InspireMD-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-30-2023-and-Provide-a-Corporate-Business-Update.html","2023-03-02 08:00:00",1.3621971788323977
"NTLA","Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/03/02/2619120/0/en/Intellia-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-NTLA-2002-an-In-Vivo-CRISPR-Based-Investigational-Therapy-for-the-Treatment-of-Heredit.html","2023-03-02 07:00:00",8.202846102426344
"IMCR","Immunocore Reports 2022 Financial Results and Provides Business Update","Press releases","https://www.globenewswire.com/news-release/2023/03/01/2618009/0/en/Immunocore-Reports-2022-Financial-Results-and-Provides-Business-Update.html","2023-03-01 07:00:00",-3.960510457325292
"PCRX","Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/02/28/2617015/0/en/Pacira-BioSciences-Reports-Full-Year-and-Fourth-Quarter-2022-Financial-Results.html","2023-02-28 08:00:00",1.7858704523723128
"IMRX","Immuneering Announces Participation in March Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/28/2616995/0/en/Immuneering-Announces-Participation-in-March-Investor-Conferences.html","2023-02-28 08:00:00",0.5423796729523904
"OVID","Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/02/28/2617028/0/en/Ovid-Therapeutics-to-Present-at-the-43rd-Annual-Cowen-Healthcare-Conference.html","2023-02-28 08:00:00",0.12571342020685167
"AKYA","Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel","Directors and Officers","https://www.globenewswire.com/news-release/2023/02/28/2617008/0/en/Akoya-Biosciences-Announces-Appointment-of-Jennifer-Kamocsay-as-General-Counsel.html","2023-02-28 08:00:00",0.12571342020685167
"WINT","Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/02/28/2616971/0/en/Windtree-Announces-Publication-on-its-SERCA2a-Activator-Drug-Candidate-for-Chronic-and-Acute-Heart-Failure.html","2023-02-28 08:00:00",-7.9953090613736055
"TGTX","TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/02/28/2616931/8790/en/TG-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results.html","2023-02-28 07:30:00",-7.030597449117858
"KBLB","Kraig Biocraft Laboratories Adds Two New Positions on Research Team to Accelerate Implementation of its Spider Silk Technology Roadmap","Management statements","https://www.globenewswire.com/news-release/2023/02/28/2616891/0/en/Kraig-Biocraft-Laboratories-Adds-Two-New-Positions-on-Research-Team-to-Accelerate-Implementation-of-its-Spider-Silk-Technology-Roadmap.html","2023-02-28 07:05:00",0.12571342020685167
"IMCR","Immunocore to present at upcoming investor conferences","Press releases","https://www.globenewswire.com/news-release/2023/02/28/2616858/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html","2023-02-28 07:00:00",1.3800951148388174
"BCAB","BioAtla Announces Change in Executive Leadership","Directors and Officers","https://www.globenewswire.com/news-release/2023/02/27/2616085/0/en/BioAtla-Announces-Change-in-Executive-Leadership.html","2023-02-27 08:07:00",-0.8804657630010364
"WINT","Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/27/2616022/0/en/Windtree-Announces-Istaroxime-Scientific-Abstract-Has-Been-Accepted-at-the-2023-Technology-and-Heart-Failure-Therapeutics-Conference.html","2023-02-27 08:00:00",-0.5906109709707957
"IMRX","Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/27/2616045/0/en/Immuneering-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Updates.html","2023-02-27 08:00:00",-0.667251436291537
"WINT","Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office","Patents","https://www.globenewswire.com/news-release/2023/02/24/2615205/0/en/Windtree-Therapeutics-Announces-Issuance-of-New-Istaroxime-Patent-from-U-S-Patent-and-Trademark-Office.html","2023-02-24 08:00:00",4.807836273401432
"WINT","Windtree Therapeutics Announces Reverse Stock Split","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/02/23/2614644/0/en/Windtree-Therapeutics-Announces-Reverse-Stock-Split.html","2023-02-23 12:00:00",-35.77587560963339
"SCPH","scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/02/23/2614259/0/en/scPharmaceuticals-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html","2023-02-23 08:00:00",-0.6343152361904637
"BCAB","BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma","Clinical Study","https://www.globenewswire.com/news-release/2023/02/23/2614225/0/en/BioAtla-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-BA3182-a-CAB-EpCAMxCAB-CD3-Bispecific-T-Cell-Engager-for-the-Treatment-of-Advanced-Adenocarcinoma.html","2023-02-23 08:00:00",-1.3886772820714617
"NTLA","Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2023/02/23/2614167/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html","2023-02-23 07:30:00",3.941779545924675
"VBLT","VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/02/23/2614116/0/en/VBL-Therapeutics-and-Notable-Labs-Announce-Definitive-Merger-Agreement.html","2023-02-23 07:00:00",67.70377909234094
"BTAI","BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/23/2614089/0/en/BioXcel-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-9-2023.html","2023-02-23 07:00:00",1.0953794877918765
"IMCR","Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023","Press releases","https://www.globenewswire.com/news-release/2023/02/23/2614106/0/en/Immunocore-to-Report-Fourth-Quarter-and-Full-Year-2022-Earnings-and-Host-Call-on-March-1-2023.html","2023-02-23 07:00:00",0.16221396918298225
"CCCC","C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/23/2614105/0/en/C4-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Business-Highlights.html","2023-02-23 07:00:00",-2.1091131176315905
"IMCR","Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV","Health","https://www.globenewswire.com/news-release/2023/02/22/2613010/0/en/Immunocore-announces-initial-Phase-1-safety-and-pharmacodynamic-activity-data-with-first-soluble-TCR-therapy-for-people-living-with-HIV.html","2023-02-22 07:00:00",-1.626513614956716
"FBIO","Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","Clinical Study","https://www.globenewswire.com/news-release/2023/02/16/2609775/28889/en/Helocyte-Inc-Announces-Positive-Data-from-Stem-Cell-Transplant-Donor-Vaccination-Trial-to-be-Presented-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-ASTC.html","2023-02-16 08:30:00",2.605032177553647
"OCUP","Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/16/2609773/0/en/Ocuphire-Announces-APX3330-Phase-2-Data-Presentations-at-Retina-Meetings.html","2023-02-16 08:30:00",2.559172344056394
"VBLT","VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash","Other News","https://www.globenewswire.com/news-release/2023/02/16/2609663/0/en/VBL-Therapeutics-Announces-Agreement-to-Sell-Manufacturing-Facility-and-Certain-Related-Assets-for-7-1-Million-in-Cash.html","2023-02-16 08:00:00",-0.10686266670428268
"NTLA","Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/16/2609595/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2022-Earnings-and-Company-Updates.html","2023-02-16 07:30:00",-1.7142379022744298
"TALS","Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan","Major shareholder announcements","https://www.globenewswire.com/news-release/2023/02/16/2609545/0/en/Talaris-Therapeutics-Announces-Plans-to-Explore-Strategic-Alternatives-and-Implements-Restructuring-Plan.html","2023-02-16 07:00:00",10.1144426569192
"ICCC","ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/15/2609049/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Year-Ended-December-31-2022.html","2023-02-15 11:55:00",0.6756669009633398
"EYEN","Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals","Health","https://www.globenewswire.com/news-release/2023/02/15/2608912/0/en/Eyenovia-Announces-Development-Collaboration-Agreement-with-Formosa-Pharmaceuticals.html","2023-02-15 09:51:00",9.300567832176869
"FBIO","Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex","Clinical Study","https://www.globenewswire.com/news-release/2023/02/15/2608720/28889/en/Study-Published-in-American-Journal-of-Hematology-Demonstrates-First-Reported-Evidence-of-Safe-and-Successful-Boosting-of-Cytomegalovirus-Vaccine-Specific-T-Cell-Immunity-in-a-Stem.html","2023-02-15 08:30:00",0.5549652151095731
"ALERS.PA","Eurobio Scientific : Wietse Mulder, CEO de GenDx,  détient 2% du capital","European Regulatory News","https://www.globenewswire.com/news-release/2023/02/14/2607947/0/fr/Eurobio-Scientific-Wietse-Mulder-CEO-de-GenDx-d%C3%A9tient-2-du-capital.html","2023-02-14 11:45:00",-0.6129255496499264
"ALERS.PA","Eurobio Scientific: Wietse Mulder, CEO of GenDx, holds a 2% stake","European Regulatory News","https://www.globenewswire.com/news-release/2023/02/14/2607947/0/en/Eurobio-Scientific-Wietse-Mulder-CEO-of-GenDx-holds-a-2-stake.html","2023-02-14 11:45:00",-0.6129255496499264
"RAD.AX","Radiopharm Theranostics Initiates Process for Nasdaq Listing","Exchange announcement","https://www.globenewswire.com/news-release/2023/02/14/2607567/0/en/Radiopharm-Theranostics-Initiates-Process-for-Nasdaq-Listing.html","2023-02-14 08:00:00",4.231307335448499
"NSPR","InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing","Company Announcement","https://www.globenewswire.com/news-release/2023/02/14/2607549/0/en/InspireMD-Announces-Hiring-of-Medical-Device-Commercial-Veteran-Shane-Gleason-as-General-Manager-of-North-America-and-VP-of-Global-Marketing.html","2023-02-14 08:00:00",-1.254197106685593
"PCIB.OL","PCI Biotech: Invitation to Q4 2022 results presentation","European Regulatory News","https://www.globenewswire.com/news-release/2023/02/13/2606763/0/en/PCI-Biotech-Invitation-to-Q4-2022-results-presentation.html","2023-02-13 09:35:00",-9.622806228178819
"FBIO","Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","Stock Market News","https://www.globenewswire.com/news-release/2023/02/10/2606152/28889/en/Fortress-Biotech-Announces-Closing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html","2023-02-10 12:50:00",2.165558972079972
"PEPG","PepGen to Participate in the SVB Securities Global Biopharma Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/02/09/2604938/0/en/PepGen-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html","2023-02-09 08:00:00",0.7151313350296655
"ALERS.PA","Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO","European Regulatory News","https://www.globenewswire.com/news-release/2023/02/08/2604261/0/en/Eurobio-Scientific-formalises-the-appointment-of-Anne-Sophie-H%C3%A9relle-as-Group-CFO.html","2023-02-08 11:45:00",1.7728328197877352
"OVID","Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments","Management Changes","https://www.globenewswire.com/news-release/2023/02/08/2603920/0/en/Ovid-Therapeutics-Expands-Epilepsy-Development-Expertise-with-New-Appointments.html","2023-02-08 08:00:00",-0.6896118391795756
"FBIO","Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","Prospectus/Announcement of Prospectus","https://www.globenewswire.com/news-release/2023/02/08/2603922/28889/en/Fortress-Biotech-Announces-Pricing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html","2023-02-08 08:00:00",-14.980038268339255
"BTAI","BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/02/08/2603791/0/en/BioXcel-Therapeutics-to-Host-BXCL701-Key-Opinion-Leader-Day-to-Highlight-Company-s-Investigational-Oral-Innate-Immune-Activator-for-Rare-Form-of-Prostate-Cancer.html","2023-02-08 07:00:00",3.265790791049475
"CCCC","C4 Therapeutics to Present at Two Virtual February 2023 Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/08/2603789/0/en/C4-Therapeutics-to-Present-at-Two-Virtual-February-2023-Conferences.html","2023-02-08 07:00:00",0.4961577943786032
"HARP","Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/07/2602863/0/en/Harpoon-Therapeutics-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html","2023-02-07 07:30:00",0.23424138948623494
"AKYA","Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/02/06/2602048/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-6th-2023-and-Participate-at-Two-Upcoming-Investor-Conferences.html","2023-02-06 08:05:00",-0.04639084562515104
"RVVTF","Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development","Health","https://www.globenewswire.com/news-release/2023/02/06/2602026/0/en/Revive-Therapeutics-Secures-MDMA-Supply-from-PharmAla-Biotech-for-MDMA-Transdermal-Patch-Development.html","2023-02-06 08:00:00",10.62082898119574
"SCPH","scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","Stock Market News","https://www.globenewswire.com/news-release/2023/02/06/2601997/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","2023-02-06 08:00:00",1.1189627628603216
"MLTX","MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa","Company Announcement","https://www.globenewswire.com/news-release/2023/02/02/2600382/0/en/MoonLake-Immunotherapeutics-completes-patient-enrollment-and-randomization-ahead-of-schedule-in-a-Phase-2-trial-of-the-Nanobody-sonelokimab-in-moderate-to-severe-hidradenitis-suppu.html","2023-02-02 08:00:00",-0.6607149028962818
"AKYA","Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting","Health","https://www.globenewswire.com/news-release/2023/02/01/2599401/0/en/Akoya-Biosciences-to-Present-First-of-its-Kind-Spatial-Multiomics-Dataset-at-2023-AGBT-General-Meeting.html","2023-02-01 08:00:00",0.7568894327516831
"IMCR","Immunocore to present at upcoming investor conferences","Calendar of Events","https://www.globenewswire.com/news-release/2023/02/01/2599292/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html","2023-02-01 07:00:00",0.6225438727613036
"SCPH","scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/01/31/2598379/0/en/scPharmaceuticals-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html","2023-01-31 08:00:00",0.04408313339450737
"SCPH","scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/30/2597485/0/en/scPharmaceuticals-Provides-FUROSCIX-furosemide-injection-Commercial-Update.html","2023-01-30 08:00:00",1.764400894862661
"CCCC","C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors","Clinical Study","https://www.globenewswire.com/news-release/2023/01/30/2597422/0/en/C4-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Tumors.html","2023-01-30 07:00:00",-0.05538501317535845
"KBLB","Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/26/2595921/0/en/Kraig-Biocraft-Laboratories-Delivers-the-First-Two-Hybrid-Dragon-Silk-Silkworm-Strains-for-Commercial-Production.html","2023-01-26 07:05:00",-0.694392091148881
"CAPR","Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients","Clinical Study","https://www.globenewswire.com/news-release/2023/01/25/2595142/0/en/Capricor-Therapeutics-Announces-Positive-18-Month-Results-from-Ongoing-HOPE-2-Open-Label-Extension-Study-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-Patients.html","2023-01-25 08:00:00",-4.2011839583424715
"RVVTF","Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/13/2588683/0/de/Revive-Therapeutics-legt-aktualisiertes-Informationspaket-zur-Unterst%C3%BCtzung-der-bevorstehenden-Sitzung-des-Typs-C-vor-die-von-der-FDA-f%C3%BCr-die-ge%C3%A4nderte-Pr%C3%BCfplanvereinbarung-der-kli.html","2023-01-13 10:16:00",3.5679119659501755
"ANAB","AnaptysBio Announces Stock Repurchase Plan","Stock Market News","https://www.globenewswire.com/news-release/2023/01/13/2588623/0/en/AnaptysBio-Announces-Stock-Repurchase-Plan.html","2023-01-13 09:00:00",4.915951763411942
"RVVTF","Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/12/2588205/0/en/Revive-Therapeutics-To-Submit-Updated-Briefing-Package-in-Support-of-Upcoming-Type-C-Meeting-Granted-by-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine.html","2023-01-12 13:15:00",-8.7687597684665
"EYEN","Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/12/2587812/0/en/Eyenovia-Reveals-Positive-Evidence-That-Optejet-Delivery-Technology-Decreased-Inflammation-From-Preserved-Glaucoma-Solutions-Compared-to-Drops.html","2023-01-12 08:00:00",3.43264440155003
"NTLA","Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema","Product / Services Announcement","https://www.globenewswire.com/news-release/2023/01/11/2586939/0/en/Intellia-Therapeutics-Awarded-Innovation-Passport-in-the-United-Kingdom-for-NTLA-2002-an-Investigational-Genome-Editing-Treatment-for-Hereditary-Angioedema.html","2023-01-11 07:30:00",-0.18442226981448037
"BTAI","BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer","Clinical Study","https://www.globenewswire.com/news-release/2023/01/11/2586890/0/en/BioXcel-Therapeutics-Announces-Promising-Top-Line-Results-from-Phase-2-Trial-of-BXCL701-in-Aggressive-Form-of-Rare-Prostate-Cancer.html","2023-01-11 07:00:00",0.08473374156650146
"BMRA","Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board","Health","https://www.globenewswire.com/news-release/2023/01/10/2586154/0/en/Biomerica-Appoints-Mayo-Clinic-Gastroenterologist-Dr-Brian-E-Lacy-to-the-Company-s-Scientific-Advisory-Board.html","2023-01-10 08:19:00",1.9219736220287709
"AKRO","Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy","Management Changes","https://www.globenewswire.com/news-release/2023/01/10/2586110/0/en/Akero-Therapeutics-Appoints-Patrick-Lamy-as-Senior-Vice-President-Commercial-Strategy.html","2023-01-10 08:00:00",0.5428402781100226
"BCAB","BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones","Clinical Study","https://www.globenewswire.com/news-release/2023/01/10/2586086/0/en/BioAtla-Provides-Clinical-Program-Updates-and-Upcoming-2023-Milestones.html","2023-01-10 08:00:00",-35.07588938944807
"RVVTF","Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants","Health","https://www.globenewswire.com/news-release/2023/01/09/2585635/0/en/Revive-Therapeutics-Announces-Publication-Showing-Bucillamine-s-Potential-Impact-on-COVID-19-Omicron-Variants.html","2023-01-09 15:34:00",29.37862210872282
"ORIC","ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones","Other News","https://www.globenewswire.com/news-release/2023/01/09/2585167/0/en/ORIC-Pharmaceuticals-Provides-Corporate-Update-and-Highlights-Key-Upcoming-Milestones.html","2023-01-09 08:00:00",2.4187641161518045
"KRON","Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology","Partnerships","https://www.globenewswire.com/news-release/2023/01/09/2585048/0/en/Kronos-Bio-Announces-Discovery-Collaboration-with-Genentech-to-Advance-Novel-Therapies-Against-Transcriptional-Targets-in-Oncology.html","2023-01-09 07:00:00",26.15410107858128
"IMCR","Immunocore announces strategic priorities including pipeline expansion for 2023 -2024","Press releases","https://www.globenewswire.com/news-release/2023/01/09/2585008/0/en/Immunocore-announces-strategic-priorities-including-pipeline-expansion-for-2023-2024.html","2023-01-09 07:00:00",2.5624010939659154
"ADAG","Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial","Clinical Study","https://www.globenewswire.com/news-release/2023/01/09/2585049/0/en/Adagene-Announces-Interim-Data-Demonstrating-Safety-and-Confirmed-Clinical-Responses-of-Anti-CTLA-4-SAFEbody-ADG126-up-to-10-mg-kg-with-Repeat-Cycles-in-Combination-with-Anti-PD-1-.html","2023-01-09 07:00:00",1.9099108376426772
"CCCC","C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines","Research Analysis and Reports","https://www.globenewswire.com/news-release/2023/01/09/2585029/0/en/C4-Therapeutics-Announces-2023-Strategic-Priorities-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html","2023-01-09 07:00:00",0.3027766741111149
"OVID","Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial","Clinical Study","https://www.globenewswire.com/news-release/2023/01/05/2583684/0/en/Ovid-Therapeutics-Dosed-Healthy-Volunteers-with-OV329-in-Phase-1-Trial.html","2023-01-05 08:00:00",-0.5210461362847579
"NTLA","Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones","Company Announcement","https://www.globenewswire.com/news-release/2023/01/05/2583572/0/en/Intellia-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2023-Key-Milestones.html","2023-01-05 07:30:00",-0.7717687867112533
"AKRO","Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference","Trade Show","https://www.globenewswire.com/news-release/2023/01/04/2582867/0/en/Akero-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","2023-01-04 08:00:00",-0.41765356024481576
"CERT","Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation","Mergers and Acquisitions","https://www.globenewswire.com/news-release/2023/01/04/2582816/0/en/Certara-Acquires-Vyasa-an-Artificial-Intelligence-Company-that-Delivers-Predictions-to-Accelerate-Scientific-Innovation.html","2023-01-04 07:31:00",2.0280736750956354
"IMCR","Immunocore to present at the 41st Annual  J.P. Morgan Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2023/01/04/2582742/0/en/Immunocore-to-present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","2023-01-04 07:00:00",-0.6377524920071179
"BCAB","BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/12/22/2578554/0/en/BioAtla-to-Participate-in-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html","2022-12-22 08:00:00",1.5497353512957415
"BTAI","BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2022/12/22/2578481/0/en/BioXcel-Therapeutics-to-Present-at-41st-Annual-J-P-Morgan-Healthcare-Conference.html","2022-12-22 07:00:00",0.11277866363336564
"BCDA","BioCardia Letter to Shareholders","Health","https://www.globenewswire.com/news-release/2022/12/22/2578489/0/en/BioCardia-Letter-to-Shareholders.html","2022-12-22 07:00:00",-0.2939678088113689
"FBIO","Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2022/12/19/2576277/28889/en/Fortress-Biotech-Appoints-Lucy-Lu-M-D-to-its-Board-of-Directors.html","2022-12-19 08:00:00",3.396092409051468
"SCPH","scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer","Directors and Officers","https://www.globenewswire.com/news-release/2022/12/19/2576257/0/en/scPharmaceuticals-Inc-Announces-Appointment-of-Rachael-Nokes-as-Chief-Financial-Officer.html","2022-12-19 08:00:00",0.4180295209269551
"BTAI","BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease","Clinical Study","https://www.globenewswire.com/news-release/2022/12/19/2576149/0/en/BioXcel-Therapeutics-Announces-First-Patient-Dosed-in-TRANQUILITY-III-Phase-3-Trial-for-Acute-Treatment-of-Agitation-in-Patients-with-Alzheimer-s-Disease.html","2022-12-19 07:00:00",0.9453243565846297
"RZLT","Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema","Company Announcement","https://www.globenewswire.com/news-release/2022/12/15/2574408/0/en/Rezolute-Announces-Initiation-of-a-Phase-2-Study-of-RZ402-in-Patients-with-Diabetic-Macular-Edema.html","2022-12-15 07:00:00",1.9348110384245036
"SCPH","scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event","Calendar of Events","https://www.globenewswire.com/news-release/2022/12/14/2573598/0/en/scPharmaceuticals-to-Participate-in-the-12th-Annual-LifeSci-Partners-Corporate-Access-Event.html","2022-12-14 08:00:00",0.08956286987768447
"MLTX","MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis","Press releases","https://www.globenewswire.com/news-release/2022/12/14/2573631/0/en/MoonLake-Immunotherapeutics-screens-first-patient-in-Phase-2-study-of-the-Nanobody-sonelokimab-in-active-psoriatic-arthritis.html","2022-12-14 08:00:00",0.08956286987768447
"FBIO","Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa","Partnerships","https://www.globenewswire.com/news-release/2022/12/14/2573643/28889/en/Urica-Therapeutics-Expands-Exclusive-License-Agreement-with-Fuji-Yakuhin-Co-Ltd-to-Develop-Dotinurad-in-Additional-Territories-Including-Turkey-and-the-Middle-East-and-North-Africa.html","2022-12-14 08:00:00",0.08956286987768447
"MYCOF","Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.","Stock Market News","https://www.globenewswire.com/news-release/2022/12/12/2572149/0/en/Mydecine-Innovations-Group-Closes-Sale-of-Its-Wholly-Owned-Subsidiary-Mindleap-Health-Inc.html","2022-12-12 11:39:00",22.28734339039984
"MYCO.CN","Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.","Stock Market News","https://www.globenewswire.com/news-release/2022/12/12/2572149/0/en/Mydecine-Innovations-Group-Closes-Sale-of-Its-Wholly-Owned-Subsidiary-Mindleap-Health-Inc.html","2022-12-12 11:39:00",-14.561430345902846
"BMRA","Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/12/08/2570250/0/en/Biomerica-Receives-KFDA-and-Ministry-of-Health-Approval-for-Colorectal-Screening-and-Breast-Screening-Tests-in-Saudi-Arabia-and-UAE.html","2022-12-08 08:19:00",1.635420836965817
"AKRO","Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/12/08/2570081/0/en/Efruxifermin-Granted-FDA-Breakthrough-Therapy-Designation-for-NASH.html","2022-12-08 07:00:00",0.4214314431853952
"PEPG","PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies","Clinical Study","https://www.globenewswire.com/news-release/2022/12/07/2569253/0/en/PepGen-Announces-IND-Enabling-Preclinical-Data-Supporting-Progression-of-PGN-EDODM1-into-Clinical-Studies.html","2022-12-07 08:00:00",-0.20660266351737083
"FBIO","Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference","Trade Show","https://www.globenewswire.com/news-release/2022/12/06/2568308/28889/en/Fortress-Biotech-to-Participate-in-Cantor-Medical-Aesthetic-Dermatology-Ophthalmology-MedTech-Diagnostic-Conference.html","2022-12-06 08:30:00",-1.386028464783881
"OVID","Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)","Calendar of Events","https://www.globenewswire.com/news-release/2022/12/02/2566798/0/en/Ovid-Therapeutics-to-Present-Data-on-Its-Epilepsy-Programs-at-American-Epilepsy-Society-Annual-Meeting-2022.html","2022-12-02 10:00:00",1.0514648592772666
"ANAB","AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer","Health","https://www.globenewswire.com/news-release/2022/12/02/2566746/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agent-JEMPERLI-dostarlimab-gxly-meets-primary-endpoint-in-Phase-3-RUBY-trial-in-primary-advanced-or-recurrent-endometrial-cancer.html","2022-12-02 09:00:00",0.19621453331780253
"PCIB.OL","PCI Biotech: Employee share option scheme","European Regulatory News","https://www.globenewswire.com/news-release/2022/11/25/2562697/0/en/PCI-Biotech-Employee-share-option-scheme.html","2022-11-25 12:08:00",-6.060508863446167
"TALS","Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/11/22/2560659/0/en/Talaris-Therapeutics-to-Participate-at-the-5th-Annual-Evercore-ISI-HealthCONx-Conference.html","2022-11-22 07:00:00",0.8914633071482946
"ANAB","AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/21/2560251/0/en/AnaptysBio-to-Participate-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference.html","2022-11-21 13:56:00",-1.0846161320771457
"MYCOF","Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement","Changes in company's own shares","https://www.globenewswire.com/news-release/2022/11/21/2560184/0/en/Mydecine-Innovations-Group-Files-Prospectus-Supplement-and-Announces-Closing-Under-Share-Subscription-Agreement.html","2022-11-21 12:01:00",2.234901198877694
"MYCO.CN","Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement","Changes in company's own shares","https://www.globenewswire.com/news-release/2022/11/21/2560184/0/en/Mydecine-Innovations-Group-Files-Prospectus-Supplement-and-Announces-Closing-Under-Share-Subscription-Agreement.html","2022-11-21 12:01:00",0.012674414324516353
"YTEN","Yield10 Bioscience to Present at the CG AgriFood Tech Innovation Virtual Forum","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/21/2559891/34378/en/Yield10-Bioscience-to-Present-at-the-CG-AgriFood-Tech-Innovation-Virtual-Forum.html","2022-11-21 08:30:00",-0.43026976702740927
"KBLB","Kraig Biocraft Laboratories Completes Closeout of $8 Million Financing, Extinguishing All Convertible Debentures with Yorkville Advisors","Financing Agreements","https://www.globenewswire.com/news-release/2022/11/21/2559756/0/en/Kraig-Biocraft-Laboratories-Completes-Closeout-of-8-Million-Financing-Extinguishing-All-Convertible-Debentures-with-Yorkville-Advisors.html","2022-11-21 07:05:00",0.35097950537681305
"PCIB.OL","PCI Biotech: Invitation to Q3 2022 results presentation","European Regulatory News","https://www.globenewswire.com/news-release/2022/11/17/2558508/0/en/PCI-Biotech-Invitation-to-Q3-2022-results-presentation.html","2022-11-17 11:42:00",-6.422631620857552
"KBLB","Kraig Biocraft Laboratories poised to Close Out Yorkville Convertible Debenture with Strongest Financial Position in Corporate History","Financing Agreements","https://www.globenewswire.com/news-release/2022/11/15/2555972/0/en/Kraig-Biocraft-Laboratories-poised-to-Close-Out-Yorkville-Convertible-Debenture-with-Strongest-Financial-Position-in-Corporate-History.html","2022-11-15 07:05:00",-1.5261183574140447
"MLTX","MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update","Press releases","https://www.globenewswire.com/news-release/2022/11/14/2554939/0/en/MoonLake-Immunotherapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Recent-Business-Update.html","2022-11-14 08:00:00",0.9106589179594161
"ADAG","Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/10/2553382/0/en/Adagene-Announces-Clinical-Data-at-SITC-2022-on-Anti-CTLA-4-NEObody-ADG116-Showing-Differentiated-Safety-and-Anti-tumor-Activity-in-Heavily-Pre-treated-Patients-with-Difficult-to-T.html","2022-11-10 09:05:00",-6.078613757366813
"IMRX","Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/11/10/2553314/0/en/Immuneering-Reports-Third-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html","2022-11-10 09:00:00",1.2504747636865197
"SPRY","ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis","Trade Show","https://www.globenewswire.com/news-release/2022/11/10/2553122/0/en/ARS-Pharmaceuticals-Announces-Presentation-of-Clinical-Data-Supporting-neffy-epinephrine-nasal-spray-for-the-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis.html","2022-11-10 08:00:00",2.2199690692254803
"TALS","Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/11/10/2552990/0/en/Talaris-Therapeutics-Announces-Third-Quarter-Financial-Results-and-Corporate-Update.html","2022-11-10 07:00:00",-0.9234186809841782
"ANAB","AnaptysBio to Participate in Upcoming November Investor Conferences","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/09/2552375/0/en/AnaptysBio-to-Participate-in-Upcoming-November-Investor-Conferences.html","2022-11-09 14:10:00",-0.08576605405624574
"OVID","Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/11/08/2550886/0/en/Ovid-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Corporate-Highlights.html","2022-11-08 08:00:00",-0.30529625141825006
"BCAB","BioAtla to Participate in the Jefferies London Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/08/2550890/0/en/BioAtla-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html","2022-11-08 08:00:00",-0.30529625141825006
"TSHA","Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/11/08/2550703/0/en/Taysha-Gene-Therapies-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html","2022-11-08 07:00:00",0.6947027949074336
"NSPR","InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/11/08/2550713/0/en/InspireMD-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update.html","2022-11-08 07:00:00",-0.30529625141825006
"CERT","Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase","Changes in company's own shares","https://www.globenewswire.com/news-release/2022/11/07/2549670/0/en/Arsenal-Capital-Partners-Increases-Investment-in-Global-Biosimulation-Leader-Certara-with-449M-Stock-Purchase.html","2022-11-07 08:00:00",12.502496254282988
"AKRO","Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/07/2549564/0/en/Akero-Therapeutics-to-Present-Late-Breaking-Oral-and-Poster-presentations-on-EFX-Today-at-AASLD-s-The-Liver-Meeting-2022.html","2022-11-07 07:30:00",2.029495722422285
"TALS","Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance","Health","https://www.globenewswire.com/news-release/2022/11/07/2549491/0/en/Talaris-Therapeutics-Presents-Data-on-Mechanisms-of-FCR001-Activity-to-Induce-Immune-Tolerance.html","2022-11-07 07:00:00",-0.36136185186839986
"BCAB","BioAtla Announces $65 Million Underwritten Offering of its Common Stock","Stock Market News","https://www.globenewswire.com/news-release/2022/11/04/2548838/0/en/BioAtla-Announces-65-Million-Underwritten-Offering-of-its-Common-Stock.html","2022-11-04 09:08:00",25.272275927197608
"CCCC","C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/11/03/2547375/0/en/C4-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html","2022-11-03 07:00:00",-2.185806061886203
"BMRA","Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting","Clinical Study","https://www.globenewswire.com/news-release/2022/11/02/2546506/0/en/Biomerica-InFoods-IBS-Data-Presented-at-the-2022-American-College-of-Gastroenterology-ACG-Annual-Scientific-Meeting.html","2022-11-02 08:19:00",-0.42699599435564484
"RZLT","Rezolute to Present at the Jefferies London Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2022/11/01/2545290/0/en/Rezolute-to-Present-at-the-Jefferies-London-Healthcare-Conference.html","2022-11-01 07:00:00",6.082997567298371
"NSPR","InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/10/25/2540789/0/en/InspireMD-to-Report-Third-Quarter-2022-Financial-Results-on-November-8-2022-and-Provide-Corporate-Business-Update.html","2022-10-25 08:00:00",-1.6317790552574911
"RENB","Enochian BioSciences Forges Ahead With Focused Approach, Promising Future","Law & Legal Issues","https://www.globenewswire.com/news-release/2022/10/24/2539913/0/en/Enochian-BioSciences-Forges-Ahead-With-Focused-Approach-Promising-Future.html","2022-10-24 08:00:00",-3.2710769674408517
"RZLT","Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting","Health","https://www.globenewswire.com/news-release/2022/10/20/2538145/0/en/Rezolute-Announces-Presentation-at-The-Retina-Society-55th-Annual-Scientific-Meeting.html","2022-10-20 07:00:00",-2.6247573765833976
"TALS","Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial","Clinical Study","https://www.globenewswire.com/news-release/2022/10/20/2538153/0/en/Talaris-Therapeutics-Provides-Update-on-FREEDOM-1-Phase-3-Clinical-Trial.html","2022-10-20 07:00:00",-8.963365557590027
"RENB","Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform","Patents","https://www.globenewswire.com/news-release/2022/10/17/2535485/0/en/Enochian-BioSciences-Awarded-U-S-Patent-For-Its-Promising-Oncology-Platform.html","2022-10-17 08:30:00",1.4270380032946073
"TALS","Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting","Health","https://www.globenewswire.com/news-release/2022/10/17/2535311/0/en/Talaris-Therapeutics-Announces-Upcoming-Presentations-at-American-Society-of-Nephrology-Annual-Meeting.html","2022-10-17 07:00:00",0.8247252079803449
"BMRA","Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/10/14/2534713/0/en/Walmart-to-Expand-Sales-of-Biomerica-s-Aware-Breast-Self-Exam-Product-will-now-be-available-in-over-2400-Walmart-stores.html","2022-10-14 09:18:00",25.55765290007117
"FBIO","Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock","Stock Market News","https://www.globenewswire.com/news-release/2022/10/05/2528702/28889/en/Fortress-Biotech-Announces-Timing-of-Regular-Monthly-Dividend-for-October-November-and-December-2022-for-its-9-375-Series-A-Cumulative-Redeemable-Perpetual-Preferred-Stock.html","2022-10-05 08:30:00",1.2117328246881933
"TALS","Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa","Calendar of Events","https://www.globenewswire.com/news-release/2022/10/04/2527628/0/en/Talaris-Therapeutics-to-Present-at-the-2022-Cell-Gene-Meeting-on-the-Mesa.html","2022-10-04 07:00:00",-0.8385973607993301
"CCCC","C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers","Regulatory information","https://www.globenewswire.com/news-release/2022/09/29/2525008/0/en/C4-Therapeutics-Receives-Study-May-Proceed-Letter-from-U-S-FDA-to-Initiate-Phase-1-2-Clinical-Trial-of-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Cance.html","2022-09-29 07:00:00",-0.10837309284580776
"ORPHA.CO","Orphazyme reports financial results in Interim Report First Half 2022","European Regulatory News","https://www.globenewswire.com/news-release/2022/09/26/2522740/0/en/Orphazyme-reports-financial-results-in-Interim-Report-First-Half-2022.html","2022-09-26 11:25:00",-3.7682986239305842
"MLTX","MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis","Company Announcement","https://www.globenewswire.com/news-release/2022/09/26/2522464/0/en/MoonLake-Immunotherapeutics-to-initiate-global-Phase-2-study-of-the-Nanobody-sonelokimab-in-patients-with-active-psoriatic-arthritis.html","2022-09-26 08:00:00",-1.2230478791404915
"CCCC","C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022","Calendar of Events","https://www.globenewswire.com/news-release/2022/09/26/2522365/0/en/C4-Therapeutics-to-Present-at-Bank-of-America-Securities-Precision-Oncology-Conference-2022.html","2022-09-26 07:00:00",0.41853743547516764
"TALS","Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/09/21/2520016/0/en/Talaris-Therapeutics-to-Present-at-William-Blair-s-Innovations-in-Solid-Organ-and-Hematopoietic-Stem-Cell-Transplant-Virtual-Event.html","2022-09-21 07:00:00",-1.5063067894231421
"ORPHA.CO","Updated financial calendar for 2022","European Regulatory News","https://www.globenewswire.com/news-release/2022/09/19/2518652/0/en/Updated-financial-calendar-for-2022.html","2022-09-19 13:41:00",4.993870572915038
"KBLB","Kraig Biocraft Laboratories Engages Textile Expert to Develop New Innovative Yarns and Fabrics applications for Dragon Silk™","Stock Market News","https://www.globenewswire.com/news-release/2022/09/12/2513873/0/en/Kraig-Biocraft-Laboratories-Engages-Textile-Expert-to-Develop-New-Innovative-Yarns-and-Fabrics-applications-for-Dragon-Silk.html","2022-09-12 07:05:00",-0.5361516584006762
"RZLT","Rezolute Announces Presentation at the 60th Annual ESPE Meeting","Calendar of Events","https://www.globenewswire.com/news-release/2022/09/07/2511306/0/en/Rezolute-Announces-Presentation-at-the-60th-Annual-ESPE-Meeting.html","2022-09-07 07:00:00",1.4002434205371732
"KRON","Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia","Clinical Study","https://www.globenewswire.com/news-release/2022/08/22/2502156/0/en/Kronos-Bio-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Lanraplenib-in-Combination-with-Gilteritinib-in-Acute-Myeloid-Leukemia.html","2022-08-22 08:00:00",-0.43742898778016004
"KBLB","Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam","Company Announcement","https://www.globenewswire.com/news-release/2022/08/17/2499853/0/en/Kraig-Biocraft-Laboratories-Expands-Operational-Footprint-in-Vietnam.html","2022-08-17 07:05:00",0.882012668665188
"TALS","Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/08/15/2498089/0/en/Talaris-Therapeutics-Announces-Second-Quarter-Financial-Results-and-Corporate-Update.html","2022-08-15 07:00:00",-6.464759050816671
"CCCC","C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights","Earnings Releases and Operating Results","https://www.globenewswire.com/news-release/2022/08/04/2492273/0/en/C4-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html","2022-08-04 08:00:00",-0.8033549999705739
"KBLB","Kraig Biocraft Laboratories Posts Behind the Scenes Look into the Laboratory R&D Processes for Creating Recombinant Spider Silk","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/08/04/2492190/0/en/Kraig-Biocraft-Laboratories-Posts-Behind-the-Scenes-Look-into-the-Laboratory-R-D-Processes-for-Creating-Recombinant-Spider-Silk.html","2022-08-04 07:05:00",0.019306813243325196
"CCCC","C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2022/08/02/2490309/0/en/C4-Therapeutics-Appoints-Experienced-Clinical-Development-Leaders-Laura-Bessen-M-D-and-Donna-Grogan-M-D-to-Board-of-Directors.html","2022-08-02 08:00:00",-1.602531913812875
"VBLT","VBL Therapeutics Announces Workforce Reduction","Restructuring / Recapitalization","https://www.globenewswire.com/news-release/2022/08/02/2490344/0/en/VBL-Therapeutics-Announces-Workforce-Reduction.html","2022-08-02 08:00:00",-2.2184029484838828
"KBLB","Kraig Biocraft Laboratories Apparel Brand SpydaSilk™ Attends Largest International Textile and Garment Expo in Vietnam","Trade Show","https://www.globenewswire.com/news-release/2022/08/01/2489283/0/en/Kraig-Biocraft-Laboratories-Apparel-Brand-SpydaSilk-Attends-Largest-International-Textile-and-Garment-Expo-in-Vietnam.html","2022-08-01 07:05:00",0.6893362472896473
"MLTX","MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH","Press releases","https://www.globenewswire.com/news-release/2022/07/26/2485842/0/en/MoonLake-Immunotherapeutics-signs-development-and-manufacturing-agreement-with-Vetter-Pharma-International-GmbH.html","2022-07-26 08:00:00",-8.91109349141852
"RENB","Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor","Health","https://www.globenewswire.com/news-release/2022/07/25/2485214/0/en/Enochian-BioSciences-Appoints-Dr-Richard-Whitley-As-Senior-Scientific-Advisor.html","2022-07-25 10:15:00",-10.45871976666882
"KBLB","Kraig Biocraft Laboratories Releases First Behind the Scenes Look into the Production of Recombinant Spider Silk","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/07/20/2482545/0/en/Kraig-Biocraft-Laboratories-Releases-First-Behind-the-Scenes-Look-into-the-Production-of-Recombinant-Spider-Silk.html","2022-07-20 07:05:00",-0.05098840406684258
"KBLB","Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/07/18/2480940/0/en/Kraig-Biocraft-Laboratories-Enters-Next-Phase-of-Business-Plan-Signs-Deal-with-Contract-Manufacturer-to-Produce-Metric-Tons-of-Recombinant-Spider-Silk.html","2022-07-18 07:05:00",-0.8438708900359273
"KBLB","Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/07/06/2474783/0/en/Kraig-Biocraft-Laboratories-Introduces-New-Enhanced-Line-of-Dragon-Silk-Silkworms-for-Commercial-Production.html","2022-07-06 07:05:00",-0.039269530799017106
"TALS","Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update","Health","https://www.globenewswire.com/news-release/2022/06/30/2471997/0/en/Talaris-Therapeutics-Provides-FREEDOM-1-Phase-3-Clinical-Update.html","2022-06-30 07:00:00",0.2364705621053084
"KBLB","Kraig Biocraft Laboratories Takes Next Step in Launching Spydasilk™ Apparel Brand","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/06/27/2469367/0/en/Kraig-Biocraft-Laboratories-Takes-Next-Step-in-Launching-Spydasilk-Apparel-Brand.html","2022-06-27 07:05:00",-0.24866726161133726
"KBLB","Senior Kraig Biocraft Laboratories Leaders Travel to Vietnam for High-level Meetings and Fiber Production Initiatives","Other News","https://www.globenewswire.com/news-release/2022/06/08/2458586/0/en/Senior-Kraig-Biocraft-Laboratories-Leaders-Travel-to-Vietnam-for-High-level-Meetings-and-Fiber-Production-Initiatives.html","2022-06-08 07:05:00",0.4353676819911784
"RZLT","Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer","Health","https://www.globenewswire.com/news-release/2022/06/01/2454045/0/en/Rezolute-Announces-Promotion-of-Brian-Roberts-M-D-to-Chief-Medical-Officer.html","2022-06-01 07:00:00",6.600389107782958
"TALS","Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study","Conference Calls/ Webcasts","https://www.globenewswire.com/news-release/2022/06/01/2454050/0/en/Talaris-Therapeutics-Announces-Conference-Call-to-Highlight-Presentations-at-the-American-Transplant-Congress-ATC-and-Provide-a-Data-Update-from-its-Phase-3-FREEDOM-1-Study.html","2022-06-01 07:00:00",1.3158438158622043
"KBLB","Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/05/17/2444799/0/en/Kraig-Biocraft-Laboratories-Enters-Biomedical-Field-with-First-Sample-Shipments-of-Fibers-and-Fabrics-for-Tissue-Engineering.html","2022-05-17 07:05:00",12.67607278822545
"TALS","Talaris Therapeutics Announces Changes to Board of Directors","Directors and Officers","https://www.globenewswire.com/news-release/2022/05/17/2444766/0/en/Talaris-Therapeutics-Announces-Changes-to-Board-of-Directors.html","2022-05-17 07:00:00",2.518801642974067
"VBLT","VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update","Calendar of Events","https://www.globenewswire.com/news-release/2022/05/17/2444762/0/en/VBL-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html","2022-05-17 07:00:00",-5.034300800214224
"CCCC","C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors","Health","https://www.globenewswire.com/news-release/2022/05/16/2443855/0/en/C4-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CFT8634-an-Orally-Bioavailable-BiDAC-Degrader-for-the-Treatment-of-Synovial-Sarcoma-and-SMARCB1.html","2022-05-16 08:00:00",-1.1053283088324615
"MLTX","MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa","Company Announcement","https://www.globenewswire.com/news-release/2022/05/12/2441762/0/en/MoonLake-Immunotherapeutics-starts-Phase-2-trial-of-the-Nanobody-Sonelokimab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa.html","2022-05-12 07:00:00",-4.059396673356705
"VBLT","VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17","Calendar of Events","https://www.globenewswire.com/news-release/2022/05/10/2439661/0/en/VBL-Therapeutics-to-Report-First-Quarter-2022-Financial-Results-on-May-17.html","2022-05-10 08:00:00",-1.5872558438627036
"RZLT","Rezolute, Inc. Announces Closing of Registered Direct Offering","Warrants and Certificates","https://www.globenewswire.com/news-release/2022/05/04/2435821/0/en/Rezolute-Inc-Announces-Closing-of-Registered-Direct-Offering.html","2022-05-04 09:33:00",-0.2873185291005754
"VBLT","VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May","Calendar of Events","https://www.globenewswire.com/news-release/2022/05/03/2434479/0/en/VBL-Therapeutics-to-Participate-in-Upcoming-Scientific-and-Industry-Conferences-in-May.html","2022-05-03 08:00:00",2.2250680970750905
"KBLB","Kraig Biocraft Laboratories Strengthens Q2 Spider Silk Production Expansion with New Vendor Quality Assurance Program","Management statements","https://www.globenewswire.com/news-release/2022/05/03/2434401/0/en/Kraig-Biocraft-Laboratories-Strengthens-Q2-Spider-Silk-Production-Expansion-with-New-Vendor-Quality-Assurance-Program.html","2022-05-03 07:05:00",-12.627868441151282
"VBLT","VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer","Product / Services Announcement","https://www.globenewswire.com/news-release/2022/04/26/2429037/0/en/VBL-Therapeutics-Receives-FDA-Fast-Track-Designation-for-Ofra-Vec-for-the-Treatment-of-Platinum-Resistant-Ovarian-Cancer.html","2022-04-26 08:00:00",-0.7538888297860346
"JSPR","Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2022/03/10/2400877/0/en/Jasper-Therapeutics-to-Participate-in-the-Oppenheimer-32nd-Annual-Healthcare-Conference.html","2022-03-10 08:00:00",1.439088890131586
"JSPR","Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer","Directors and Officers","https://www.globenewswire.com/news-release/2022/02/28/2393128/0/en/Jasper-Therapeutics-Announces-Appointment-of-Ronald-Martell-as-Chief-Executive-Officer.html","2022-02-28 08:00:00",11.467106641585426
"JSPR","Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting","Health","https://www.globenewswire.com/news-release/2021/12/08/2348326/0/en/Jasper-Therapeutics-to-Present-Data-on-JSP191-Conditioning-in-SCID-patients-at-the-2021-American-Society-of-Hematology-Annual-Meeting.html","2021-12-08 08:30:00",0.5353095873912967
"JSPR","Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy","Product / Services Announcement","https://www.globenewswire.com/news-release/2021/11/09/2330363/0/en/Jasper-Therapeutics-Announces-Research-Collaboration-with-AVROBIO-to-Evaluate-JSP191-as-Conditioning-Agent-in-Clinical-Studies-of-Ex-Vivo-Lentiviral-Gene-Therapy.html","2021-11-09 08:00:00",-0.842397289118269
"JSPR","Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference","Calendar of Events","https://www.globenewswire.com/news-release/2021/11/08/2329239/0/en/Jasper-Therapeutics-to-Present-at-the-Credit-Suisse-30th-Annual-Virtual-Healthcare-Conference.html","2021-11-08 08:00:00",-1.4363501094678237
"ANVS","Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference","Calendar of Events","https://www.globenewswire.com/news-release/2020/12/03/2139244/0/en/Annovis-Bio-to-Present-at-the-New-York-Academy-of-Sciences-Alzheimer-s-Disease-Therapeutics-Alternatives-to-Amyloid-2020-Virtual-Conference.html","2020-12-03 09:15:00",-2.3774152458898943
"ANVS","Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium","Calendar of Events","https://www.globenewswire.com/news-release/2020/11/16/2127426/0/en/Annovis-Bio-to-Participate-in-A-G-P-s-Virtual-Healthcare-Symposium.html","2020-11-16 09:15:00",2.501535892872974
"NSPR","InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR","Product / Services Announcement","https://www.globenewswire.com/news-release/2020/06/25/2053527/0/en/InspireMD-Announces-Late-Breaking-Presentation-of-Early-SIBERIA-Clinical-Trial-Results-to-be-Featured-in-an-e-Course-at-EuroPCR.html","2020-06-25 10:00:00",2.7214561078314
